Antihistamines General Statement (Monograph)

Drug class: Antihistamine Drugs
ATC class: R06A
VA class: AH000

Introduction

Antihistamines, which inhibit the effects of histamine at H₁ receptors, have been classified as first generation (i.e., relatively sedating) or second generation (i.e., relatively nonsedating).

Uses for Antihistamines General Statement

Antihistamines are most often used to provide symptomatic relief of allergic symptoms caused by histamine release. The drugs are not curative and merely provide palliative therapy. Antihistamines are used only as adjunctive therapy to epinephrine and other standard measures in the treatment of anaphylactic reactions and laryngeal edema after the acute manifestations have been controlled. Individual patients vary in their response to antihistamines. A specific antihistamine that provides dramatic relief without adverse effects to one patient may produce intolerable adverse effects in another patient. Trial of various antihistamines may be necessary to determine which drug will provide relief while causing minimal adverse effects.

Nasal Allergies and the Common Cold

Antihistamines are most beneficial in the management of nasal allergies. Seasonal allergic rhinitis (e.g., hay fever) and perennial (nonseasonal) allergic rhinitis are benefited more than perennial nonallergic (vasomotor) rhinitis. Orally administered antihistamines generally provide symptomatic relief of rhinorrhea, sneezing, oronasopharyngeal irritation or itching, lacrimation, and red, irritated, or itching eyes associated with the early response to histamine.¹⁰⁰ ¹⁴⁹ ¹⁶⁸ ¹⁶⁹ ¹⁷⁰ ⁴⁸⁷ ⁴⁹⁴ ⁵⁰⁹ The drugs generally are not effective in relieving symptoms of nasal obstruction, which are characteristic of the late allergic reaction,¹⁰⁰ ¹⁷⁰ ⁴⁸⁷ although limited data indicate that cetirizine and levocetirizine may relieve some symptoms of late allergic reactions.⁵⁸¹ ⁶⁸¹ ⁶⁸² Antihistamines (e.g., azelastine) also may be administered intranasally for the symptomatic relief of seasonal allergic rhinitis.⁵²⁶ ⁵²⁷ ⁵²⁸ In comparative studies, intranasal azelastine was more effective than placebo and at least as effective as oral antihistamines (e.g., cetirizine, terfenadine [no longer commercially available in the US]) or intranasal corticosteroids in relieving allergic rhinitis.⁵²⁹ ⁵³⁰ ⁵³¹ ⁵³² ⁵³³ ⁵³⁴ ⁵³⁵ ⁵³⁶ ⁵³⁷ ⁵³⁸ ⁵³⁹ However, unlike intranasal corticosteroids, azelastine does not appear to exhibit local histologic anti-inflammatory activity;⁵²⁹ ⁵³⁰ therefore, beneficial effects on nasal obstruction appear to result principally from antihistaminic and/or other activity.⁵³⁰ ⁵³¹ ⁵³⁵

Chronic nasal congestion and headache caused by edema of the paranasal sinus mucosa are often refractory to antihistamine therapy. In the treatment of hay fever, antihistamines are more likely to be beneficial when therapy is initiated at the beginning of the hay fever season when pollen counts are low (e.g., before pollination begins) and if used regularly during the pollen season. Antihistamines are less likely to be effective when pollen counts are high, when pollen exposure is prolonged, and when nasal congestion is prominent.¹⁴⁹ ¹⁵¹ ¹⁶⁸

Although antihistamines frequently are used for symptomatic relief in the common cold, evidence of effectiveness remains to be clearly established.¹⁰⁰ ¹²⁹ ¹³⁰ ³⁹⁸ ⁴⁰¹ ⁴⁰² ⁴⁶⁷ ⁴⁸⁷ ⁴⁹⁴ ⁵²⁵ ⁵⁴⁰ ⁵⁶⁴ ⁵⁶⁵ Antihistamines cannot prevent, cure, or shorten the course of the common cold,¹⁰⁰ ¹²⁹ ¹³⁰ ³⁹⁸ ⁴⁰⁰ ⁴⁰² but may provide some symptomatic relief.¹³⁰ ¹⁶⁹ ³⁹⁰ ³⁹² ⁴⁰⁰ ⁴⁰¹ ⁵¹⁹ ⁵⁴⁰ ⁵⁶⁴ ⁵⁶⁵ Conventional (prototypical, first generation) antihistamines (e.g., those with anticholinergic activity) are considered effective in relieving rhinorrhea and sneezing associated with the common cold,¹³⁰ ¹⁶⁹ ³⁹⁰ ³⁹² ⁴⁰⁰ ⁵⁴⁰ ⁵⁶⁴ but evidence of efficacy in relieving oronasopharyngeal itching, lacrimation, or itching eyes associated with this condition currently is lacking.¹⁶⁹ Nonsedating (second generation) antihistamines do not appear to be effective in relieving rhinorrhea, suggesting that histamine is not a principal mediator of this manifestation.⁵¹⁹ ⁵²⁴ ⁵⁶⁴ The extent to which histamine contributes to other manifestations of the common cold currently is unclear, but pathogenesis of the full constellation of symptoms that constitute the common cold appears to be complex, involving a number of mediators and neurologic mechanisms.⁵¹⁹ ⁵²⁰ ⁵²¹ ⁵²² ⁵²³

Routine, prolonged administration of fixed combinations containing antihistamines, nasal decongestants, anticholinergics, analgesic-antipyretics, caffeine, antitussives, and/or expectorants has been questioned.¹⁰⁰ ³⁹⁰ Single-ingredient products generally are safer than combination products,¹⁰⁰ while also facilitating dosage adjustment.¹⁰⁰ ³⁹⁰ There is no evidence that combinations containing 2 or more antihistamines are more effective than one antihistamine or that combinations of subtherapeutic doses of 2 or more antihistamines are more effective than therapeutic doses of one antihistamine.¹⁰⁰ ³⁹⁰ ³⁹⁷ ³⁹⁸ Oral antihistamine combinations containing an analgesic-antipyretic and/or nasal decongestant; an antitussive and nasal decongestant; an analgesic-antipyretic, antitussive, and nasal decongestant; or an antitussive may be rational if each ingredient has demonstrated clinical effectiveness and is present in therapeutic dosage.¹⁰⁰ ³⁹⁰ ³⁹⁷ ³⁹⁸ ³⁹⁹ Selective use of such combinations can provide a convenient and rational approach for relief of concurrent symptoms (e.g., rhinorrhea, nasal congestion, cough), which often are present in allergic rhinitis and other conditions (e.g., common cold), by allowing the patient to use a single combination rather than multiple single-entity preparations.¹⁰⁰ ³⁹⁰ ³⁹⁸ ⁴⁸⁷ Combination preparations generally should be used only when symptoms amenable to each ingredient are present concurrently.¹⁰⁰ ³⁹⁰ ³⁹⁸ Combinations containing an antihistamine and an expectorant, anticholinergic agent, or bronchodilator are not considered rational.¹⁰⁰ ³⁹⁰

Although cough and cold preparations that contain antihistamines, nasal decongestants, cough suppressants, and/or expectorants commonly were used in pediatric patients younger than 2 years of age, systematic reviews of controlled trials have concluded that nonprescription (over-the-counter, OTC) cough and cold preparations are no more effective than placebo in reducing acute cough and other symptoms of upper respiratory tract infection in these patients.⁶⁹³ Furthermore, adverse events, including deaths, have been (and continue to be) reported in pediatric patients younger than 2 years of age receiving these preparations.⁶⁹³ (See Cautions: Pediatric Precautions.)

Other Allergic Conditions

Antihistamines are often effective in the treatment of allergic dermatoses and other dermatoses associated with histamine release, but effectiveness varies with the causative agent and symptoms may return when the drug is stopped. Antihistamines have been used in the symptomatic treatment of chronic idiopathic urticaria;¹⁷⁶ ¹⁷⁷ ¹⁷⁸ ¹⁷⁹ ⁵⁰⁹ ⁵⁶⁷ ⁵⁶⁸ ⁵⁶⁹ ⁵⁷⁰ ⁵⁷¹ ⁵⁷² ⁵⁷³ ⁶⁶⁹ ⁶⁷⁰ ⁶⁸³ ⁶⁸⁴ occasionally, patients who do not experience adequate relief with an antihistamine (H₁-receptor antagonist) alone may benefit from the addition of an H₂-receptor antagonist.¹⁷⁶ ¹⁷⁷ ¹⁷⁸ ¹⁷⁹ However, in one study, the addition of an H₂-receptor antagonist did not provide a substantial increase in response (as determined by reduction in whealing).¹⁷⁵ Some antihistamines also may symptomatically relieve pruritus accompanying atopic dermatitis, contact dermatitis, pruritus ani or vulvae, and insect bites. Some evidence suggests that first generation antihistamines such as hydroxyzine and diphenhydramine may be more effective than second generation antihistamines (e.g., terfenadine [no longer commercially available in the US], loratadine) for the relief of pruritus associated with certain allergic dermatoses (e.g., atopic dermatitis), but additional study is needed to elucidate further the relative efficacy of these drugs as antipruritics.⁴⁸⁷ ⁴⁹⁵ ⁴⁹⁶ Antihistamines also may be used in the treatment of dermatographism. Patients with dermatographism or other urticarial conditions who do not experience adequate relief with an antihistamine (H₁-receptor antagonist) alone may benefit from the addition of an H₂-receptor antagonist to enhance relief of pruritus and wheal formation.¹⁷³ ¹⁷⁴ ³²¹ ⁴⁸⁷

Antihistamines are useful in the management of allergic conjunctivitis caused by foods or inhaled allergens. Allergic or hypersensitivity reactions to penicillin, streptomycin, sulfonamides, and other drugs may be amenable to antihistamine therapy. Pruritus and urticaria accompanying these conditions usually are temporarily relieved; edema is more resistant and serum sickness is not benefited.

Symptoms of mild transfusion reactions not caused by ABO incompatibility or pyrogens may be alleviated by antihistamines. The drugs should not be added to blood being transfused. Antihistamines may be administered prophylactically to patients with a history of transfusion reactions, but the drugs should not be given routinely to patients receiving blood. Antihistamines also may be useful to prevent sequelae following desensitization procedures and allergic reactions to radiographic contrast media. It must be kept in mind that prophylactic use of antihistamines may mask incipient signs of allergic reactions, and the patient’s hypersensitivity may not be recognized until a serious reaction occurs.

Although epinephrine is the initial drug of choice for patients with anaphylactic or anaphylactoid reactions, antihistamines are useful in the ancillary treatment of pruritus, urticaria, angioedema, and bronchospasm associated with these reactions.⁴⁸⁷ ⁴⁹² ⁴⁹³ Concurrent use of H₁- and H₂-receptor antagonists appears to reduce the adverse effects of histamine on the peripheral vasculature and myocardium during anaphylaxis.⁴⁸⁷ ⁴⁹²

Asthma

Antihistamines may provide some benefit in certain asthmatic patients, but the drugs usually are not effective in treating bronchial asthma per se and should not be used in the treatment of severe acute asthma attacks. In addition, antihistamines are not included in the usual recommended regimens for the management of asthma, including long-term control of the disease.⁵⁶⁶ Antihistamine and decongestant combinations may provide symptomatic relief (e.g., of rhinitis) in patients with chronic rhinitis and persistent asthma, but the drugs have not been shown to have a protective effect on lower airways; other agents (e.g., inhaled corticosteroids) are for protective effects on lower airways.⁵⁶⁶ In general, patients with predictable seasonal asthma should receive long-term anti-inflammatory therapy (e.g., inhaled corticosteroids, mast-cell stabilizers), initiated prior to the anticipated onset of exposure to allergens and continued throughout the season.⁵⁶⁶ The drugs may be used with caution to treat hay fever or other airway disorder with a histamine-mediated component in patients with such disorders and asthma. Although some clinicians believe that the anticholinergic effects (e.g., reduction of nasal secretions) of some of these drugs may cause thickening of bronchial secretions resulting in further airway obstruction in asthmatics, especially those with status asthmaticus, most experts consider complete avoidance of currently available antihistamines in asthmatics unjustified.⁴⁶⁷ ⁴⁸¹ ⁴⁸⁴ ⁴⁸⁷ (See Cautions: Precautions and Contraindications.)

Motion Sickness and Vertigo

Some antihistamines (e.g., dimenhydrinate, diphenhydramine, meclizine, promethazine) are useful for the prevention and treatment of nausea, vomiting, and/or vertigo associated with motion sickness³²⁸ ³⁴¹ ³⁴² ³⁴³ ³⁴⁴ ³⁴⁵ ³⁴⁶ ³⁴⁷ ³⁴⁸ and they are considered the drugs of choice for the management of this condition.³⁴¹ ³⁴² ³⁴⁵ ³⁴⁶ ³⁴⁷ Dimenhydrinate and meclizine have also been used in the symptomatic treatment of vertigo associated with diseases affecting the vestibular system (e.g., labyrinthitis, Ménière’s disease). Nonphenothiazine antihistamines are less effective than the phenothiazines in controlling nausea and vomiting not related to vestibular stimulation.

Nausea and Vomiting of Pregnancy

Doxylamine succinate is used in fixed combination with pyridoxine hydrochloride for the management of nausea and vomiting of pregnancy in women who have not responded to conservative management.⁷⁰⁵ ⁷⁰⁶

Chemotherapy-induced Nausea and Vomiting

Some antihistamines (e.g., diphenhydramine) may be useful as adjunctive antiemetic agents to prevent chemotherapy-induced nausea and vomiting†; however, the American Society of Clinical Oncology currently does not recommend that antihistamines be used alone as antiemetic agents in patients receiving chemotherapy.⁶⁸⁰

Insomnia

Some antihistamines, especially the ethanolamines such as diphenhydramine and doxylamine, are used for their sedative effects as nighttime sleep aids.¹⁹⁷ ⁴⁰⁷ ⁴⁰⁸ The US Food and Drug Administration (FDA) states that diphenhydramine currently is the only antihistamine commercially available in the US that has been shown to be both safe and effective for self-medication as a nighttime sleep aid.⁴⁰⁷ In individuals who experience occasional sleeplessness or those who have difficulty falling asleep, diphenhydramine (administered as either the citrate or hydrochloride salt) is more effective than placebo in reducing sleep onset (i.e., time to fall asleep) and increasing the depth and quality of sleep.¹⁹⁷ ⁴⁰⁷ Although the safety and efficacy of doxylamine as a nighttime sleep aid have not been fully established,¹⁹⁷ ⁴⁰⁷ the FDA states that, pending further accumulation of data, doxylamine-containing nighttime sleep aids that have been approved for this use may continue to be marketed in the US.⁴⁰⁷ Some proprietary sleep aids also may continue to contain pyrilamine despite a lack of substantial evidence of safety and efficacy for use of this antihistamine as a nighttime sleep aid;¹⁹⁷ ⁴⁰⁷ however, many such preparations have been or are likely to be reformulated with other antihistamines (e.g., diphenhydramine).⁴⁰⁷

Other Systemic Uses

Some antihistamines such as diphenhydramine have been used effectively as antitussives. Diphenhydramine also may be useful in the management of tremor early in the course of parkinsonian syndrome⁶⁷³ ⁶⁷⁴ ⁶⁷⁵ and in the management of drug-induced extrapyramidal reactions.⁶⁷⁶

Topical and Other Local Uses

Diphenhydramine and tripelennamine (no longer commercially available in the US; extemporaneous formulation would be necessary) are used topically for temporary relief of pruritus and pain associated with various skin conditions including minor burns, sunburn, minor cuts or scrapes, insect bites, or minor skin irritations.¹⁹⁶ ³⁴⁹ The drugs may provide effective localized antipruritic activity when applied topically if pruritus and discomfort are histamine mediated; the weak local anesthetic action of the drugs also may contribute to the overall effect.³⁴⁹ However, many clinicians suggest that topical diphenhydramine not be used on large areas of the body or more often than directed,⁶⁷² since increased percutaneous absorption of the drug may occur that can result in systemic adverse effects and toxicity.⁵⁵⁶ ⁵⁵⁷ (See Acute Toxicity: Manifestations.) Topical diphenhydramine also should not be used for self-medication in the management of varicella (chickenpox) or measles without first consulting a clinician.⁶⁷²

Some antihistamines also have been used for their topical or local anesthetic effects in ophthalmic, urologic, proctologic, gastroscopic, otolaryngologic, and dental procedures. However, topical use of antihistamines generally is discouraged because sensitivity reactions (e.g., sensitization, hypersensitivity) may result.¹¹ ⁴⁴ ⁵⁰ ¹⁴⁹ ¹⁵¹ ³⁴⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ ³⁵⁹ ³⁶⁸ ³⁷⁹ ³⁸⁰ ⁴³⁶ (See Cautions: Sensitivity Reactions.) In addition, use of certain antihistamines (e.g., diphenhydramine) for local anesthesia via local infiltration also is discouraged because of the risk of local tissue necrosis.⁴¹¹ ⁴³⁷ If the drugs are used topically as antipruritics, therapy generally should be short-term (i.e., for no longer than 7 days) because of the increasing risk of sensitivity reactions from prolonged or repeated use.³⁴⁹ Antihistamines are more effective, especially if pruritus is generalized, and are less likely to cause sensitivity reactions when the drugs are administered systemically rather than applied topically.³⁴⁹

Antihistamines General Statement Dosage and Administration

Administration

Antihistamines usually are administered orally. Although some of these drugs may be given IV, IM, or subcutaneously, most antihistamines are not administered parenterally because they frequently cause local irritation. Some antihistamines also may be administered topically¹⁹⁶ ³⁴⁹ or intranasally.⁵²⁶ ⁵²⁷ ⁵²⁸ Topical use of antihistamines generally is discouraged since sensitivity reactions (e.g., sensitization, hypersensitivity) may result.¹¹ ⁴⁴ ⁵⁰ ¹⁴⁹ ¹⁵¹ ³⁴⁵ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ ³⁵⁹ ³⁶⁸ ³⁷⁹ ³⁸⁰ In addition, topical preparations containing diphenhydramine should not be used more often than directed for any condition, applied on large areas of the body, or used concomitantly with other preparations containing diphenhydramine, including those used orally,⁶⁷² since increased serum concentrations of diphenhydramine may occur that can result in CNS toxicity.⁵⁵⁶ ⁵⁷⁵ ⁵⁷⁶ (See Acute Toxicity: Manifestations.) Topical diphenhydramine also should not be used for self-medication in the management of varicella (chickenpox) or measles without first consulting a clinician.⁶⁷²

Dosage

Dosage of antihistamines should be individualized according to the patient’s response and tolerance.

Cautions for Antihistamines General Statement

Adverse effects, which vary in incidence and severity with the individual drug, are caused by all antihistamines, although serious toxicity rarely occurs. Individual patients vary in their susceptibility to the adverse effects of these drugs, and such effects may disappear despite continued therapy. Geriatric patients may be particularly susceptible to dizziness, sedation, and hypotension. Most mild reactions may be relieved by a reduction in dosage or changing to another antihistamine.

Severe cardiovascular effects, including prolongation of the QT interval, arrhythmias, cardiac effects, hypotension, palpitations, syncope, dizziness and/or death have been reported in patients receiving astemizole (no longer commercially available in the US) or terfenadine (no longer commercially available in the US).⁴¹³ ⁴¹⁴ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²² ⁴²³ ⁴³¹ ⁴³⁴ ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁶⁶ ⁴⁷⁶ ⁵¹⁴ These cardiotoxic effects usually were associated with higher than recommended dosages and/or increased plasma concentrations of the drugs and their active metabolites.⁴¹³ ⁴¹⁴ ⁴¹⁶ ⁴¹⁷ ⁴¹⁹ ⁴²¹ ⁴²⁴ ⁴²⁵ ⁴²⁶ ⁴²⁷ ⁴²⁸ ⁴²⁹ ⁴³⁰ ⁴³¹ ⁴³² ⁴³³ ⁴³⁴ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵³ ⁴⁵⁴ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶¹ ⁴⁶² ⁴⁶³ ⁴⁶⁴ ⁴⁶⁵ ⁴⁶⁶ ⁴⁷⁶ ⁵¹² ⁵¹⁴

CNS Effects

CNS depression is common with usual dosage of antihistamines, especially with the ethanolamine derivatives. Sedation, ranging from mild drowsiness to deep sleep, occurs most frequently; however, in the treatment of allergies, this effect may be therapeutically useful. Dizziness, lassitude, disturbed coordination, and muscular weakness may also occur. In some patients, the sedative effects disappear spontaneously after the antihistamine has been administered for 2–3 days. Individuals who perform potentially hazardous tasks requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle) should be warned about possible drowsiness, dizziness, or weakness.⁷⁰⁵ ⁷⁰⁶ Patients also should be warned to avoid consuming alcoholic beverages while taking antihistamines, since alcohol may potentiate these CNS effects.¹⁶⁹ ³⁵⁰ ³⁹⁰ ⁴⁰⁷ ⁵⁰⁹ ⁷⁰⁵ ⁷⁰⁶ In addition, patients already receiving other CNS depressants (e.g., sedatives, tranquilizers) should be warned not to undertake self-medication with an antihistamine without first consulting their clinician.³⁵⁰ ⁴⁰⁷ ⁴⁹¹ Patients using diphenhydramine or doxylamine for self-medication should be warned that the drugs may cause marked drowsiness.¹⁰⁰ ¹⁶⁹ ¹⁹⁷ ³⁵⁰ ³⁹⁰ Acrivastine, desloratadine, fexofenadine, loratadine, and, possibly, cetirizine and levocetirizine appear to cause fewer adverse CNS effects, including effects on psychomotor performance and reactivity, than other currently available (first generation) antihistamines and therefore commonly have been referred to as relatively “nonsedating” or second generation antihistamines.¹⁵⁴ ¹⁵⁵ ¹⁵⁶ ¹⁵⁹ ¹⁶⁵ ¹⁸⁰ ¹⁸¹ ¹⁸² ¹⁸³ ¹⁸⁴ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁰ ¹⁹¹ ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁵⁹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷² ⁴⁷³ ⁴⁹⁵ ⁴⁹⁶ ⁴⁹⁷ ⁴⁹⁸ ⁴⁹⁹ ⁵¹⁶ ⁵¹⁷ ⁵⁰⁹ ⁶⁹⁵ However, while most second generation antihistamines do not appear to potentiate the effects of CNS depressants, including alcohol,¹⁶¹ ¹⁹² ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁹⁷ ⁴⁹⁸ ⁴⁹⁹ acrivastine, cetirizine, and levocetirizine may potentiate such effects, although less prominently than first generation antihistamines.⁴⁹⁴ ⁴⁹⁸ ⁴⁹⁹ ⁵⁰⁹ ⁶⁸⁵

Some patients, especially children, receiving antihistamines may experience paradoxical excitement characterized by restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, and even seizures. There have been several reports of toxic psychosis in children who received concomitant oral and topical diphenhydramine for relief of pruritus associated with varicella (chickenpox), poison ivy, or sunburn.⁵⁵⁶ ⁵⁵⁷ ⁵⁷⁵ ⁵⁷⁶ (See Acute Toxicity: Manifestations.) In addition, central anticholinergic syndrome characterized by hallucinations, agitation, and confusion occurred in several children receiving usual or excessive dosages of cyproheptadine.⁶⁶² Patients should be warned that phenindamine may be particularly likely to occasionally cause insomnia and nervousness in some individuals.¹⁰⁰ ¹⁶⁹ ³⁵⁰ Antihistamines also may precipitate epileptiform seizures in patients with focal lesions of the cerebral cortex, and the drugs should be administered with caution in patients with seizure disorders.

An acute dystonic reaction, which consisted of trismus, difficulty in swallowing, dysarthria, rigidity, and motor incoordination, and was accompanied by mental confusion and tremors, was reported in at least 1 patient receiving IV diphenhydramine.⁴⁰⁹

GI and Hepatic Effects

Adverse GI effects of antihistamines include epigastric distress, anorexia, nausea, vomiting, diarrhea, or constipation. GI symptoms may be decreased by administering the drug with meals or with milk. Cholestasis,³⁹² ³⁹³ ³⁹⁵ hepatitis,³⁹² ³⁹³ ³⁹⁴ hepatic failure,³⁹¹ hepatic function abnormality,³⁹¹ and jaundice³⁹¹ ³⁹² ³⁹³ ³⁹⁴ ³⁹⁵ ³⁹⁶ have been reported rarely in patients receiving antihistamines (e.g., cyproheptadine, terfenadine).

Sensitivity Reactions

Antihistamines can cause sensitivity reactions (e.g., sensitization, hypersensitivity) following topical application¹¹ ⁴⁴ ⁵⁰ ¹⁴⁹ ¹⁵¹ ³⁴⁵ ³⁴⁹ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ ³⁵⁹ ³⁶⁰ ³⁶¹ ³⁶² ³⁶³ ³⁶⁴ ³⁶⁸ ³⁶⁹ ³⁷⁰ ³⁷⁹ ³⁸⁰ or systemic administration,⁵⁰ ¹⁴⁹ ¹⁵¹ ³⁴⁵ ³⁶⁰ ³⁶¹ ³⁶⁴ ³⁶⁹ ³⁷⁰ ³⁷⁹ ³⁸¹ ³⁸² ³⁸³ ³⁸⁸ ⁴³⁶ but such reactions are more likely following topical use of the drugs,¹⁴⁹ ¹⁵¹ ³⁴⁵ ³⁴⁹ ³⁵⁵ ³⁵⁶ ³⁶¹ ³⁶⁴ ³⁶⁹ ³⁷⁰ ³⁷⁹ especially ethylenediamine derivatives.⁴⁴ ⁵⁰ ³⁵⁵ ³⁵⁶ ³⁶¹ ³⁶² ³⁷⁹ ³⁸⁰ Antihistamines can act as haptens³⁴⁹ and cause IgE-mediated (type I) hypersensitivity reactions³⁴⁹ ³⁶⁹ ³⁸¹ ³⁸³ ³⁸⁸ or T cell-mediated (type IV) sensitization reactions.⁴⁴ ⁵⁰ ¹⁴⁹ ³⁴⁹ ³⁵⁵ ³⁵⁶ ³⁵⁹ ³⁶⁰ ³⁶¹ ³⁶² ³⁷⁹ Type I reactions appear to occur rarely, but type IV reactions occur more frequently, particularly following topical application of the drugs.¹⁴⁹ ³⁴⁹ ³⁵⁵ ³⁵⁶ ³⁶¹ ³⁶³ ³⁶⁴ ³⁶⁹ ³⁷⁹ ³⁸¹ ³⁸³ Sensitization following topical use of antihistamines results in allergic contact dermatitis, which may be manifested as eczema, pruritus, and inflammation, at the site of application.⁴⁴ ⁵⁰ ³⁴⁹ ³⁵⁵ ³⁵⁶ ³⁵⁹ ³⁶⁰ ³⁶¹ ³⁶² ³⁶³ ³⁶⁴ ³⁶⁸ ³⁷⁹ ³⁸⁰ Once local sensitization to an antihistamine occurs, the dermatitis can recur following subsequent topical or systemic exposure to the drug⁴⁴ ⁵⁰ ³⁵⁵ ³⁶⁰ ³⁶¹ ³⁶⁴ ³⁷⁹ or a chemically related drug (including local anesthetics).⁴⁴ ⁵⁰ ³⁵⁵ ³⁵⁶ ³⁶⁰ ³⁶¹ ³⁶⁴ ³⁷⁹ Photosensitivity (principally photoallergic dermatitis) reactions, which may be manifested as eczema, pruritus, papular rash, and erythema on exposed skin, also have occurred following topical³⁶⁵ ³⁶⁶ or systemic administration³⁶⁵ ³⁶⁷ ⁵⁰⁹ of antihistamines, and cross-sensitivity with chemically related drugs can occur.³⁶⁷

Cardiovascular Effects

Although antihistamines exhibit anticholinergic and local anesthetic effects, including quinidine-like effects on cardiac conduction, and certain drugs have been investigated for potential antiarrhythmic activity, adverse cardiovascular effects are uncommon and usually limited to overdosage situations. When adverse cardiac effects have occurred, they generally were characteristic anticholinergic and/or local anesthetic (quinidine-like) effects such as tachycardia, palpitation, ECG changes (e.g., widened QRS), and arrhythmias (e.g., extrasystole, heart block). Other cardiovascular effects reported with antihistamines include hypotension and hypertension; in some cases, hypotension may result in part from α-adrenergic blocking activity of the antihistamine.

Serious cardiac effects, including prolongation of the QT interval corrected for rate (QT_c), ST-U abnormalities, arrhythmias (e.g., ventricular tachycardia, atypical ventricular tachycardia [torsades de pointes], ventricular fibrillation, heart block), arrest, hypotension, palpitations, syncope, dizziness, and/or death (secondary to ventricular tachyarrhythmia), have been reported rarely in patients receiving terfenadine⁴¹³ ⁴¹⁴ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²² ⁴²³ ⁴³¹ ⁴³⁴ ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁶⁶ ⁴⁷⁶ ⁵¹⁴ or astemizole.⁴²⁴ ⁴²⁵ ⁴²⁶ ⁴²⁷ ⁴²⁸ ⁴²⁹ ⁴³⁰ ⁴³¹ ⁴³² ⁴³³ ⁴³⁴ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵³ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶¹ ⁴⁶² ⁴⁶³ ⁵⁰⁷ ⁵¹² Astemizole and terfenadine are no longer commercially available in the US.⁴⁵⁶ ⁶⁵⁹ ⁶⁶⁰ These cardiotoxic effects usually were associated with higher than recommended dosages and/or increased plasma concentrations of the drugs and their active metabolites,⁴¹³ ⁴¹⁴ ⁴¹⁶ ⁴¹⁷ ⁴¹⁹ ⁴²¹ ⁴²⁴ ⁴²⁵ ⁴²⁶ ⁴²⁷ ⁴²⁸ ⁴²⁹ ⁴³⁰ ⁴³¹ ⁴³² ⁴³³ ⁴³⁴ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵³ ⁴⁵⁹ ⁴⁶¹ ⁴⁶⁶ ⁴⁷⁶ ⁵¹⁴ although serious cardiac effects also have been reported occasionally at usual astemizole or terfenadine dosages.⁴¹³ ⁴¹⁴ ⁴¹⁷ ⁴¹⁸ ⁴²⁴ ⁴³³ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁶ ⁴⁵⁹ ⁴⁶¹ ⁴⁷⁶ ⁵¹² While patients with impaired liver function and, possibly, geriatric patients may have been at particular risk of accumulation of these antihistamines and associated cardiotoxic effects,⁴¹³ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²² ⁴²⁴ ⁴³³ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁶ ⁴⁵⁹ ⁴⁶⁶ ⁴⁷⁶ ⁵¹² these effects have been reported rarely in apparently healthy individuals with no associated risk factors.⁴¹³ ⁴¹⁴ ⁴¹⁷ ⁴¹⁸ ⁴⁷⁶

Patients who were receiving concomitant therapy with an azole (including imidazole derivative [e.g., ketoconazole] and triazole derivative [e.g., itraconazole]) antifungal, a macrolide (e.g., clarithromycin, erythromycin, troleandomycin) anti-infective, mibefradil (no longer commercially available in the US), quinine, or grapefruit juice also appeared to be at substantial risk of such toxicity, probably secondary to interference with metabolism of the antihistamine.⁴¹³ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²³ ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶⁶ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁴⁷⁹ ⁴⁸⁰ ⁴⁸⁷ ⁴⁹⁰ ⁵⁰⁷ ⁵¹¹ ⁵¹² ⁵¹³ ⁵¹⁵ ⁵¹⁸ ⁵⁴² ⁵⁴³ ⁵⁴⁴ In addition, concomitant use of terfenadine or astemizole with most human immunodeficiency virus (HIV) protease inhibitors, quinupristin and dalfopristin, zileuton, or serotonin-reuptake inhibitors has not been recommended since HIV protease inhibitors, quinupristin and dalfopristin, zileuton, and serotonin-reuptake inhibitors have been associated with increased plasma concentrations of these antihistamines and potentially serious and/or life-threatening adverse effects could have occurred as a result of these drugs’ effects on the metabolism of astemizole or terfenadine.⁴¹³ ⁵¹⁸ ⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁰ ⁵⁵¹ ⁵⁵² ⁵⁵³ ⁵⁵⁴ ⁵⁷⁴ ⁶⁶⁴

The potential for similar drug interactions and cardiac effects with loratadine remains to be elucidated more fully.⁴⁷⁰ ⁵⁰⁵ ⁵⁰⁶ However, acrivastine and loratadine have not been shown to prolong the QT interval when administered alone.⁴⁸⁷ Prolongation of the QT_c interval has been reported in a limited number of healthy adults receiving desloratadine dosages of 45 mg daily (9 times the recommended daily dosage) for 10 days; however, the manufacturer states that no clinically relevant adverse events were reported.⁶⁷⁰

The manufacturer of cetirizine states that no clinically important prolongation of the QT_c interval has been reported in healthy adult men receiving cetirizine during controlled clinical studies.⁵⁰⁹ The manufacturer of levocetirizine (the R enantiomer of cetirizine) states that no clinically important prolongation of the QT_c interval has been reported following administration of a single dose of levocetirizine.⁶⁸⁵ The effects of multiple-dose administration are not known, but levocetirizine is not expected to have clinically important effects on the QT_c interval based on results of QT_c studies with cetirizine and the lack of reports of QT_c interval prolongation during postmarketing surveillance of that drug.⁶⁸⁵ The manufacturer of cetirizine also states that concomitant administration of the antihistamine with drugs known to inhibit cytochrome P-450 microsomal enzymes (e.g., azithromycin, erythromycin, ketoconazole) has not been associated with clinically important changes in ECG parameters (e.g., QT_c intervals) and that no clinically important interactions have been reported in patients receiving cetirizine concomitantly with azithromycin, erythromycin, or ketoconazole.⁵⁰⁹ ⁵⁸⁰ ⁵⁸⁴

The manufacturer of fexofenadine states that no statistically significant mean increases in the QT_c interval have been reported in healthy adults or patients with seasonal allergic rhinitis receiving fexofenadine hydrochloride dosages up to 400 mg twice daily (for 6 days) or 60–240 mg twice daily (for 2 weeks), respectively, during controlled clinical studies.⁵¹⁶ ⁵¹⁷

The mechanism of the cardiotoxic effects of astemizole and terfenadine has not been fully understood,⁴¹⁷ ⁴²⁵ ⁴²⁶ ⁴⁶¹ ⁴⁶² ⁴⁶⁶ ⁴⁷⁶ and it appeared to be contrary to what would have been expected from studies on cardiac histamine H₁-receptors;⁴²⁶ ⁴³⁹ ⁴⁶³ ⁴⁶⁴ ⁴⁶⁵ the possibility that H₃-receptors (mediating a regulatory feedback mechanism) may have been involved had been suggested.⁴²⁶ Limited evidence from animal models using terfenadine has suggested that the cardiotoxic effects of the drug may have resulted at least in part from blockade of the potassium channel involved in repolarization of cardiac cells (i.e., blockade of the delayed rectifier potassium current I_K).⁴⁵⁵ ⁴⁶² ⁴⁷⁶ ⁵¹⁴ ⁵¹⁶ Unlike other antihistamines, anticholinergic and/or local anesthetic effects appeared to be unlikely causes of the cardiac effects of these 2 second generation (relatively “nonsedating”) antihistamines.⁴²⁶

It has been recommended that usual dosages of terfenadine (i.e., 60 mg twice daily) and astemizole (i.e., 10 mg daily) not be exceeded because of the risk of potentially life-threatening cardiotoxic effects.⁴¹³ ⁴¹⁷ ⁴¹⁹ ⁴³⁰ ⁴³³ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁹ ⁴⁷⁶ Because of this risk, patients were advised not to temporarily increase (e.g., double) the prescribed dosage in an attempt to accelerate or improve symptomatic relief provided by these drugs.⁴¹³ ⁴¹⁹ ⁴²⁴ ⁴³³ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁹ ⁴⁷⁶

Patients with hepatic impairment, geriatric patients, those receiving drugs or who had underlying conditions that might have prolonged the QT interval, and those who were receiving drugs that could have produced electrolyte abnormalities such as hypokalemia or hypomagnesemia may have been at increased risk of cardiac arrhythmias during terfenadine or astemizole therapy.⁴¹³ ⁴¹⁹ ⁴²⁴ ⁴³³ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁹ ⁴⁶⁶ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ Therefore, administration of these antihistamines was not recommended in such patients.⁴¹³ ⁴¹⁹ ⁴²⁴ ⁴³³ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁹ ⁴⁷⁶ ⁴⁷⁷ Terfenadine or astemizole also should not have been used in patients receiving a macrolide (e.g., clarithromycin, erythromycin, troleandomycin) anti-infective, an azole antifungal (including imidazole [e.g., itraconazole] and triazole [e.g., itraconazole] derivatives), or mibefradil; in addition, use of these antihistamines in patients receiving any other drug (e.g., quinine, most HIV protease inhibitors, serotonin-reuptake inhibitors, zileuton) that potentially could inhibit their metabolism was not recommended.⁴¹³ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁵ ⁴⁵⁹ ⁴⁶⁶ ⁴⁷⁵ ⁴⁷⁶ ⁴⁹⁰ ⁵⁰⁸ ⁵¹³ ⁵¹⁴ ⁵¹⁸ ⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁰ ⁵⁵¹ ⁵⁵² ⁵⁵³ ⁵⁵⁴ ⁵⁷⁴ It also has been recommended that astemizole or terfenadine not be taken with grapefruit juice.⁴¹³ ⁵¹² Concomitant administration of astemizole with therapeutic doses of quinine was contraindicated.⁵¹¹ ⁵¹² ⁵¹³ ⁵¹⁴

Other Adverse Effects

Adverse anticholinergic effects of antihistamines include dryness of mouth, nose, and throat; dysuria; urinary retention; impotence; vertigo; visual disturbances; blurred vision; diplopia; tinnitus; acute labyrinthitis; insomnia; tremors; nervousness; irritability; and facial dyskinesia. Tightness of the chest, thickening of bronchial secretions, wheezing, nasal stuffiness, sweating, chills, early menses, toxic psychosis, headache, faintness, and paresthesia have occurred.

Rarely, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, and pancytopenia have been reported in patients receiving some antihistamines. Increased appetite and/or weight gain also occurred in patients receiving antihistamines (cyproheptadine).

Precautions and Contraindications

Antihistamines having substantial anticholinergic activity (usually conventional [prototypical, first generation] including ethanolamines) should be administered with caution, if at all, in patients with angle-closure glaucoma, prostatic hypertrophy (which may result in difficulty in urination), stenosing peptic ulcer, pyloroduodenal obstruction, or bladder neck obstruction. Because it was suggested that the anticholinergic effect of antihistamines might reduce the volume and cause thickening of bronchial secretions and thus result in obstruction of respiratory passages, it had been recommended that the drugs be used with caution and only under the direction of a clinician in patients with asthma or chronic obstructive pulmonary disease if clearance of bronchial secretions was a problem.¹⁶⁹ ⁴⁶⁷ ⁴⁸⁷ While some clinicians¹⁰⁰ ⁴⁸¹ ⁴⁸² and manufacturers³²⁰ ³⁹¹ ⁴¹¹ ⁴⁸⁴ ⁴⁸⁷ continue to warn against use of the drugs in patients with asthma because of potential effects of anticholinergic activity on the volume and fluidity of bronchial secretions, most experts⁴⁶⁷ ⁴⁸⁶ ⁵⁰⁰ and clinicians³⁸² ⁴⁸¹ ⁴⁸² ⁴⁸⁴ ⁴⁸⁷ believe that there currently is little, if any, direct evidence of antihistamine-induced exacerbation of asthma secondary to bronchial drying nor substantiation for avoiding use of currently available antihistamines in asthmatic patients.⁴⁶⁷ ⁴⁸¹ ⁵⁰⁰ Antihistamines usually should not be used, unless under the direction of a clinician, in patients who have a breathing problem (e.g., emphysema, chronic bronchitis),⁴⁶⁷ ⁴⁸⁵ ⁴⁸⁶ and these drugs generally should not be used in asthmatics who previously experienced a serious antihistamine-induced adverse bronchopulmonary effect.⁴⁶⁷ ⁴⁸¹ ⁴⁶⁷ ⁴⁸¹ In addition, antihistamines should be used with caution in patients with increased intraocular pressure, hyperthyroidism, cardiovascular disease, or hypertension. The drugs are contraindicated in patients with asthmatic attacks. For self-medication, cough preparations containing an antihistamine (e.g., diphenhydramine) should not be used for persistent or chronic cough or breathing problems such as those occurring with smoking, asthma, chronic bronchitis, or emphysema, or for cough accompanied by excessive phlegm, unless directed by a clinician.⁵⁰¹ A persistent cough may be indicative of a serious condition.⁵⁰¹ If cough persists for more than one week, is recurrent, or is accompanied by fever, rash, or persistent headache, a clinician should be consulted.⁵⁰¹

Patients should be advised that CNS depression (e.g., drowsiness) is common with first generation antihistamines, even at usual dosages and particularly with ethanolamine derivatives. (See Cautions: CNS Effects.) In addition, patients should be warned that additive CNS depression may occur when first generation antihistamines or possibly, cetirizine or levocetirizine is administered concomitantly with other CNS depressants, including alcohol.⁶⁸⁵ (See Drug Interactions: CNS Depressants.) Patients receiving acrivastine, a second generation antihistamine, also should be warned of the possibility of such effects.⁴⁹⁴ ⁴⁹⁸ ⁴⁹⁹

Diphenhydramine toxicity (e.g., dilated pupils, facial flushing, hallucinations, ataxic gait, urinary retention) has been reported in pediatric patients following topical application of diphenhydramine to large areas of the body (often areas with broken skin) or following concomitant use of topical and oral preparations containing diphenhydramine.⁵⁵⁶ (See Acute Toxicity: Manifestations.) Therefore, the US Food and Drug Administration (FDA) and many clinicians warn that oral diphenhydramine should not be used concomitantly with any other preparations containing the drug, including those used topically.⁵⁵⁶ ⁶⁷² In addition, topical preparations containing diphenhydramine should not be used more often than directed for any condition, applied on large areas of the body, or used concomitantly with other preparations containing diphenhydramine, including those used orally,⁶⁷² since increased serum concentrations of diphenhydramine may occur that can result in CNS toxicity.⁵⁵⁶ ⁵⁵⁷ ⁵⁷⁵ ⁵⁷⁶ (See Acute Toxicity: Manifestations.) Patients should be advised to consult a clinician prior to use of topical diphenhydramine for the management of varicella (chickenpox) or measles.⁶⁷²

Although diphenhydramine appears to have low abuse potential, several children, adolescents, and at least one adult with chronic hematologic and antineoplastic diseases have exhibited drug-seeking behavior and anticholinergic effects after chronic intermittent rapid IV administration of the drug.⁶⁶¹

While astemizole and terfenadine were commercially available in the US, individuals receiving these second generation antihistamines were warned that patients with hepatic impairment (e.g., cirrhosis, hepatitis); geriatric patients; those who were concomitantly receiving an azole-derivative anti-infective (e.g., fluconazole, itraconazole, ketoconazole, metronidazole, miconazole), a macrolide antibiotic (e.g., clarithromycin, erythromycin, troleandomycin), mibefradil (no longer commercially available in the US), or other potent inhibitors of the cytochrome P-450 isoenzyme (CYP3A) (including most HIV protease inhibitors, quinupristin and dalfopristin, zileuton, or serotonin-reuptake inhibitors) responsible for the metabolism of astemizole or terfenadine (see Drug Interactions); those who were having underlying conditions that might prolong the QT interval corrected for rate (QT_c) (e.g., hypokalemia, hypomagnesemia, bradycardia, congenital QT syndrome); those who were receiving drugs that might prolong the QT_c interval (e.g., certain antiarrhythmic agents, bepridil hydrochloride, certain psychotropic agents, probucol [no longer commercially available in the US], cisapride, sparfloxacin, pentamidine); or those who were receiving drugs (e.g., diuretics) that could produce electrolyte abnormalities, such as hypokalemia or hypomagnesemia, may have experienced prolongation of the QT_c interval and may have been at increased risk of cardiac arrhythmias (e.g., ventricular tachycardia, atypical ventricular tachycardia [torsades de pointes], ventricular fibrillation) when they were receiving recommended dosages of astemizole or terfenadine.⁴¹⁶ ⁴³⁴ ⁴⁵⁷ ⁴⁵⁸ ⁴⁶⁶ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁴⁷⁸ ⁵¹² ⁵¹⁵ ⁵⁹⁴ ⁵⁹⁵ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶¹⁵ ⁶⁴³ ⁶⁴⁵ ⁶⁴⁶ ⁶⁵⁸ ⁶⁶⁴ Therefore, administration of astemizole or terfenadine was not recommended in such patients.⁴³⁴ ⁴⁷⁷ ⁵¹² ⁵⁹⁴ ⁵⁹⁷ ⁶⁰⁵ ⁶⁰⁶ ⁶⁴³ ⁶⁶⁴

In addition, astemizole or terfenadine was contraindicated in patients with disease states (e.g., severe hepatic impairment) or receiving concomitant therapy (e.g., itraconazole, ketoconazole, clarithromycin, erythromycin, troleandomycin, mibefradil) known to impair metabolism of the antihistamine.⁴¹⁹ ⁴⁴³ ⁴⁷⁷ ⁵¹⁰ ⁵¹² ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶³⁴ Astemizole also was contraindicated in patients receiving concomitant therapy with quinine.⁵¹²

Pediatric Precautions

Antihistamines should not be administered to premature or full-term neonates. Young children may be more susceptible than adults to the toxic effects of antihistamines.³⁰⁷ ³⁰⁸ (See Acute Toxicity.) Adults responsible for the supervision of a child receiving an antihistamine should be warned that children may be at increased risk for experiencing CNS stimulant effects with antihistamines.¹⁰⁰ ¹⁶⁹ ³⁰⁷ (See Cautions: CNS Effects.) Although the relationship and possible mechanism(s) have not been elucidated,²⁰³ ²⁰⁴ ²⁰⁵ ²⁰⁶ ²⁰⁷ respiratory depression, sleep apnea, and sudden infant death syndrome (SIDS) have occurred in a number of infants and young children who were receiving usual dosages of phenothiazine-derivative antihistamines (i.e., promethazine, trimeprazine [no longer commercially available in the US]).²⁰² ²⁰³ ²⁰⁶ ²⁰⁷ In addition, death has been reported in children younger than 2 years of age receiving carbinoxamine-containing preparations⁶⁹⁶ ⁶⁹⁷ or cough and cold preparations containing an antihistamine with or without other agents (e.g., cough suppressants, expectorants, nasal decongestants).⁶⁹³

In a report published by the US Centers for Disease Control and Prevention (CDC), cough and cold preparations containing carbinoxamine, pseudoephedrine, acetaminophen, and/or dextromethorphan were determined by medical examiners or coroners to be the underlying cause of death in 3 infants 6 months of age or younger during 2005.⁶⁹³ ⁶⁹⁴ The actual cause of death might have been overdosage of one drug, interaction of different drugs, an underlying medical condition, or a combination of drugs and underlying medical conditions.⁶⁹³ In addition, an estimated 1519 children younger than 2 years of age were treated in emergency departments in the US during 2004–2005 for adverse events, including overdoses, associated with cold and cough preparations.⁶⁹³

The dosages at which cold and cough preparations can cause illness or death in pediatric patients younger than 2 years of age are not known, and there are no specific dosage recommendations (i.e., approved by the US Food and Drug Administration [FDA]) for the symptomatic treatment of cold and cough for patients in this age group.⁶⁹³ Because of the absence of dosage recommendations, limited published evidence of effectiveness, and risks for toxicity (including fatal overdosage).⁶⁹³ ⁶⁹⁴ FDA stated that nonprescription cough and cold preparations should not be used in children younger than 2 years of age;⁶⁹⁹ the agency continues to assess safety and efficacy of these preparations in older children.⁷⁰² ⁷⁰⁴ Meanwhile, because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations agreed to voluntarily revise the product labeling to state that such preparations should not be used in children younger than 4 years of age.⁷⁰¹ ⁷⁰² ⁷⁰³ ⁷⁰⁴ FDA recommends that parents and caregivers adhere to the dosage instructions and warnings on the product labeling that accompanies the preparation if administering to children and consult with their clinician about any concerns.⁷⁰¹ ⁷⁰² ⁷⁰³ Clinicians should ask caregivers about use of nonprescription cough and cold preparations to avoid overdosage.⁶⁹³

Because antihistamines may cause drowsiness that can be potentiated by other CNS depressants (e.g., sedatives, tranquilizers), an antihistamine should be used in children receiving one of these drugs only under the direction of a clinician.³⁵⁰ Antihistamines should not be used in children who have a breathing problem (e.g., chronic bronchitis) or glaucoma unless otherwise directed by a clinician.⁴⁸⁵ It also has been recommended that antihistamines not be used in children with asthma, liver disease, or seizure disorder unless under the direction of a clinician.³⁹⁰ Overdosage of doxylamine has been reported in children.⁷⁰⁵ ⁷⁰⁶ Manifestations of doxylamine overdosage in children have included coma, generalized tonic-clonic (grand mal) seizures, cardiorespiratory arrest, and death.⁷⁰⁵ ⁷⁰⁶ Children appear to be at high risk for cardiorespiratory arrest secondary to doxylamine overdosage.⁷⁰⁵ ⁷⁰⁶ For additional information, see the individual monographs in 4:00.

Acute toxicity has been reported in pediatric patients following topical application of diphenhydramine to large areas of the body (often areas with broken skin) or following concomitant use of topical and oral preparations containing diphenhydramine.⁵⁵⁶ (See Cautions: Precautions and Contraindications, and also see Acute Toxicity.)

While it is desirable to avoid the use of alcohol-containing antihistamine preparations in children because of potential toxicity,¹⁰⁰ ³⁹⁰ ⁴⁰³ inclusion of alcohol in some preparations may be a pharmaceutical necessity (e.g., as a solvent) and therefore complete avoidance of such preparations may not be possible.³⁹⁰ ⁴⁰³ According to a final rule issued in 1995 by FDA, over-the-counter (OTC) oral preparations intended for use in children younger than 6 years of age, children 6–11 years of age, or children 12 years of age and older may contain up to 0.5, 5, or 10% alcohol, respectively.⁶⁷⁸ ⁶⁷⁹

Pregnancy and Lactation

Pregnancy

Antihistamines should not be used in women who are or may become pregnant unless the potential benefits justify the possible risks to the fetus. Some manufacturers caution that antihistamines should not be used during the third trimester because of the risk of severe reactions (e.g., seizures) to the drugs in neonates and premature infants.¹⁴³ ³²⁰ For additional information, see the individual monographs in 4:00.

Doxylamine succinate in fixed combination with pyridoxine hydrochloride is intended for use in the management of nausea and vomiting of pregnancy.⁷⁰⁵ ⁷⁰⁶ ⁷¹⁰ Historically, there was considerable controversy regarding the teratogenic potential, if any, of doxylamine succinate;¹⁶⁹ ²⁶⁸ ²⁶⁹ ²⁷⁰ ²⁷¹ ²⁷³ ²⁷⁴ ²⁷⁵ ²⁷⁶ ²⁷⁷ ²⁷⁸ ²⁷⁹ ²⁸⁰ ²⁸¹ ²⁸² ²⁸³ ²⁸⁴ ²⁸⁵ ²⁸⁶ ²⁸⁷ ²⁸⁸ ²⁸⁹ ²⁹⁰ ²⁹¹ ²⁹² ²⁹³ ²⁹⁴ ²⁹⁵ ²⁹⁶ ²⁹⁷ ²⁹⁸ ²⁹⁹ ³⁰⁰ ³⁰¹ ³⁰² ³⁰³ ³⁰⁴ ³⁰⁵ ³⁰⁶ ³⁵⁰ however, after evaluating extensive data and information concerning the possible teratogenicity of the drug, FDA concluded that it is unlikely that doxylamine succinate is teratogenic.³⁵⁰ In addition, FDA states that the removal of products containing doxylamine succinate that previously were commercially available for the management of nausea and vomiting of pregnancy was not for reasons of safety or effectiveness.⁷⁰⁹ Numerous epidemiologic studies (including cohort studies, case-control studies, and meta-analyses) have been performed to investigate possible teratogenic effects of doxylamine succinate in fixed combination with pyridoxine hydrochloride in pregnant women and have found no evidence of an increased risk of fetal malformations.⁷⁰⁵ ⁷⁰⁶ ⁷¹¹ ⁷¹²

Lactation

Most manufacturers state that antihistamines should not be administered to nursing women, since the drugs may inhibit lactation and small amounts appear to be distributed into milk. Adverse effects (e.g., excitement, irritability, and sedation) have been reported in infants presumably exposed to antihistamines (e.g., doxylamine) through human milk.⁷⁰⁵ ⁷⁰⁶ Infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of antihistamines (e.g., doxylamine).⁷⁰⁵ ⁷⁰⁶

Because of the potential for serious adverse reactions (e.g., CNS effects) to antihistamines in nursing infants, a decision should be made whether to discontinue nursing or antihistamines, taking into account the importance of the drugs to the woman. The manufacturer of doxylamine in fixed combination with pyridoxine states that this preparation should notbe used in nursing women.⁷⁰⁵ ⁷⁰⁶

Drug Interactions

CNS Depressants

Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol. If antihistamines are used concomitantly with other depressant drugs, caution should be used to avoid overdosage. Patients should be advised to avoid alcoholic beverages during antihistamine therapy.³⁵⁰ ⁴⁰⁷ ⁵⁸⁵ ⁵⁸⁶ Patients already receiving another CNS depressant (e.g., sedatives, tranquilizers) should not undertake self-medication with an antihistamine without first consulting a physician.³⁵⁰ ⁴⁰⁷ ⁵⁸⁵ ⁵⁸⁶ Unlike first generation antihistamines, most second generation antihistamines (e.g., astemizole [no longer commercially available in the US], loratadine, terfenadine [no longer commercially available in the US]) do not appear to potentiate the sedative effects of CNS depressants;¹⁶¹ ¹⁹² ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁵⁶ ⁴⁹⁷ ⁴⁹⁸ ⁴⁹⁹ ⁶⁵⁹ ⁶⁶⁰ however, acrivastine, cetirizine, and levocetirizine, which also have been classified as second generation antihistamines, may potentiate such effects, although less prominently than first generation antihistamines.⁴⁹⁴ ⁴⁹⁸ ⁴⁹⁹ ⁵⁰⁹ ⁶⁸⁵

It also should be considered that monoamine oxidase (MAO) inhibitors may prolong and intensify some anticholinergic effects (e.g., dryness) of antihistamines.⁷⁰⁵ ⁷⁰⁶ The manufacturer of doxylamine in fixed combination with pyridoxine hydrochloride states that the drug is contraindicated in patients receiving MAO inhibitors.⁷⁰⁵ ⁷⁰⁶

Epinephrine

Phenothiazine-type antihistamines (e.g., methdilazine [no longer commercially available in the US], promethazine, trimeprazine [no longer commercially available in the US]) may block and reverse the vasopressor effect of epinephrine. If patients receiving phenothiazines require a vasopressor agent, norepinephrine or phenylephrine should be used; epinephrine should not be used.

Drugs and Foods Affecting Hepatic Microsomal Enzymes

Concomitant administration of astemizole or terfenadine with drugs that can inhibit the metabolism of these antihistamines has resulted in accumulation of potentially cardiotoxic concentrations of astemizole or terfenadine and/or their active metabolites.⁴¹³ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁴ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶⁶ ⁴⁷⁷ ⁵⁰⁸ (See Cautions: Cardiovascular Effects.) Both human and animal data have indicated that associated cardiotoxic effects resulted principally from accumulation of unchanged astemizole (and its main metabolite desmethylastemizole) or unchanged terfenadine.⁴⁶⁶ ⁴⁷⁶ ⁴⁷⁷ ⁴⁷⁸ ⁵¹² ⁵⁴¹ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶¹⁵ ⁶¹⁶ ⁶¹⁷ ⁶³⁸

Serious, potentially life-threatening cardiac effects have occurred when astemizole or terfenadine was used concomitantly with certain azole antifungal (including imidazole derivative [e.g., ketoconazole] and triazole derivative [e.g., itraconazole]) or macrolide (e.g., clarithromycin, erythromycin, troleandomycin) anti-infectives, mibefradil (no longer commercially available in the US), or quinine sulfate (a single dose of 430 mg), probably secondary to inhibition of metabolism of the antihistamine by these drugs.⁴¹³ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²³ ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁴ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶⁶ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁴⁹⁰ ⁵⁰⁸ ⁵¹¹ ⁵¹² ⁵¹³ ⁵¹⁴ ⁵¹⁵ Therefore, while astemizole or terfenadine was commercially available in the US,⁴⁵⁶ ⁶⁵⁹ ⁶⁶⁰ concomitant therapy with these or other known inhibitors of astemizole or terfenadine metabolism was contraindicated.⁴¹⁶ ⁴¹⁸ ⁴¹⁹ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁷⁷ ⁵¹² ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶⁴³ No clinically adverse effects or changes in the QT_c intervals were reported after concomitant administration of erythromycin or ketoconazole with fexofenadine, the active metabolite of terfenadine.⁵¹⁶ ⁵¹⁷ The increased safety profile of fexofenadine compared with the parent drug, terfenadine, may result from the lack of fexofenadine-induced cardiotoxicity in addition to only minimal metabolism of fexofenadine in the liver by the cytochrome P-450 microsomal enzyme system.⁵¹⁴ ⁵¹⁶ ⁵¹⁷

Concomitant use of terfenadine or astemizole with other chemically related azole-derivative anti-infective (e.g., fluconazole, miconazole, metronidazole), most human immunodeficiency virus (HIV) protease inhibitors, quinupristin and dalfopristin, zileuton, or serotonin-reuptake inhibitors has not been recommended since these drugs may have increased plasma concentrations of terfenadine and/or astemizole and potentially serious and/or life-threatening adverse effects could have occurred.⁴¹³ ⁵¹⁸ ⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁰ ⁵⁵¹ ⁵⁵² ⁵⁵³ ⁵⁵⁴ ⁵⁷⁴ ⁶⁶⁴

Grapefruit juice also may have inhibited metabolism of terfenadine.⁴¹³ ⁵¹⁴ ⁵¹⁸ ⁵⁴¹ ⁵⁴⁴ ⁵⁵⁵ Increased oral bioavailability of unchanged terfenadine observed with concomitant administration of the drug and grapefruit juice has been associated with prolongation of the QT interval averaging 3.3% (range: -1.6 to 9.5%);⁵⁴¹ mean QT interval corrected for rate (QT_c) increased by 4–14 msec compared with administration of terfenadine with water.⁴¹³ ⁵¹⁴ ⁵¹⁸ ⁵⁴¹ ⁵⁴⁴ ⁵⁵⁵ Therefore, it has been recommended that astemizole or terfenadine not be taken concomitantly with grapefruit juice.⁵¹² ⁵⁹⁶ ⁶⁰⁷

Ketoconazole and Other Azole Antifungal Agents

Prolongation of the QT interval and QT interval corrected for rate (QT_c) and, rarely, serious cardiovascular effects, including arrhythmias (e.g., ventricular tachycardia, atypical ventricular tachycardia [torsades de pointes, ventricular fibrillation]), cardiac arrest, palpitations, hypotension, dizziness, syncope, and death, have been reported in patients receiving recommended dosages of astemizole or terfenadine concomitantly with ketoconazole.⁴¹⁶ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴³⁴ ⁴⁴³ ⁴⁵⁸ ⁴⁷⁵ ⁴⁷⁶ ⁵¹² ⁵¹⁵ ⁵⁹⁴ ⁵⁹⁵ ⁵⁹⁶ ⁵⁹⁷ ⁵⁹⁸ ⁵⁹⁹ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶⁴³ Ketoconazole has markedly inhibited the metabolism of astemizole or terfenadine, probably via inhibition of the cytochrome P-450 microsomal enzyme system, which resulted in increased plasma concentrations of unchanged astemizole (and its principal metabolite desmethylastemizole) or unchanged terfenadine; clearance of the active carboxylic acid metabolite of terfenadine also may have been reduced.⁴³⁴ ⁴⁵⁸ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁵¹² ⁵⁹⁷ ⁵⁹⁸ ⁶⁰⁵ ⁶⁴³ Increased plasma concentrations of unchanged astemizole (and its principal metabolite desmethylastemizole) or unchanged terfenadine has been associated with prolongation of the QT and QT_c intervals.⁴¹⁶ ⁴¹⁹ ⁴²⁰ ⁴⁴³ ⁴⁵⁸ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁵¹² ⁵⁹⁴ ⁵⁹⁷ ⁵⁹⁹ ⁶⁰⁵ ⁶⁴³ Similar alterations in astemizole or terfenadine pharmacokinetics and adverse cardiac effects (prolongation of the QT_c interval, cardiac arrest, and ventricular arrhythmias [e.g., torsades de pointes]) have been reported in patients receiving the antihistamine concomitantly with itraconazole.⁴⁵⁷ ⁴⁷⁷ ⁴⁷⁸ ⁴⁹⁰ ⁵¹² ⁵⁹⁴ ⁵⁹⁶ ⁶⁰⁵ ⁶⁰⁷ ⁶¹² Therefore, while commercially available in the US,⁴⁵⁶ ⁶⁵⁹ ⁶⁶⁰ astemizole and terfenadine were contraindicated in patients receiving ketoconazole or itraconazole.⁴¹⁸ ⁴⁵⁷ ⁴⁵⁸ ⁴⁷⁷ ⁵¹² ⁵¹⁵ ⁵⁹⁴ ⁶⁰⁵ ⁶⁴³ In addition, it has been recommended that astemizole and terfenadine also not be used in patients receiving drugs that are structurally related to these antifungals (e.g., triazoles such as fluconazole, imidazoles such as miconazole, nitroimidazoles such as metronidazole).⁵¹² ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁷

Increased plasma concentrations of loratadine and its active metabolite desloratadine (descarboethoxyloratadine) also have been reported in controlled clinical studies in healthy men receiving 10 mg of loratadine once daily concomitantly with ketoconazole dosages of 200 mg every 12 hours.⁴⁷⁰ ⁵⁰² In these studies, area under the plasma concentration-time curve (AUC) of loratadine increased by 307% following concomitant administration with ketoconazole while AUC of desloratadine increased by 73% following concomitant administration with ketoconazole.⁴⁷⁰ ⁵⁰² However, no clinically important changes, as measured by ECG and laboratory evaluations, vital signs, and adverse effects, were reported after concomitant administration of ketoconazole with loratadine.⁴⁷⁰ In addition, no changes in QT_c intervals, sedation, or syncope were reported in these individuals.⁴⁷⁰ ⁵⁰² Plasma concentrations of ketoconazole appeared to be unchanged in individuals receiving loratadine concomitantly.⁴⁷⁰ In addition, increased plasma concentrations of loratadine (AUC increased by 180%) and desloratadine (AUC increased by 56%) have been reported in a limited number of individuals receiving a single 20-mg dose of loratadine concomitantly with a ketoconazole dosage of 200 mg twice daily.⁴⁸⁸ ⁵⁰² However, no changes in QT_c intervals were reported 2, 6, and 24 hours after concomitant administration of the drugs.⁴⁸⁸ ⁵⁰² Adverse effects were similar in individuals receiving loratadine alone compared with those receiving loratadine concomitantly with ketoconazole.⁴⁸⁸ ⁵⁰²

The manufacturer of cetirizine states that no clinically important drug interactions have been reported in patients receiving cetirizine concomitantly with ketoconazole.⁵⁰⁹

Increased plasma concentrations of fexofenadine have been reported in 2 studies in healthy individuals receiving 120 mg of fexofenadine twice daily concomitantly with ketoconazole 400 mg once daily.⁵¹⁶ In these studies, AUC of fexofenadine increased by 164% following concomitant administration with ketoconazole while peak plasma concentrations of fexofenadine increased by 135%.⁵¹⁶ However, no clinically important adverse effects or changes in the QT_c intervals were reported after concomitant administration of ketoconazole with fexofenadine.⁵¹⁶ ⁵¹⁷

Macrolides

Erythromycin and clarithromycin have altered the metabolism of astemizole or terfenadine.⁴¹⁹ ⁴³⁴ ⁴⁴³ ⁴⁴⁵ ⁴⁶⁶ ⁴⁷⁷ ⁵⁰⁷ ⁵¹² ⁵¹⁵ ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁶ ⁶⁰⁷ ⁶¹³ ⁶⁴³ In some individuals, concomitant administration of erythromycin with astemizole or terfenadine has resulted in increased plasma concentrations of unchanged astemizole (and its principal metabolite desmethylastemizole) or unchanged terfenadine (and its active carboxylic metabolite fexofenadine).⁵¹² ⁵⁹⁶ ⁶⁰⁶ ⁶⁰⁷ Prolongation of the QT_c, ST-U abnormalities, and ventricular tachycardia, including torsades de pointes, have been reported in some patients receiving astemizole or terfenadine concomitantly with erythromycin or the structurally related macrolides clarithromycin, troleandomycin, or josamycin.⁴¹⁶ ⁴³⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁶⁶ ⁴⁷⁶ ⁵⁰⁷ ⁵¹² ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁶ ⁶⁰⁷ ⁶⁵⁵ Cardiac arrest and death have occurred in patients receiving erythromycin concomitantly with astemizole or terfenadine.⁵¹⁰ ⁵¹² ⁶⁰⁶ Therefore, while commercially available in the US,⁴⁵⁶ ⁶⁵⁹ ⁶⁶⁰ astemizole or terfenadine was contraindicated in patients receiving clarithromycin, erythromycin, or troleandomycin.⁴¹⁶ ⁴¹⁸ ⁴⁴⁶ ⁴⁴⁸ ⁴⁴⁹ ⁴⁷⁷ ⁵¹² ⁵¹⁵ ⁵⁸² ⁵⁹⁴ ⁶⁰⁶ ⁶¹³ ⁶⁵⁵

Limited data have suggested that azithromycin⁶⁰⁶ ⁶⁰⁷ ⁶⁰⁸ ⁶¹⁰ ⁶¹¹ ⁶³² and dirithromycin⁶⁰⁶ ⁶⁰⁹ ⁶³³ did not appear to alter the metabolism of terfenadine.⁵⁹³ ⁶⁰⁶ ⁶⁰⁸ ⁶⁰⁹ ⁶¹⁰ ⁶¹¹ ⁶³³

Increased plasma concentrations of loratadine and its active metabolite desloratadine have been reported in controlled clinical studies in healthy men receiving 10 mg of loratadine once daily concomitantly with erythromycin dosages of 500 mg every 8 hours for 10 days.⁴⁷⁰ ⁵⁰² ⁵⁰³ In these studies, AUC of loratadine increased by 40% following concomitant administration with erythromycin, while AUC of desloratadine increased by 46%.⁴⁷⁰ ⁵⁰² ⁵⁰³ However, no clinically important changes, as measured by ECG and laboratory evaluations, vital signs, and adverse effects, were reported after concomitant administration of erythromycin with loratadine.⁴⁷⁰ ⁵⁰³ In addition, no changes in QT_c intervals, sedation, or syncope were reported in these individuals.⁴⁷⁰ ⁵⁰² ⁵⁰³ Although the clinical importance has not been established, decreased plasma concentrations of erythromycin (AUC decreased by 15–18%) have been reported in these patients receiving loratadine concomitantly.⁴⁷⁰ ⁵⁰³

Increased plasma concentrations of loratadine and desloratadine also have been reported in a controlled drug interaction study in healthy men receiving 10 mg of loratadine every 24 hours concomitantly with clarithromycin dosages of 500 mg every 12 hours for 10 days.⁶⁶³ In this study, peak steady-state plasma concentrations and AUC of loratadine increased by 36 and 76%, respectively, following concomitant administration with clarithromycin for 10 days while peak steady-state plasma concentrations and AUC of desloratadine increased by 69 and 49%, respectively, compared with administration of loratadine alone.⁶⁶³ Although mean maximum QT_c interval was modestly increased (by less than 3% and not exceeding 439 msec) when loratadine was administered concomitantly with clarithromycin, such increase was similar to that observed when loratadine was administered alone and probably was not clinically important.⁶⁶³ The pharmacokinetics of clarithromycin were not affected by concomitant loratadine.⁶⁶³

Increased plasma concentrations of desloratadine and 3-hydroxydesloratadine have been reported in a controlled clinical study in healthy individuals receiving 7.5 mg of desloratadine once daily concomitantly with erythromycin dosages of 500 mg every 8 hours for 10 days.⁶⁷⁰ In this study, AUC of desloratadine or 3-hydroxydesloratadine increased by 14 or 40%, respectively, while peak plasma concentrations increased by 24 or 43%, respectively, following concomitant administration with erythromycin.⁶⁷⁰ In another study in healthy individuals receiving 5 mg of desloratadine once daily concomitantly with azithromycin (500 mg followed by 250 mg once daily for 4 days), AUC of desloratadine or 3-hydroxydesloratadine increased by 5 or 4%, respectively, while peak plasma concentrations increased by 15%.⁶⁷⁰ However, no clinically important changes, as measured by ECG and laboratory evaluations, vital signs, and adverse effects, were reported after concomitant administration of erythromycin or azithromycin with desloratadine.⁶⁷⁰

The manufacturer of cetirizine states that no clinically important drug interactions have been reported in patients receiving cetirizine concomitantly with azithromycin or erythromycin.⁵⁰⁹

Increased plasma concentrations of fexofenadine have been reported in 2 studies in healthy individuals receiving 120 mg of fexofenadine twice daily concomitantly with erythromycin dosages of 500 mg every 8 hours.⁵¹⁶ In these studies, AUC of fexofenadine increased by 109% following concomitant administration with erythromycin, while peak plasma concentrations of fexofenadine increased by 82%.⁵¹⁶ However, no clinically important adverse effects or changes in the QT_c intervals were reported after concomitant administration of erythromycin with fexofenadine.⁵¹⁶ ⁵¹⁷

HIV Protease Inhibitors

In vitro, ritonavir has been shown to inhibit the metabolism of terfenadine, but the clinical importance of this in vitro finding is not known.⁵⁹⁶ ⁶⁰⁷ Several manufacturers of HIV protease inhibitors and some clinicians state that specific in vivo pharmacokinetic drug interaction studies between these antihistamines and HIV protease inhibitors currently are not available.⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁴ Concomitant use of astemizole or terfenadine with HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir) has not been recommended,⁵¹² ⁵⁸² ⁵⁹⁶ ⁶⁰⁷ because of the theoretical risk that the HIV protease inhibitor could produce substantially increased plasma concentrations of unchanged astemizole or terfenadine resulting in potentially serious and/or life-threatening adverse effects.⁵¹² ⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁴ The manufacturers of indinavir and ritonavir state that concomitant use of either drug with astemizole or terfenadine is contraindicated because such use may precipitate potentially life-threatening adverse effects.⁶⁵⁶ ⁶⁵⁷

Serotonin-reuptake Inhibitors

In vitro, fluvoxamine, nefazodone, or sertraline and/or their metabolites have been shown to inhibit metabolism of terfenadine probably secondary to inhibition of the cytochrome P-450 (CYP34A) enzyme system, but the clinical importance of these in vitro findings is not known.⁵⁵³ ⁵⁹⁶ ⁶⁰⁷ ⁶⁴¹ Concomitant administration of astemizole or terfenadine and any of the serotonin-reuptake inhibitors (i.e., fluoxetine, fluvoxamine, nefazodone, paroxetine, sertraline) has not been recommended since substantially increased plasma concentrations of unchanged astemizole or terfenadine could occur resulting in an increased risk of serious adverse cardiac effects.⁵¹² ⁵⁵³ ⁵⁸² ⁵⁹⁶ ⁶⁰⁷ The manufacturer of fluvoxamine and some clinicians state that concomitant use of the antidepressant with terfenadine or astemizole is contraindicated.⁵⁵¹ ⁵⁵² However, at least one manufacturer (i.e., of sertraline) states that in vivo drug interaction studies with sertraline and terfenadine have failed to confirm any important alteration in plasma terfenadine concentrations by the antidepressant and that a clinically important interaction is unlikely.⁶⁴⁷

Increased plasma concentrations of desloratadine and 3-hydroxydesloratadine have been reported in a controlled clinical study in healthy individuals who were pretreated with fluoxetine for 23 days prior to receiving 5 mg of desloratadine once daily concomitantly with fluoxetine 20 mg once daily for 7 days.⁶⁷⁰ In this study, peak plasma concentrations of desloratadine or 3-hydroxydesloratadine increased by 15 or 17%, respectively, while AUC of 3-hydroxydesloratadine increased by 13%, following concomitant administration with fluoxetine.⁶⁷⁰ However, no clinically important changes, as measured by ECG and laboratory evaluations, vital signs, and adverse effects, were reported after concomitant administration of fluoxetine with desloratadine.⁶⁷⁰

Zileuton

Increased plasma concentrations of terfenadine have been reported in one study in healthy individuals receiving 60 mg of terfenadine every 12 hours concomitantly with zileuton dosages of 600 mg every 6 hours for 7 days.⁵⁷⁴ ⁵⁹⁶ ⁶⁰⁷ In this study, AUC and peak plasma concentrations of terfenadine increased by about 35%, resulting from a 22% decrease in the clearance of unchanged terfenadine.⁵⁷⁴ ⁵⁹⁶ ⁶⁰⁷ Although no adverse cardiac effects (e.g., substantial changes in QT_c intervals) were reported in these individuals, concomitant administration of astemizole or terfenadine with zileuton is not recommended since pharmacokinetics of the antihistamines may be impaired resulting in an increased risk of serious adverse cardiac effects.⁵¹² ⁵⁷⁴ ⁵⁸² ⁵⁹⁶ ⁶⁰⁷

Quinine and Chemically Related Drugs

There has been some evidence indicating that quinine may alter the pharmacokinetics of astemizole.⁵¹¹ ⁵¹² ⁶¹⁴ Quinine is extensively metabolized in the liver; however, only limited information exists about the specific cytochrome P-450 microsomal isoenzymes responsible for the drug’s metabolism.⁶¹⁵ Increased plasma concentrations of astemizole and desmethylastemizole were reported in a study in healthy men receiving 10 mg of astemizole orally once daily for 24 days and 20 mg of quinine sulfate every 4 hours for 4 consecutive doses on the 22nd day and then a single 430-mg dose on the 24th day of the study.⁶¹⁴ In this study, slight increases in the maximum plasma concentration and AUC of astemizole were associated with concomitant administration of the 20-mg doses of quinine sulfate; however, no clinically or statistically significant changes in QT interval were observed.⁶¹⁴ Maximum plasma concentrations and AUCs of astemizole and desmethylastemizole increased threefold following concomitant administration of the antihistamine and the 430-mg dose of quinine sulfate; these increases were associated with increases in the QT interval.⁶¹⁴ Therefore, the manufacturer of astemizole has stated that concomitant administration of astemizole and therapeutic doses (i.e., more than 80 mg daily) of quinine sulfate were contraindicated.⁵¹²

Although increases in plasma concentrations of astemizole and its desmethyl metabolite also may occur in patients receiving the antihistamine concomitantly with food products containing quinine (e.g., tonic water), such increases are small and not associated with clinically or statistically significant prolongation of the QT interval when consumption is limited to approximately 1 L (32 oz) of tonic water a day (about 80 mg of quinine sulfate).⁶¹⁴ Since consumption of larger daily amounts of quinine in tonic water may be associated with risk in patients receiving astemizole, patients who consume large amounts of tonic water daily may wish to consult their clinician.⁵⁹³

Histamine H2-Receptor Antagonists and Xanthine Derivatives

The manufacturer of terfenadine has stated that detectable plasma concentrations of unchanged terfenadine were not present and mean pharmacokinetic parameters (e.g., AUC, elimination half-life, peak plasma concentration) for the carboxylic acid metabolite fexofenadine did not appear to be affected in a study in which a single dose of terfenadine was given to individuals receiving multiple doses of cimetidine.⁴⁴³ ⁵⁹⁷ ⁶⁰⁴ Other data also suggest that an interaction between the drugs seems unlikely.⁵⁹³ While the potential for such a drug interaction has not been established, cardiotoxic effects also occurred following a terfenadine overdosage in at least one patient who was receiving cimetidine.⁵⁹⁷ In addition, torsades de pointes and prolongation of QT interval were reported in a patient receiving terfenadine 60 mg twice daily concomitantly with cimetidine 400 mg twice daily, and some clinicians state that concomitant use of terfenadine and cimetidine is not recommended.⁶⁴² ⁶⁴⁴

Increased plasma concentrations of loratadine and its active metabolite desloratadine have been reported in controlled clinical studies in healthy men receiving 10 mg of loratadine once daily concomitantly with cimetidine dosages of 300 mg 4 times daily (every 6 hours) for 10 days.⁴⁷⁰ ⁵⁰² ⁵⁰³ In these studies, AUC of loratadine increased by 103% following concomitant administration with cimetidine, while AUC of descarboethoxyloratadine increased by 6% following concomitant administration with cimetidine.⁴⁷⁰ ⁵⁰² ⁵⁰³ However, no clinically important changes, as measured by ECG and laboratory evaluations, vital signs, and adverse effects, were reported after concomitant administration of cimetidine with loratadine.⁴⁷⁰ ⁵⁰³ In addition, no changes in QT_c intervals, sedation, or syncope were reported in these individuals.⁴⁷⁰ ⁵⁰² ⁵⁰³ Plasma concentrations of cimetidine appeared to be unchanged in individuals receiving loratadine concomitantly.⁴⁷⁰

Increased plasma concentrations of desloratadine have been reported in a controlled clinical study in healthy individuals receiving 5 mg of the drug once daily concomitantly with cimetidine (600 mg every 12 hours for 14 days under steady-state conditions).⁶⁷⁰ In this study, peak plasma concentrations and AUC of desloratadine increased by 12 and 19%, respectively, following concomitant administration with cimetidine.⁶⁷⁰ However, no clinically important changes, as measured by ECG and laboratory evaluations, vital signs, and adverse effects, were reported after concomitant administration of cimetidine with desloratadine.⁶⁷⁰

Other Drugs

To date, the number of patients receiving loratadine concomitantly with ranitidine or theophylline has been too small to rule out a possible drug interaction between loratadine and such drugs and therefore, the manufacturers have recommended that loratadine be used with caution in patients receiving them.⁴⁸⁸

Grapefruit Juice

Concomitant oral administration of grapefruit juice with terfenadine has been reported to increase bioavailability of terfenadine.⁵⁴¹ ⁵⁴² ⁵⁴⁴ ⁵⁵⁵ ⁵⁹⁶ ⁶⁰⁷ ⁶¹⁶ ⁶¹⁷ ⁶⁴³ ⁶⁴⁹ This increased bioavailability of terfenadine was associated with prolongation of the QT interval averaging 3.3% (range: -1.6 to 9.5%); mean QT_c intervals increased by 4–14 msec compared with administration of terfenadine with water.⁵⁴¹ ⁵⁴⁴ ⁵⁵⁵ ⁵⁹⁶ ⁶⁰⁷ ⁶¹⁵ The interaction between grapefruit juice and terfenadine bioavailability appears to result from inhibition, probably prehepatic,⁵⁴¹ ⁵⁴⁴ ⁵⁵⁵ ⁵⁷⁴ ⁶¹⁶ ⁶¹⁹ ⁶²⁰ ⁶²¹ ⁶²² ⁶²³ ⁶²⁴ ⁶³⁶ ⁶³⁷ of the cytochrome P-450 enzyme system by some constituent(s) in the juice.⁵⁴¹ ⁵⁴⁴ ⁵⁷⁴ ⁶¹⁸ ⁶¹⁹ ⁶²⁰ ⁶²¹ ⁶²² ⁶²³ ⁶²⁴ ⁶²⁵ ⁶²⁶ ⁶²⁷ ⁶²⁸ ⁶²⁹ ⁶³⁰ ⁶³¹ ⁶³⁶ ⁶³⁷ Patients have been discouraged to ingest grapefruit juice concomitantly with terfenadine;⁵⁴¹ ⁵⁴² in addition, concomitant administration of astemizole with grapefruit juice has not been recommended since substantially increased plasma concentrations of unchanged astemizole also could occur resulting in an increased risk of serious adverse cardiac effects.⁵¹² ⁵⁸²

Concomitant oral administration of grapefruit juice with desloratadine does not appear to alter bioavailability of the drug.⁶⁷¹

Laboratory Test Interferences

Antihistamines may suppress inhalation-challenge testing with histamine or antigen as well as the wheal and flare reactions to antigen skin testing.³⁰⁹ ³¹⁰ ³¹¹ ³¹² ³¹³ ³¹⁴ ³¹⁵ ³¹⁶ ³¹⁷ Considerable interindividual variation in the extent and duration of suppression has been reported, depending on the antigen and test technique, antihistamine and dosage regimen, time since the last dose, and individual response to testing.³⁰⁹ ³¹¹ ³¹² ³¹⁶ ³¹⁷ In one study, usual oral dosages of chlorpheniramine or diphenhydramine suppressed the wheal response for about 2 days after the last dose, promethazine or tripelennamine suppressed whealing for about 3 days, and hydroxyzine suppressed whealing for about 4 days.³⁰⁹ Combined use of an H₁- and H₂-antagonist appears to have a synergistic suppressive effect on immediate and late cutaneous reactions to skin test antigens.³¹⁶ ³¹⁷ Whenever possible, antihistamines should be discontinued about 4 days prior to skin testing procedures since they may prevent otherwise positive reactions to dermal reactivity indicators. Some evidence suggests that loratadine or terfenadine should be discontinued at least 7 days prior to such testing and that the results of such tests should be interpreted with caution even if testing were performed 4–6 weeks after astemizole discontinuance.⁴⁸⁷

In one study, topical application of an antihistamine (i.e., 2% pyrilamine maleate cream) to the skin test site 10 minutes after antigen testing decreased pruritus but did not suppress wheal or flare 10 minutes after application.³¹⁸

Acute Toxicity

Manifestations

Although antihistamines have relatively high therapeutic indexes, overdosage may result in death, especially in infants and children. There have been several reports of toxicity, often occurring within 24–48 hours of repeated topical application of diphenhydramine, in children with pruritus associated with varicella (chickenpox), poison ivy, or sunburn.⁵⁵⁶ ⁵⁵⁷ Such toxicity included toxic psychosis (sometimes mimicking varicella encephalitis) and occurred in children who received oral and topical diphenhydramine concomitantly.⁵⁵⁶ ⁵⁵⁷ ⁵⁷⁵ ⁵⁷⁶ The toxicity usually was associated with increased (60–1900 ng/mL) serum concentration of diphenhydramine.⁵⁵⁶ ⁵⁵⁷ Topical diphenhydramine usually was applied to large areas of the body and usually was contained in Caladryl, a commercially available lotion containing 1% diphenhydramine and 8% calamine; such combination is no longer commercially available in the US since Caladryl has been reformulated by the manufacturer to contain pramoxine hydrochloride with calamine or zinc acetate.⁵⁶³ In general, overdosage of diphenhydramine may cause CNS stimulation and/or depression; in young children, CNS stimulation is dominant. Symptoms of antihistamine toxicity in children may resemble atropine overdosage and include fixed dilated pupils, abnormal eye movements, flushed face, dry mouth, urinary retention, fever, excitation, hallucinations, disorientation, delusions, agitation, bizarre behavior, confusion, jitteriness, restlessness, irritability, hyperactivity, delirium, twitching, tiredness, abnormal tongue movement, unsteady gait, trembling extremities, slurred speech, ataxia, incoordination, athetosis, tonic-clonic seizures, and postictal depression. Children recovered gradually from these adverse CNS effects, usually within 24–48 hours following removal of the topical preparation and discontinuance of all diphenhydramine-containing preparations.⁵⁵⁶ ⁵⁵⁷

Overdosage in adults usually causes CNS depression with drowsiness or coma which may be followed by excitement, seizures, and finally postictal depression. In children and adults, cerebral edema and upper nephron nephrosis, a deepening coma, tachycardia, QRS widening, heart block, cardiorespiratory collapse/arrest,³⁹¹ cardiogenic shock, and death may occur. The risk of cardiotoxicity has been particularly likely with astemizole and terfenadine;⁴¹³ ⁴¹⁷ ⁴¹⁹ ⁴³⁰ ⁴³³ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁹ ⁴⁶¹ ⁴⁸⁷ however, these 2 antihistamines are no longer commercially available in the US.⁴⁵⁶ ⁶⁵⁹ ⁶⁶⁰ (See Cautions: Cardiovascular Effects.) Symptoms of overdosage occur within 30 minutes to 2 hours after ingestion; death may occur within 18 hours. Toxic effects may persist for prolonged (e.g., several days) periods after acute overdosage of antihistamines (e.g., astemizole) with long elimination half-lives. Rhabdomyolysis (evidenced by myoglobinuria) has been associated with overdosage of doxylamine.⁴¹⁰ Acute toxicity has been reported following topical overdosage of diphenhydramine⁴⁵¹ ⁴⁵² or tripelennamine²¹³ (no longer commercially available in the US) in children.

Treatment

Treatment of acute antihistamine overdosage consists of symptomatic and supportive therapy including artificial respiration, if necessary. If the patient is conscious, has not lost the gag reflex, and is not having seizures, emesis should be induced; however, the manufacturer of trimeprazine (no longer commercially available in the US) stated that emesis should not be induced because dystonic reaction of the head and neck may cause aspiration of gastric contents. The manufacturer of carbinoxamine maleate also states that emesis should not be induced; activated charcoal should be administered and gastric lavage should be considered following ingestion of a potentially life-threatening amount of carbinoxamine maleate.⁶⁷⁷

While phenothiazine-type antihistamines may exhibit an antiemetic effect, ipecac syrup still may be effective in oral poisonings with these agents if given early (usually within 1 hour) before toxic or antiemetic effects appear. If emesis cannot be induced, gastric lavage and administration of activated charcoal are indicated; an endotracheal tube with cuff inflated should be in place to prevent aspiration of gastric contents. Saline cathartics (e.g., magnesium sulfate) may be administered.

Vasopressor agents, such as norepinephrine or phenylephrine, may be administered if necessary. Epinephrine should not be used, especially with phenothiazine overdosage, because epinephrine may lower the blood pressure further. Analeptic agents should not be used since they may cause seizures. Physostigmine may be useful to counteract the CNS anticholinergic effects of antihistamine intoxication. Diazepam can be given IV in the management of seizures that do not respond to physostigmine. Hyperthermia may be treated with cold packs or sponging with tepid water; sponging with alcohol should not be used.

If hypotension and/or cardiac arrhythmias occur (reported mainly with overdosage of astemizole or terfenadine), appropriate therapy should be instituted.⁵⁹² ⁵⁹³ ⁵⁹⁴ Antiarrhythmic agents that can prolong the QT interval (e.g., class 1A agents) should be avoided in treating overdosage-associated arrhythmias in which prolongation of the QT_c interval is a manifestation.⁴¹⁶ ⁵⁹⁴ ⁵⁹⁷ ⁶⁰⁰ ⁶⁰¹ While arrhythmias may resolve spontaneously following discontinuance of the antihistamine,⁴¹⁶ ⁴²⁰ when necessary, therapy for ventricular tachyarrhythmias with associated QT prolongation (e.g., torsades de pointes) can include temporary atrial or ventricular pacing, IV magnesium sulfate, IV isoproterenol, and/or DC cardioversion (for initial management of sustained, symptomatic runs).⁴¹⁶ ⁴²¹ ⁴²³ ⁶⁰⁰ ⁶⁰¹ ⁶⁰² ⁶⁰³

Pharmacology

Histamine is a physiologically active, endogenous substance (autacoid) that binds to and activates histamine H₁- and H₂-receptors at various sites in the body.¹⁴⁹ ¹⁵⁰ ¹⁵¹ ³⁷¹ ³⁸⁹ ⁴⁸⁷ H₃-receptors, which may be involved in feedback control of histamine synthesis and release, also have been described.³⁷¹ ³⁷² ³⁷³ ³⁷⁴ ³⁷⁵ The principal pharmacologic effects of histamine involve the cardiovascular system, extravascular smooth muscle (e.g., bronchial tree), and exocrine glands (e.g., stimulation of salivary, gastric, lacrimal, and bronchial secretions).¹⁴⁹ ¹⁵⁰ ¹⁵¹ ³⁷¹ ³⁷⁸ ³⁸⁹ Histamine also can stimulate some nerve endings and thus causes pruritus.¹⁴⁹ Characteristic cardiovascular effects of histamine include direct and indirect microvascular dilation, hypotension, tachycardia, and flushing (involving H₁- and H₂-receptors) and increased vascular permeability (thought to principally involve H₁-receptors). Intracutaneous injection of histamine produces a “triple response” of local reddening, a bright halo or flare, and wheal formation.¹⁴⁹ ¹⁵⁰ ¹⁵¹ ³⁷¹ ³⁷⁶ In allergic conditions, histamine and other substances (e.g., leukotrienes, prostaglandins, kinins, serotonin, platelet-activating factor) are secreted from mast cells, basophils, and other cells in response to antigenic stimulation.¹⁴⁹ ¹⁵⁰ ¹⁵² ¹⁵³ ¹⁷² ³⁷¹ ³⁷⁸ Histamine binds to and activates specific receptors in the nose, eyes, respiratory tract, and skin, causing characteristic allergic signs and symptoms.¹⁰⁰ ¹⁴⁹ ¹⁵⁰ ¹⁵² ¹⁵³

The term antihistamine has historically been used to describe drugs that act as H₁-receptor antagonists.¹⁴⁹ ¹⁵⁰ Although drugs that antagonize H₂-receptors also are commercially available (e.g., cimetidine, famotidine, nizatidine, ranitidine), these drugs generally are not referred to as antihistamines but rather as H₂-receptor antagonists.¹⁴⁹ ¹⁵⁰ Antihistamines competitively antagonize most of the smooth muscle stimulating actions of histamine on the H₁-receptors of the GI tract, uterus, large blood vessels, and bronchial muscle. Contraction of the sphincter of Oddi and bile duct may be mediated in part by H₁-receptors, and opiate-induced contraction of biliary smooth muscle has been antagonized by antihistamines.³⁷⁷ The drugs only are feebly antagonistic to bronchospasm induced by antigen-antibody reactions. Antihistamines also effectively antagonize the action of histamine that results in increased capillary permeability and the formation of edema. H₁-receptor antagonists also suppress flare and pruritus that accompany the endogenous release of histamine. Antihistamines appear to act by blocking H₁-receptor sites, thereby preventing the action of histamine on the cell; they do not chemically inactivate or physiologically antagonize histamine nor do they prevent the release of histamine. Antihistamines do not block the stimulating effect of histamine on gastric acid secretion, which is mediated by H₂-receptors of the parietal cells.

The basic ethylamine group common to antihistamines also is common to anticholinergics, ganglionic and adrenergic blocking agents, local anesthetics, and antispasmodics; antihistamines therefore may be expected to exhibit some of the activities of these other classes of drugs. Some antihistamines also demonstrate a quinidine-like effect on myocardial conduction, and they may enhance the pressor action of norepinephrine. The antiemetic and antimotion-sickness actions of some antihistamines appear to result, at least in part, from their central anticholinergic and CNS depressant properties. The effects of diphenhydramine on parkinsonian syndrome and drug-induced extrapyramidal reactions are also apparently related to its central anticholinergic effects.

Although the antipruritic effect of systemically administered or locally applied antihistamines in conditions associated with histamine-induced pruritus appears to result from a peripheral antihistaminic effect and possibly a local anesthetic effect,¹⁴⁹ ¹⁷¹ ³⁴⁹ the sedative effect of systemically administered antihistamines also appears to contribute to their antipruritic activity.¹¹ ¹⁷¹ The drugs are more effective antipruritics when administered systemically than when applied topically, especially when pruritus is generalized.³⁴⁹ Because pruritus can involve mediators other than histamine, the antipruritic efficacy of antihistamines is not routine.³⁴⁹

Antihistamines General Statement Pharmacokinetics

Limited information is available on the pharmacokinetics of most antihistamines.

Absorption

Antihistamines generally are well absorbed following oral or parenteral administration, but various salts may differ in activity and toxicity because of differences in solubility or absorption. The least soluble antihistamines are often the least toxic and may have a slow onset but prolonged duration of action. Following oral administration of antihistamines, symptomatic relief of allergic reactions usually begins within 15–30 minutes and usually is maximal within 1 hour. The duration of action is variable but symptoms usually are relieved for 3–6 hours after oral administration of most antihistamines. There may be some decrease in effectiveness with prolonged use of these drugs, although a substantial degree of tolerance to the antihistaminic effects generally does not occur. However, tolerance to the sedative effects may occur.

Some antihistamines (e.g., astemizole [no longer commercially available in the US], cetirizine, desloratadine, loratadine) exhibit a slower onset of action and/or prolonged duration of effect. Following single- and multiple-dose administration, the long-acting antihistamine loratadine exhibits antihistaminic effects beginning within 1–3 hours, reaching a maximum at 8–10 hours, and lasting in excess of 24 hours.⁴⁷⁰ Following single- and multiple-dose administration of a 5-mg dose of desloratadine, the antihistaminic effect of the drug is apparent within 1 hour and lasts for 24 hours.⁶⁷⁰ Following oral administration of a single 10-mg dose of cetirizine hydrochloride in healthy individuals, the antihistaminic effect of the drug is apparent within 20–60 minutes and lasts for at least 24 hours.⁵⁰⁹ Following oral administration of a 5-mg dose of levocetirizine dihydrochloride in patients with allergic rhinitis, the antihistaminic effect of the drug is apparent within 1 hour and lasts for at least 24 hours. ⁶⁸⁵

Topically applied antihistamines generally do not readily penetrate intact skin, especially when salts of the drugs are used.³⁴⁹ However, percutaneous absorption can occur,²¹³ ²¹⁴ ²¹⁵ ³¹⁹ ³⁴⁹ ⁵⁵⁶ especially when the stratum corneum is disrupted,³⁴⁹ ⁵⁵⁶ and rarely may result in systemic effects and toxicity.⁴⁴ ³¹⁹ ³⁴⁹ ³⁵⁶ ⁵⁵⁶

Distribution

The distribution of most antihistamines has not been fully characterized. Those compounds that have been studied show highest concentrations in the lungs and lower concentrations in spleen, kidneys, brain, muscle, and skin. Protein binding of these agents ranges from 50–99%.

Unlike other currently available antihistamines, second generation (also referred to as relatively “nonsedating”) antihistamines such as acrivastine, astemizole, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and terfenadine (no longer commercially available in the US) appear to distribute poorly or not appreciably into the CNS at usual dosages.¹⁵⁴ ¹⁵⁵ ¹⁵⁶ ¹⁵⁷ ¹⁵⁸ ¹⁵⁹ ¹⁶⁰ ¹⁶¹ ¹⁶² ¹⁶³ ¹⁶⁴ ¹⁶⁵ ¹⁶⁶ ¹⁶⁷ ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁷⁰ ⁴⁷¹ ⁴⁷² ⁴⁷³ ⁴⁷⁴ ⁴⁸⁷ ⁴⁹⁵ ⁴⁹⁶ ⁴⁹⁷ ⁴⁹⁸ ⁵¹⁶ ⁶⁶⁹ ⁶⁷⁰ ⁶⁹⁵ It is thought that this lack of CNS distribution results principally from the inability of these agents to cross the tightly fused outer membranes of endothelial cells lining the brain capillaries.⁴⁸⁷ ⁴⁹⁸ Cetirizine, because of its substantial polarity, also does not readily cross the blood-brain barrier;⁵⁰⁹ ⁵⁸³ ⁵⁸⁴ however, some data indicate that the drug may cause more somnolence than other second generation antihistamines.⁵⁸³ Levocetirizine also is considered mildly sedating.⁶⁹⁵

Small amounts of the drugs appear to be distributed into milk.

Elimination

The metabolic fate of most antihistamines is not clearly established. The drugs usually appear to be extensively metabolized, mainly in the liver. Some second generation antihistamines (e.g., astemizole, loratadine, terfenadine) are metabolized principally by the cytochrome P-450 microsomal enzyme system, mainly by the isoenzyme 3A4 (CYP3A4), although other isoenzymes, including CYP1A2 and CYP2D6, also may be involved.¹⁵⁶ ¹⁵⁷ ¹⁶¹ ⁴⁷⁷ ⁵¹² ⁵⁸⁷ ⁵⁸⁸ ⁵⁸⁹ ⁵⁹⁰ ⁵⁹¹ ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁷ ⁶³⁵ ⁶⁵⁰ ⁶⁵¹ ⁶⁵² ⁶⁵³ ⁶⁵⁴ Desloratadine also is extensively metabolized; however, the enzyme(s) responsible for metabolism of the drug has not been identified.⁶⁷⁰ Other second generation antihistamines (e.g., cetirizine, fexofenadine, levocetirizine) appear to be only minimally metabolized in the liver.⁵⁰⁹ ⁵⁷⁵ ⁵⁷⁶ ⁶⁴⁸ ⁶⁸⁵

Metabolism of some antihistamines that are extensively metabolized in the liver (e.g., astemizole, terfenadine) may be substantially reduced in patients with hepatic impairment and possibly in geriatric patients.⁴¹³ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²² ⁴²⁴ ⁴³³ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁶ ⁴⁵⁹ ⁴⁶⁶ ⁴⁷⁶ ⁵¹² In addition, metabolism also may be substantially reduced in patients concomitantly receiving foods (e.g., grapefruit juice)⁵¹² ⁵⁴¹ ⁵⁴² ⁵⁴³ ⁵⁴⁴ ⁵⁵⁵ ⁵⁹⁶ ⁶⁰⁷ ⁶¹⁶ ⁶¹⁷ or drugs (e.g., certain azole-derivative anti-infective agents, including fluconazole, itraconazole, ketoconazole, metronidazole, and miconazole; certain macrolide antibiotics, including clarithromycin, erythromycin, and troleandomycin; mibefradil [no longer commercially available in the US]; possibly certain human immunodeficiency virus [HIV] protease inhibitors, including indinavir, nelfinavir, ritonavir, and saquinavir; possibly some serotonin-reuptake inhibitors, including fluoxetine, fluvoxamine, nefazodone, paroxetine, and sertraline; zileuton; quinine) that affect the hepatic microsomal enzyme system.⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁵⁵ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁴⁷⁸ ⁵¹² ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁴ ⁵⁷⁴ ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁵⁹⁸ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶¹⁵ ⁶³⁹ Decreased metabolism may result in accumulation of potentially toxic concentrations of the unchanged antihistamines that may be associated with serious adverse cardiac effects.⁴¹⁸ ⁴¹⁹ ⁴²² ⁴⁴³ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁷⁶ ⁵¹² ⁵⁹⁴ ⁵⁹⁶ ⁵⁹⁷ ⁶⁰⁷ (See Cautions: Cardiovascular Effects and see Drug Interactions.)

Many antihistamines are excreted in urine as inactive metabolites within 24 hours; however, some antihistamines (e.g., terfenadine, desloratadine, loratadine, astemizole, acrivastine) have active H₁-antagonist metabolites. Negligible amounts of most antihistamines are excreted unchanged in urine; however, cetirizine and levocetirizine are excreted in urine mainly as unchanged drug.⁵⁷⁷ ⁵⁷⁸ ⁵⁷⁹ ⁵⁸³ ⁶⁸⁵ ⁶⁸⁶

Chemistry

Antihistamines (histamine H₁-receptor antagonists) competitively inhibit most of the pharmacologic actions of histamine.

Antihistamines have been classified chemically and also have been classified according to their propensity to cause sedation, with relatively sedating antihistamines (i.e., conventional, prototypical antihistamines) being classified as first generation and relatively “nonsedating” antihistamines (e.g., acrivastine, astemizole [no longer commercially available in the US], desloratadine, fexofenadine, loratadine, terfenadine [no longer commercially available in the US]) being classified as second generation.⁴³⁵ ⁴⁷¹ ⁴⁸⁷ ⁴⁹⁵ ⁴⁹⁶ ⁴⁹⁷ ⁴⁹⁸ ⁵¹⁶ Cetirizine also is considered a second generation antihistamine; however, some data indicate that it causes more sedation than other second generation antihistamines.⁵⁸³ Levocetirizine, the active R enantiomer of cetirizine, is considered a mildly sedating antihistamine⁶⁹⁵ and has been found to be slightly more sedating than desloratadine.⁶⁸⁷

FIRST GENERATION ANTIHISTAMINES
azatadine*	diphenhydramine
brompheniramine	doxylamine
carbinoxamine	hydroxyzine
chlorpheniramine	meclizine
clemastine	promethazine
cyproheptadine	triprolidine
dimenhydrinate

no longer commercially available in the US

SECOND GENERATION ANTIHISTAMINES
acrivastine	fexofenadine
astemizole	levocetirizine
cetirizine	loratadine
desloratadine	terfenadine

Most antihistamines are substituted ethylamines. In general, these molecules consist of 3 portions: R¹ = nucleus, X = a linkage such as nitrogen, oxygen, or carbon, and the ethylamine group. Antihistamines can be depicted by a general formula:

R¹ is composed of aromatic and/or heterocyclic groups, which may be separated from X by a methylene group. Hydrogenation of the rings in the R¹ portion of the molecule decreases antihistamine activity. Usually, activity of an antihistamine is increased by substitution of a halogen atom in the para position of the phenyl or benzyl group of R¹. For maximum activity, the terminal nitrogen of the ethylamine group should be a tertiary amine with methyl groups or a small cyclic moiety in R² and R³. In optically active compounds, the dextro isomer (e.g., dexchlorpheniramine, dexbrompheniramine) usually is more active than the levo isomer.

Antihistamines can be classified on the basis of X substitution as follows:

ETHYLENEDIAMINE DERIVATIVES
antazoline	pyrilamine
methapyrilene	tripelennamine

This group of antihistamines has nitrogen in the X position. Ethylenediamine derivatives have relatively weak CNS effects; however, drowsiness may occur in some patients. Adverse GI effects are common with this group of antihistamines.

ETHANOLAMINE DERIVATIVES (AMINOALKYL ETHERS)
bromodiphenhydramine*	diphenhydramine
carbinoxamine	diphenylpyraline
clemastine	doxylamine
dimenhydrinate	phenyltoloxamine

This group of antihistamines, which has oxygen in the X position, has substantial atropine-like activity. Drugs in this group commonly cause CNS depression; with usual doses, drowsiness occurs in about 50% of patients who receive ethanolamine derivative antihistamines. The incidence of adverse GI effects with these antihistamines is relatively low. Dimenhydrinate and diphenhydramine also are used as antiemetics.

ALKYLAMINES (PROPYLAMINE DERIVATIVES)
acrivastine	dimethindene
brompheniramine	pheniramine
chlorpheniramine	pyrrobutamine
dexbrompheniramine	triprolidine
dexchlorpheniramine

These antihistamines contain a carbon atom in the X position. Alkylamines cause less drowsiness and more CNS stimulation than the other antihistamines and thus are suitable for daytime use.

PHENOTHIAZINE DERIVATIVES
promethazine

In this group of antihistamines, nitrogen, as part of a phenothiazine nucleus, is in the X position. Most phenothiazines are used principally as antipsychotics; however, some are useful as antihistamines, antipruritics, and antiemetics.

PIPERAZINE DERIVATIVES
cetirizine	levocetirizine
hydroxyzine	meclizine

In this group, nitrogen, as part of a piperazine nucleus, is in the X position. Meclizine is used in the treatment of motion sickness. Hydroxyzine is used as a tranquilizer, sedative, antipruritic, and antiemetic.

no longer commercially available in the US

OTHERS
astemizole	fexofenadine
azatadine	loratadine
cyproheptadine	phenindamine
desloratadine	terfenadine

Related Monographs

For further information on chemistry and stability, pharmacokinetics, uses, and dosage and administration of antihistamines available as single entities, see the individual monographs in 4:00.

References

Only references cited for selected revisions after 1984 are available electronically.

11. Anon. Choice of antihistamines. Med Lett Drugs Ther. 1971; 13:102-4. https://pubmed.ncbi.nlm.nih.gov/4150398

44. Bleumink E. Antihistamines. In: Dukes MNG, ed. Meyler’s side effects of drugs. Vol 8. New York: Excerpta Medica; 1975:406-17.

50. Fisher AA. Antihistamine dermatitis. Cutis. 1976; 18:329,330,336. https://pubmed.ncbi.nlm.nih.gov/138569

100. Food and Drug Administration. Over-the-counter drugs: establishment of a monograph for OTC cold, cough, allergy, bronchodilator and antiasthmatic products. [21 CFR 341] Fed Regist. 1976; 41:38312-424. (Cited in previous revisions as reference #16.) (IDIS 66640)

101. Key Pharmaceuticals. Trinalin(azatadine maleate and pseudoephedrine sulfate) Repetabs prescribing information (dated 1996 Jun). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1339-40.

102. Lin C, Lim J, Scymchowicz S. Bioavailability of d-pseudoephedrine and azatadine from a repeat action tablet formulation. J Int Med Res. 1982; 10:122-5. https://pubmed.ncbi.nlm.nih.gov/7067923

103. Schering Corporation. Optimine prescribing information. In: Huff BB, ed. Physicians’ desk reference. 38th ed. Oradell, NJ: Medical Economics Company Inc; 1984:1795-7.

104. The United States pharmacopeia, 20th rev, and The national formulary, 15th ed. Suppl 3. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1982:46.

105. Falliers CJ, Redding MA. Controlled comparison of a new antihistamine-decongestant combination to its individual components. Ann Allergy. 1980; 45:75-80. https://pubmed.ncbi.nlm.nih.gov/6157338

106. Zubizaretta J. Azatadine maleate/pseudoephedrine sulfate repetabs versus placebo in the treatment of severe perennial allergic rhinitis. J Int Med Res. 1980; 8:395-9. https://pubmed.ncbi.nlm.nih.gov/6108263

107. Tarasido JC. Azatadine maleate/pseudoephedrine sulfate repetabs versus placebo in the treatment of severe seasonal allergic rhinitis. J Int Med Res. 1980; 8:391-4. https://pubmed.ncbi.nlm.nih.gov/6108262

108. Connell JT. A novel method to assess antihistamine and decongestant efficacy. Ann Allergy. 1979; 42:278-85. https://pubmed.ncbi.nlm.nih.gov/88194

109. Simons FER, Frith EM, Simons KJ. The pharmacokinetics and antihistaminic effects of brompheniramine. J Allergy Clin Immunol. 1982; 70:458-64. https://pubmed.ncbi.nlm.nih.gov/6128358

110. Bruce RB, Turnbull LB, Newman JH et al. Metabolism of brompheniramine. J Med Chem. 1968; 11:1031-4. https://pubmed.ncbi.nlm.nih.gov/4386938

111. Kabasakalian P, Taggart M, Townley E. Urinary excretion of pheniramine and its N-demethylated metabolites in man—comparison with chlorpheniramine and brompheniramine data. J Pharm Sci. 1968; 57:621-3. https://pubmed.ncbi.nlm.nih.gov/4385103

112. Hanna S, Tang A. GLC determination of chlorpheniramine in human plasma. J Pharm Sci. 1974; 63:1954-7. https://pubmed.ncbi.nlm.nih.gov/4449031

113. Peets EA, Jackson M, Symchowicz S. Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther. 1972; 180:464-74.

114. Kotzan JA, Vallner JJ, Stewart JT et al. Bioavailability of regular and controlled-release chlorpheniramine products. J Pharm Sci. 1982; 71:919-23. https://pubmed.ncbi.nlm.nih.gov/7120098

115. Simons FER, Luciuk GH, Simons KJ. Pharmacokinetics and efficacy of chlorpheniramine in children. J Allergy Clin Immunol. 1982; 69:376-81. https://pubmed.ncbi.nlm.nih.gov/7069073

116. Thompson JA, Bloedow DC, Leffert FH. Pharmacokinetics of intravenous chlorpheniramine in children. J Pharm Sci. 1981; 70:1284-6. https://pubmed.ncbi.nlm.nih.gov/7299679

117. Vallner JJ, Needham TE, Chan W et al. Intravenous administration of chlorpheniramine to seven subjects. Curr Ther Res. 1979; 26:449-53.

118. Chiou WL, Athanikar NK, Huang SM. Long half-life of chlorpheniramine. N Engl J Med. 1979; 300:501. https://pubmed.ncbi.nlm.nih.gov/759945

119. Lange WE, Theodore JM, Pruyn FJ. In vivo determination of certain aralkylamines. J Pharm Sci. 1968; 57:124-7. https://pubmed.ncbi.nlm.nih.gov/5652111

120. Kabasakalian P, Taggart M, Townley E. Urinary excretion of pheniramine and its N-demethylated metabolites–comparison with chlorpheniramine and brompheniramine data. J Pharm Sci. 1968; 57:621-3. https://pubmed.ncbi.nlm.nih.gov/4385103

121. Kabasakalian P, Taggart M, Townley E. Urinary excretion of chlorpheniramine and its N-demethylated metabolites in man. J Pharm Sci. 1968; 57:856-8. https://pubmed.ncbi.nlm.nih.gov/5657548

122. Huang SM, Athanikar NK, Sridhar K et al. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur J Clin Pharmacol. 1982; 22:359-65. https://pubmed.ncbi.nlm.nih.gov/7106172

123. Huang SM, Huang YC, Chiou WL. Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. J Pharmacokinet Biopharm. 1981; 9:725-38. https://pubmed.ncbi.nlm.nih.gov/7341757

124. Huang SM, Chiou WL. Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. J Pharmacokinet Biopharm. 1981; 9:711-23. https://pubmed.ncbi.nlm.nih.gov/7341756

125. Athanikar NK, Peng GW, Nation RL et al. Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. J Chromatogr. 1979; 162:367-76. https://pubmed.ncbi.nlm.nih.gov/528601

126. Dube LM, Bloch R, Warner RN et al. Pharmacokinetics of chlorpheniramine maleate in chronic renal failure: effect of hemodialysis and peritoneal dialysis. In: Official Program and Abstracts of Papers presented before the APhA Academy of Pharmaceutical Sciences. 1980; 10:84. Abstract.

127. Beckett AH, Wilkinson GR. Influence of urine pH and flow rate on the renal excretion of chlorpheniramine in man. J Pharm Pharmacol. 1965; 17:256-7. https://pubmed.ncbi.nlm.nih.gov/14327721

128. Lai CM, Stoll RG, Look ZM et al. Urinary excretion of chlorpheniramine and pseudoephedrine in humans. J Pharm Sci. 1979; 68:1243-6. https://pubmed.ncbi.nlm.nih.gov/41928

129. West S, Brandon B, Stolley P et al. A review of antihistamines and the common cold. Pediatrics. 1975; 56:100-7. https://pubmed.ncbi.nlm.nih.gov/240145

130. Howard JC Jr, Kantner TR, Lilienfield LS et al. Effectiveness of antihistamines in the symptomatic management of the common cold. JAMA. 1979; 242:2414-7. https://pubmed.ncbi.nlm.nih.gov/490852

131. Albert KS, Hallmark MR, Sakmar E et al. Pharmacokinetics of diphenhydramine in man. J Pharmacokinet Biopharm. 1975; 3:159-70. https://pubmed.ncbi.nlm.nih.gov/1159620

132. Carruthers SG, Shoeman DW, Hignite CE et al. Correlations between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther. 1978; 23:375-82. https://pubmed.ncbi.nlm.nih.gov/24512

133. Glazko AJ, Dill WA, Young RM et al. Metabolic disposition of diphenhydramine. Clin Pharmacol Ther. 1974; 16:1066-76. https://pubmed.ncbi.nlm.nih.gov/4447663

134. Bilzer W, Gundert-Remy U, Weber E. Relationship between antihistaminic activity and plasma level of diphenhydramine. Eur J Clin Pharmacol. 1974; 7:393-5. https://pubmed.ncbi.nlm.nih.gov/4154042

135. Glazko AJ, Dill WA. Biochemical studies on diphenhydramine (Benadryl). II. Distribution in tissues and urinary excretion. J Biol Chem. 1949; 179:403-8. https://pubmed.ncbi.nlm.nih.gov/18119256

136. Parkin DE. Probably Benadryl withdrawal manifestations in a newborn infant. J Pediatr. 1974; 85:580. https://pubmed.ncbi.nlm.nih.gov/4443870

137. O’Brien TE. Excretion of drugs in human milk. Am J Hosp Pharm. 1974; 31:844-54. https://pubmed.ncbi.nlm.nih.gov/4608122

138. Knowles JA. Excretion of drugs in milk: a review. J Pediatr. 1965; 66:1068-82. https://pubmed.ncbi.nlm.nih.gov/14288461

139. Chang T, Okerholm RA, Glazko AJ. Identification of diphenhydramine (Benadryl) metabolites in human subjects. Res Commun Chem Pathol Pharmacol. 1974; 9:391-404. https://pubmed.ncbi.nlm.nih.gov/4445562

140. Russo RM, Gururaj VJ, Allen JE. The effectiveness of diphenhydramine HCl in pediatric sleep disorders. J Clin Pharmacol. 1976; 16:284-8. https://pubmed.ncbi.nlm.nih.gov/770511

141. Food and Drug Administration. Drug efficacy study implementation; revocation of the exemption category for oral prescription drugs for cough, cold, or allergy (“paragaph XIV/category 15”); followup notice and opportunity for hearing. Docket No. 83N-0005; [DESI No. 11935] Fed Regist. 1983; 48:56854-6.

142. Schering Corporation. Disophrol Chronotab prescribing information. In: Huff BB, ed. Physicians’ desk reference. 36th ed. Oradell, NJ: Medical Economics Company Inc; 1982:1701.

143. Schering Corporation. Drixoralsustained-action tablets prescribing information. In: Huff BB, ed. Physicians’ desk reference. 36th ed. Oradell, NJ: Medical Economics Company Inc.; 1982:1703-4.

144. Schering Corporation. Disophrol tablets prescribing information. In: Huff BB, ed. Physicians’ desk reference. 33rd ed. Oradell, NJ: Medical Economics Company Inc; 1979:1527-8.

145. Schering Corporation. Disophrol Chronotab patient information. In: Huff BB, ed. Physicians’ desk reference for nonprescription drugs. 6th ed. Oradell, NJ: Medical Economics Company Inc; 1985:677-8.

146. Schering Corporation. Drixoral sustained-action tablets patient information. In: Huff BB, ed. Physicians’ desk reference for nonprescription drugs. 6th ed. Oradell, NJ: Medical Economics Company Inc; 1985:678.

147. Lederle Laboratories. Dexbrompheniramine maleate USP and pseudoephedrine sulfate USP Sequels. Pearl River, NY; 1982 Jul.

148. Schering Corporation. Disophrol tablets patient information. Kenilworth, NJ. Undated.

149. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:605-38.

150. Local hormones and autacoids: biogenic amines, purines, kinins, and prostaglandins. In: Bowman WC, Rand MJ, eds. Textbook of pharmacology. 2nd ed. Oxford: Blackwell Scientific Publications; 1980:12.1-12.41.

151. Cirillo VJ, Tempero KF. The pharmacology and therapeutic use of H₁ and H₂ antihistamines. In: Miller RR, Greenblatt DJ, eds. Drug therapy reviews. Vol 2. New York: Elsevier/North Holland Inc; 1979:24-47.

152. Hypersensitivity reactions. In: Bauman WC, Rand MJ, eds. Textbook of Pharmacology. 2nd ed. Oxford: Blackwell Scientific Publications; 1980:13.23-13.28.

153. Immune mechanisms in tissue damage. In: Stites DP, Stobo JD, Fudenberg HH et al, eds. Basic clinical immunology. 4th ed. Los Altos, CA: Lange Medical Publications; 1982:136-55.

154. Woodward JK, Munro NL. Terfenadine, the first non-sedating antihistamine. Arzneimittelforschung. 1982; 32:1154-6. https://pubmed.ncbi.nlm.nih.gov/6129860

155. Merrell Dow Pharmaceuticals Inc. Seldane prescribing information. Cincinnati, OH; 1985 May.

156. Merrell Dow Pharmaceuticals Inc. Seldane (terfenadine) monograph. Cincinnati, OH; 1985.

157. Merrell Dow Pharmaceuticals Inc. Product information form for American Hospital Formulary Service on Seldane. Cincinnati, OH; 1985 Apr 1.

158. Kinsolving CR, Munro NL, Carr AA. Separation of the CNS and H₁-receptor effects of antihistamine agents. Pharmacologist. 1973; 15:221.

159. Cheng HC, Woodward JK. Antihistaminic effect of terfenadine: a new piperidine-type antihistamine. Drug Dev Res. 1982; 2:181-96.

160. Cheng HC, Woodward JK. A kinetic study of the antihistaminic effect of terfenadine. Arzneimittelforschung. 1982; 32:1160-6. https://pubmed.ncbi.nlm.nih.gov/6129862

161. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985; 29:34-56. https://pubmed.ncbi.nlm.nih.gov/2857636

162. Koch H. Terfenadine: specific peripheral H₁-histamine receptor antagonist. Pharm Int. 1983; 4:252-3.

163. Weich NL, Martin JS. Absence of an effect of terfenadine on guinea pig brain histamine H₁-receptors in vivo determined by receptor binding techniques. Arzneimittelforschung. 1982; 32:1167-70. https://pubmed.ncbi.nlm.nih.gov/6817763

164. Rose C, Quach TT, Llorens C et al. Relationship between occupation of cerebral H₁-receptors and sedative properties of antihistamines: assessment in the case of terfenadine. Arzneimittelforschung. 1982; 32:1171-3. https://pubmed.ncbi.nlm.nih.gov/6129863

165. Nicholson AN. Antihistamines and sedation. Lancet. 1983; 2:211-2. https://pubmed.ncbi.nlm.nih.gov/6135040

166. Norman PS. New developments in treating allergic rhinitis. Drug Ther. 1984; 14:117,126,127,130-2.

167. Leeson GA, Chan KY, Knapp WC et al. Metabolic disposition of terfenadine in laboratory animals. Arzneimittelforschung. 1982; 32:1173-8. https://pubmed.ncbi.nlm.nih.gov/6817764

168. AMA Division of Drugs. AMA drug evaluations. 5th ed. Chicago: American Medical Association; 1983:1465-79.

169. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for OTC antihistamine drug products. [21 CFR Part 341] Fed Regist. 1985; 50:2200-18. (IDIS 195256)

170. Anon. Treatment of seasonal and perennial rhinitis. BMJ. 1981; 283:808-10. https://pubmed.ncbi.nlm.nih.gov/6117350 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1507045/

171. Krause L, Shuster S. Mechanism of action of antipruritic drugs. BMJ. 1983; 287:1199-200. https://pubmed.ncbi.nlm.nih.gov/6138120 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549449/

172. Naclerio RM, Proud D, Togia AG et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985; 313:65-70. https://pubmed.ncbi.nlm.nih.gov/2582257

173. Deutsch PH. Dermatographism treated with hydroxyzine and cimetidine and ranitidine. Ann Intern Med. 1984; 101:569. https://pubmed.ncbi.nlm.nih.gov/6089638

174. Cook J, Shuster S. The effect of H₁ and H₂receptor antagonists on the dermographic response. Acta Derm Venereol. 1983; 63:260-2. https://pubmed.ncbi.nlm.nih.gov/6192650

175. Cook LJ, Shuster S. Lack of effect of cimetidine in chronic-idiopathic urticaria. Acta Derm Venereol. 1983; 63:265-7. https://pubmed.ncbi.nlm.nih.gov/6192652

176. Singh G. H₂ blockers in chronic urticaria. Int J Dermatol. 1984; 23:627-8. https://pubmed.ncbi.nlm.nih.gov/6151554

177. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol. 1981; 68:262-6. https://pubmed.ncbi.nlm.nih.gov/6116728

178. Harvey RP, Schocket AL. The effect of H₁ and H₂ blockade on cutaneous histamine response in man. J Allergy Clin Immunol. 1980; 65:136-9. https://pubmed.ncbi.nlm.nih.gov/6101337

179. Monroe EW, Cohen SH, Kalbfleisch J et al. Combined H₁ and H₂ antihistamine therapy in chronic urticaria. Arch Dermatol. 1981; 117:404-7. https://pubmed.ncbi.nlm.nih.gov/6114712

180. Nicholson AN, Stone BM. Performance studies with the H₁-histamine receptor antagonists, astemizole and terfenadine. Br J Clin Pharmacol. 1982; 13:199-202. https://pubmed.ncbi.nlm.nih.gov/6120713 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402008/

181. Nicholson AN, Smith PA, Spencer MB. Antihistamines and visual function: studies on dynamic acuity and the pupillary response to light. Br J Clin Pharmacol. 1982; 14:683-90. https://pubmed.ncbi.nlm.nih.gov/6128019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1427480/

182. Luscombe DK, Nicholls PJ, Parish PA. Comparison of the effects of azatadine and terfenadine on human performance. Pharmatherapeutica. 1983; 3:370-5. https://pubmed.ncbi.nlm.nih.gov/6137832

183. Fink M, Irwin P. CNS effects of the antihistamines diphenhydramine and terfenadine (RMI 9918). Pharmakopsychiatr Neuro Psychopharmakol. 1979; 12:35-44.

184. Clarke CH, Nicholson AN. Performance studies with antihistamines. Br J Clin Pharmacol. 1978; 6:31-5. https://pubmed.ncbi.nlm.nih.gov/27204 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429387/

185. Brandon ML, Weiner M. Clinical studies of terfenadine in seasonal allergic rhinitis. Arzneimittelforschung. 1982; 32:1204-5. https://pubmed.ncbi.nlm.nih.gov/6129869

186. Dugue P, Birnbaum J, Poisson A et al. Clinical studies with terfenadine in seasonal allergic rhinitis in France. Arzneimittelforschung. 1982; 32:1206-8. https://pubmed.ncbi.nlm.nih.gov/6129870

187. Melillo G, D’Amato G, Zanussi C et al. A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis. Arzneimittelforschung. 1982; 32:1202-3. https://pubmed.ncbi.nlm.nih.gov/6129868

188. Weiner M. Sedation and antihistaminics. Arzneimittelforschung. 1982; 32:1193-5. https://pubmed.ncbi.nlm.nih.gov/6129866

189. Barlow JLR, Beitman RE, Tsai TH. Terfenadine, safety and tolerance in controlled clinical trials. Arzneimittelforschung. 1982; 32:1215-7. https://pubmed.ncbi.nlm.nih.gov/6129874

190. Howarth PH, Holgate ST. Comparative trial of two non-sedative H₁ antihistamines, terfenadine and astemizole, for hay fever. Thorax. 1984; 39:688-72.

191. Nicholson AN. Antihistaminic activity and central effects of terfenadine. Arzneimittelforschung. 1982; 32:1191-3. https://pubmed.ncbi.nlm.nih.gov/6129865

192. Moser L, Huther KJ, Koch-Weser J et al. Effects of terfenadine and diphenhydramine alone or in combination with diazepam or alcohol on psychomotor performance and subjective feelings. Eur J Clin Pharmacol. 1978; 14:417-23. https://pubmed.ncbi.nlm.nih.gov/33053

193. Parke-Davis. Benadryl (diphenhydramine hydrochloride capsules) prescribing information. In: Physicians’ desk reference. 46th ed. Montvale NJ: Medical Economics Company Inc; 1992:1691-2.

194. Parke-Davis. Benylin cough syrup patient information. In: Huff BB, ed. Physicians’ desk reference. 39th ed. Oradell, NJ: Medical Economics Company Inc; 1985:1486.

195. Forest Pharmaceuticals. Ambenyl cough syrup prescribing information. In: Physicians’ desk reference. 45th ed. Oradell, NJ: Medical Economics Company Inc; 1991:972-3.

196. Food and Drug Administration. External analgesic drug products for over-the-counter human use; tentative final monograph. [21 CFR Part 348] Fed Regist. 1983; 48:5852-69.

197. Food and Drug Administration. Over-the-counter nighttime sleep-aid and stimulant products; tentative final orders. [21 CFR Parts 338,340] Fed Regist. 1978; 114:25544-602.

198. Greenberger P, Patterson R. Safety of therapy for allergic symptoms during pregnancy. Ann Intern Med. 1978; 89:234-7. https://pubmed.ncbi.nlm.nih.gov/28058

199. Saxén I. Cleft palate and maternal diphenhydramine intake. Lancet. 1974; 1:407-8. https://pubmed.ncbi.nlm.nih.gov/4131054

200. Iuliucci JD, Gautieri RF. Morphine-induced malformations. II: Influence of histamine and diphenhydramine. J Pharm Sci. 1971; 60:420-5. https://pubmed.ncbi.nlm.nih.gov/4398382

201. Smith Kline & French. Temaril prescribing information. In: Huff BB, ed. Physicians’ desk reference. 39th ed. Oradell, NJ: Medical Economics Company Inc; 1985:1976-7.

202. Kahn A, Blum D. Possible role of phenothiazines in sudden infant death. Lancet. 1979; 2:364-5. https://pubmed.ncbi.nlm.nih.gov/89428

203. Kahn A, Blum D. Phenothiazines and sudden infant death syndrome. Pediatrics. 1982; 70:75-8. https://pubmed.ncbi.nlm.nih.gov/7088637

204. Stanton AN. Sudden infant death syndrome and phenothiazines. Pediatrics. 1983; 71:986-7. https://pubmed.ncbi.nlm.nih.gov/6856418

205. Kahn A, Blum D. Sudden infant death syndrome and phenothiazines. Pediatrics. 1983; 71:987-8.

206. Mann NP. Trimeprazine and respiratory depression. Arch Dis Child. 1981; 56:481-2. https://pubmed.ncbi.nlm.nih.gov/7259282 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627454/

207. Kahn A, Hasaerts D, Blum D. Phenothiazine-induced sleep apnea in normal infants. Pediatrics. 1985; 75:844-7. https://pubmed.ncbi.nlm.nih.gov/3991270

208. Rao GS, Krishna G, Gillette JR. Metabolism, tissue distribution and covalent binding of tripelennamine and its N-nitroso derivative in the rat. J Pharmacol Exp Ther. 1975; 195:433-40. https://pubmed.ncbi.nlm.nih.gov/1195130

209. Schaffer MI, Lin RL, Wu Chen NB et al. Spontaneous live birth with a maternal history of intravenous use of pentazocine and tripelennamine (T’s and blues). J Forensic Sci. 1983; 28:489-95. https://pubmed.ncbi.nlm.nih.gov/6683302

210. Luders RC, Williams J, Fried K et al. Determination of pyribenzamine (tripelennamine) residues in bovine milk. J Agric Food Chem. 1970; 18:1153-5. https://pubmed.ncbi.nlm.nih.gov/5483055

211. Chaudhuri NK, Servando OA, Manniello MJ et al. Metabolism of tripelennamine in man. Drug Metab Dispos. 1976; 4:372-8. https://pubmed.ncbi.nlm.nih.gov/8293

212. Weinman EO, Geissman TA. The distribution, excretion and metabolism of¹⁴C-labeled tripelennamine (pyribenzamine) by guinea pigs. J Pharmacol Exp Ther. 1959; 125:1-13. https://pubmed.ncbi.nlm.nih.gov/13621384

213. Schipior PG. An unusual case of antihistamine intoxication. J Pediatr. 1967; 71:589-91. https://pubmed.ncbi.nlm.nih.gov/4227701

214. Peck SM, Finkle B, Mayer GS et al. Effects of various modes of administration of pyribenzamine on the histamine wheal and epidermal sensitivity reactions. J Invest Dermatol. 1950; 14:177.

215. LeVan P, Sternberg TH, Perry DJ. Studies of the “antihistaminic” effect of pyribenzamine administered by various routes. Calif Med. 1951; 74:256-9. https://pubmed.ncbi.nlm.nih.gov/14821823 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1520894/

216. Reid RW, Gerbeck CM. Detection of pentazocine and tripelennamine in urine. Clin Chem. 1981; 27:10-13. https://pubmed.ncbi.nlm.nih.gov/7449089

217. Bayley M, Walsh FM, Valske MJ. Report of a fatal, acute tripelennamine intoxication. J Forensic Sci. 1975; 20:539-43. https://pubmed.ncbi.nlm.nih.gov/1151312

218. McGavack TH, Drekter IJ, Schutzer S et al. Levels for pyribenzamine and Benadryl in blood and urine following a single orally administered dose. J Allergy. 1948; 19:251-5. https://pubmed.ncbi.nlm.nih.gov/18871142

219. Darling CM. Histamine and antihistaminic agents. In: Doerge RF, ed. Wilson and Gisvold’s textbook of organic medicinal and pharmaceutical chemistry. 8th ed. Philadelphia: JB Lippincott Company; 1982:583-606.

220. Monforte JR, Gault R, Smialek J et al. Toxicological and pathological findings in fatalities involving pentazocine and tripelennamine. J Forensic Sci. 1983; 28:90-101. https://pubmed.ncbi.nlm.nih.gov/6680755

221. Chasnoff IJ, Burns WJ, Schnoll SH. Perinatal addiction: the effects of maternal narcotic and nonnarcotic substance abuse on the fetus and neonate. NIDA Res Monogr Ser. 1984; 49:220-6.

222. Dunn DW, Reynolds J. Neonatal withdrawal symptoms associated with “T’s and blues” (pentazocine and tripelennamine). Am J Dis Child. 1982; 136:644-5. https://pubmed.ncbi.nlm.nih.gov/7091098

223. Chasnoff IJ, Hatcher R, Burns WJ et al. Pentazocine and tripelennamine (T’s and blues): effects on the fetus and neonate. Dev Pharmacol Ther. 1983; 6:162-9. https://pubmed.ncbi.nlm.nih.gov/6861602

224. Anon. Pentazocine abuse rises—schedule IV status proposed. FDA Drug Bull. 1978; 8:34.

225. Lahmeyer HW, Steingold RG. Pentazocine and tripelennamine: a drug abuse epidemic? Int J Addict. 1980; 15:1219-32.

226. Showalter CV. T’s and blues: abuse of pentazocine and tripelennamine. JAMA. 1980; 224:1224-5.

227. Poklis A. Pentazocine/tripelennamine (T’s and blues) abuse: a five year survey of St. Louis, Missouri. Drug Alcohol Depend. 1982; 10:257-67. https://pubmed.ncbi.nlm.nih.gov/7166138

228. De Bard ML, Jagger JA. T’s and B’s—midwestern heroin substitute. Clin Toxicol. 1981; 18:1117-23. https://pubmed.ncbi.nlm.nih.gov/7318393

229. Itkonen J, Schnoll S, Daghestani A et al. Accelerated development of pulmonary complications due to illicit intravenous use of pentazocine and tripelennamine. Am J Med. 1984; 76:617-22. https://pubmed.ncbi.nlm.nih.gov/6711575

230. Butch AJ, Yokel RA, Sigell LT et al. Abuse and pulmonary complications of injecting pentazocine and tripelennamine tablets. Clin Toxicol. 1979; 14:301-6. https://pubmed.ncbi.nlm.nih.gov/455920

231. Lahmeyer HW, Steingold RG. Medical and psychiatric complications of pentazocine and tripelennamine abuse. J Clin Psychiatry. 1980; 41:275-8. https://pubmed.ncbi.nlm.nih.gov/7400105

232. Caplan LR, Thomas C, Banks G. Central nervous system complications of addiction to T’s and blues. Neurology. 1982; 32:623-8. https://pubmed.ncbi.nlm.nih.gov/7201092

233. Poklis A, Mackell MA. Pentazocine and tripelennamine (T’s and blues) abuse: toxicological findings in 39 cases. J Anal Toxicol. 1982; 6:110-4.

234. Heaney RM, Gotlieb N. Granulocytopenia after intravenous abuse of pentazocine and tripelennamine (“Ts and blues”). South Med J. 1983; 76:654-6. https://pubmed.ncbi.nlm.nih.gov/6844971

235. Reinhart S, Barrett SM. An acute hypertensive response after intravenous use of a new pentazocine formulation. Ann Emerg Med. 1985; 14:591-3. https://pubmed.ncbi.nlm.nih.gov/3994086

236. Burton JF, Zawadzki S, Wetherell HR et al. Mainliners and blue velvet. J Forensic Sci. 1965; 10:466-72. https://pubmed.ncbi.nlm.nih.gov/5839798

237. Zwed JJ. Pulmonary angiothrombosis caused by “blue velvet” addiction. Ann Intern Med. 1970; 73:771-4. https://pubmed.ncbi.nlm.nih.gov/5476210

238. Lerner AM, Oerther FJ. Characteristics and sequelae of paregoric abuse. Ann Intern Med. 1966; 65:1019-30. https://pubmed.ncbi.nlm.nih.gov/5923084

239. Wendt VE, Puro HE, Shapira J et al. Angiothrombotic pulmonary hypertension in addicts: “blue velvet” addiction. JAMA. 1964; 188:755-7. https://pubmed.ncbi.nlm.nih.gov/14122687

240. O’Driscoll WG, Lindley GR. Self-administration of tripelennamine by a narcotic addict. N Engl J Med. 1957; 257:376-7. https://pubmed.ncbi.nlm.nih.gov/13464943

241. Houck RJ, Bailey GL, Daroca PJ Jr et al. Pentazocine abuse: report of a case with pulmonary arterial cellulose granulomas and pulmonary hypertension. Chest. 1980; 77:227-9. https://pubmed.ncbi.nlm.nih.gov/7353425

242. Tomashefski JF Jr, Hirsch CS, Jolly PN. Microcrystalline cellulose pulmonary embolism and granulomatosis: a complication of illicit intravenous injections of pentazocine tablets. Arch Pathol Lab Med. 1981; 105:89-93. https://pubmed.ncbi.nlm.nih.gov/6893924

243. Farber HW, Mathers JAL Jr, Glauser FL. Gallium scans and serum angiotensin converting enzyme levels in talc granulomatosis and lymphocytic interstitial pneumonitis. South Med J. 1980; 73:1663-7. https://pubmed.ncbi.nlm.nih.gov/6255609

244. Farber HW, Falls R, Glauser FL. Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets. Chest. 1981; 80:178-82. https://pubmed.ncbi.nlm.nih.gov/7249763

245. Farber HW, Fairman RP, Glauser FL. Talc granulomatosis: laboratory findings similar to sarcoidosis. Am Rev Respir Dis. 1982; 125:258-61. https://pubmed.ncbi.nlm.nih.gov/6278999

246. Farber H, Glauser FL. The effect of oral hydralazine on the pulmonary hemodynamics of patients with pulmonary foreign body granulomatosis. Chest. 1982; 82:708-12. https://pubmed.ncbi.nlm.nih.gov/7140398

247. Meador KH, Sharon Z, Lewis EJ. Renal amyloidosis and subcutaneous drug abuse. Ann Intern Med. 1979; 91:565-7. https://pubmed.ncbi.nlm.nih.gov/484955

248. Mizutani T, Lewis RA, Gonatas NK. Medial medullary syndrome in a drug abuser. Arch Neurol. 1980; 37:425-8. https://pubmed.ncbi.nlm.nih.gov/7387487

249. AtLee WE Jr. Talc and corn starch emboli in eyes of drug abusers. JAMA. 1972; 219:49-51. https://pubmed.ncbi.nlm.nih.gov/5066587

250. Kresca LJ, Goldberg MF, Jampol LM. Talc emboli and retinal neovascularization in a drug abuser. Am J Ophthalmol. 1979; 87:334-9. https://pubmed.ncbi.nlm.nih.gov/434093

251. Friberg TR, Gragoudas ES, Regan CDJ. Talc emboli and macular ischemia in intravenous drug abuse. Arch Ophthalmol. 1979; 97:1089-91. https://pubmed.ncbi.nlm.nih.gov/444139

252. Schatz H, Drake M. Self-injected retinal emboli. Ophthalmology. 1979; 86:468-83. https://pubmed.ncbi.nlm.nih.gov/530595

253. Shook JE, Kallman MJ, Martin BR et al. Characterization of the interaction of pentazocine and tripelennamine: drug discrimination and mu-receptor binding assay. Pharmacol Biochem Behav. 1984; 21:877-81. https://pubmed.ncbi.nlm.nih.gov/6097919

254. Tagashira E, Kachur JF, Carter WH et al. Potentiation of narcotic-induced antinociception by tripelennamine in morphine-tolerant and drug-naive mice. J Pharmacol Exp Ther. 1984; 229:214-7. https://pubmed.ncbi.nlm.nih.gov/6707938

255. Shannon HE, Su TP. Effects of the combination of tripelennamine and pentazocine at the behavioral and molecular levels. Pharmacol Biochem Behav. 1982; 17:789-95. https://pubmed.ncbi.nlm.nih.gov/6294681

256. Su TP. Possible explanations of “T’s and blues” interaction: tripelennamine and pentazocine are potent ligands for psychotomimetic sigma-opioid receptor. Fed Proc. 1983; 42:1017.

257. Tagashira E, Kachur JF, Carter WH Jr et al. Pentazocine-tripelennamine (“T’s and Blues”) substitution studies in morphine-dependent rodents. J Pharmacol Exp Ther. 1984; 231:97-101. https://pubmed.ncbi.nlm.nih.gov/6541694

258. Bhargava HN. Mechanism of toxicity and rationale for use of the combination of pentazocine and pyribenzamine in morphine-dependent subjects. Clin Toxicol. 1981; 18:175-88. https://pubmed.ncbi.nlm.nih.gov/7194759

259. Waller DP, Katz NL, Morris RW. Potentiation of lethality in mice by combinations of pentazocine and tripelennamine. Clin Toxicol. 1980; 16:17-23. https://pubmed.ncbi.nlm.nih.gov/7389279

260. Carlson C. Talwin 50 reformulated to avert “T’s and blues” abuse. JAMA. 1983; 249:1689. https://pubmed.ncbi.nlm.nih.gov/6827745

261. Talwin Nx prescribing information. In: Huff BB, ed. Physicians’ desk reference. 39th ed. Oradell, NJ: Medical Economics Company Inc; 1985:2230-2.

262. Wyeth Laboratories. Phenergan tablets and suppositories prescribing information. Philadelphia; 1984 Oct 1.

263. Aselton P, Hershel J, Milunsky A et al. First-trimester drug use and congenital disorders. Obstet Gynecol. 1985; 65:451-5. https://pubmed.ncbi.nlm.nih.gov/3982720

264. Mortimer EA Jr. Drug toxicity from breast milk. Pediatrics. 1977; 60:780-2. https://pubmed.ncbi.nlm.nih.gov/917668

265. Lin CC, Kim HK, Lim J et al. Steady-state bioavailability of dexbrompheniramine and pseudoephedrine from a repeat-action combination tablet. J Pharm Sci. 1985; 74:25-8. https://pubmed.ncbi.nlm.nih.gov/3981411

266. Friedman H, Greenblatt DJ. The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. J Clin Pharmacol. 1985; 25:448-51. https://pubmed.ncbi.nlm.nih.gov/4056080

267. Kohlhof KJ, Stump D, Zizzamia JA. Analysis of doxylamine in plasma by high-performance liquid chromatography. J Pharm Sci. 1983; 72:961-2. https://pubmed.ncbi.nlm.nih.gov/6620159

268. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med. 1985; 313:347-52. https://pubmed.ncbi.nlm.nih.gov/4010751

269. Anon. Indications for Bendectin narrowed. FDA Drug Bull. 1981; 11:1-3. https://pubmed.ncbi.nlm.nih.gov/7215728

270. Anon. Bendectin and pyloric stenosis. FDA Drug Bull. 1983; 13:14-5.

271. Cordero JF, Oakley GP, Greenberg F et al. Is Bendectin a teratogen? JAMA. 1981; 245:2307-10.

272. Unisomproduct information. In: Huff BB, ed. Physicians’ desk reference for nonprescription drugs. 6th ed. Oradell, NJ: Medical Economics Company Inc; 1985:568.

273. Bendectin prescribing information. In: Huff BB, ed. Physicians’ desk reference. 37th ed. Oradell, NJ: Medical Economics Company Inc; 1983:1345-6.

274. Orme ML. The Debendox saga. BMJ. 1985; 291:918-9. https://pubmed.ncbi.nlm.nih.gov/3929963 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1417186/

275. Holmes LB. Teratogen update: Bendectin. Teratology. 1983; 27:277-81. https://pubmed.ncbi.nlm.nih.gov/6346560

276. Kolata G. FDA to reexamine Bendectin data. Science. 1982; 217:335. https://pubmed.ncbi.nlm.nih.gov/7046049

277. More on Bendectin. JAMA. 1981; 246:371-2. Editorial.

278. Smith RJ. Studies support Bendectin safety claim. Science. 1981; 212:1485. https://pubmed.ncbi.nlm.nih.gov/7015515

279. Kolata GB. How safe is Bendectin? Science. 1980; 210:518-9.

280. Check WA. CDC study: no evidence for teratogenicity of Bendectin. JAMA. 1979; 242:2518. https://pubmed.ncbi.nlm.nih.gov/490865

281. Smithells RW, Sheppard S. Teratogenicity testing in humans: a method demonstrating safety of Bendectin. Teratology. 1978; 17:31-6. https://pubmed.ncbi.nlm.nih.gov/625707

282. Morelock S, Hingson R, Kayne H et al. Bendectin and fetal development. Am J Obstet Gynecol. 1982; 142:209-13. https://pubmed.ncbi.nlm.nih.gov/7055187

283. Morelock S, Hingson R, Kayne H et al. Bendectin and fetal development. Am J Obstet Gynecol. 1982; 143:237. https://pubmed.ncbi.nlm.nih.gov/6123260

284. Shapiro S, Heinonen OP, Siskind V et al. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Bendectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977; 128:480-5. https://pubmed.ncbi.nlm.nih.gov/879205

285. Harron DWG, Griffiths K, Shanks RG. Debendox and congenital malformations in Northern Ireland. Br Med J. 1980; 281:1379-81. https://pubmed.ncbi.nlm.nih.gov/7437804 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1714994/

286. Barlow SM, Sullivan FM. Debendox and congenital malformations in Northern Ireland. BMJ. 1981; 282:148-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1503911/

287. Shanks RG, Griffiths K, Harron DWG. Debendox and congenital malformations in Northern Ireland. BMJ. 1981; 282:1972-3. https://pubmed.ncbi.nlm.nih.gov/6786693

288. Fleming DM, Knox JDE, Crombie DL. Debendox in early pregnancy and fetal malformation. BMJ. 1981; 283:99-101. https://pubmed.ncbi.nlm.nih.gov/6789952 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1506081/

289. Rothman KJ, Fyler DC, Goldblatt A et al. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol. 1979; 109:433-9. https://pubmed.ncbi.nlm.nih.gov/443241

290. Mitchell AA, Rosenberg L, Shapiro S et al. Birth defects related to Bendectin use in pregnancy: oral clefts and cardiac defects. JAMA. 1981; 245:2311-4. https://pubmed.ncbi.nlm.nih.gov/7230459

291. Jick H, Holmes LB, Hunter JR et al. First-trimester drug use and congenital disorders. JAMA. 1981; 246:343-6. https://pubmed.ncbi.nlm.nih.gov/7241780

292. Gibson GT, Colley DP, McMichael AJ et al. Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors: an ongoing prospective study. Med J Aust. 1981; 1:410-4. https://pubmed.ncbi.nlm.nih.gov/7254087

293. Kalter H, Warkany J. Congenital malformations. N Engl J Med. 1983; 309:312. https://pubmed.ncbi.nlm.nih.gov/6866057

294. Nestor JO. Congenital malformations. N Engl J Med. 1983; 309:312. https://pubmed.ncbi.nlm.nih.gov/6866057

295. Eskenazi B, Bracken MB. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol. 1982; 144:919-24. https://pubmed.ncbi.nlm.nih.gov/7148924

296. Mitchell AA, Schwingl PJ, Rosenberg L et al. Birth defects in relation to Bendectin use in pregnancy: II. Pyloric stenosis. Am J Obstet Gynecol. 1983; 147:737-42. https://pubmed.ncbi.nlm.nih.gov/6650593

297. Golding J, Vivian S, Baldwin JA. Maternal anti-nauseants and clefts of lip and palate. Hum Toxicol. 1983; 2:63-73. https://pubmed.ncbi.nlm.nih.gov/6840794

298. Aselton PJ, Jick H. Additional follow-up of congenital limb disorders in relation to Bendectin use. JAMA. 1983; 250:33-4. https://pubmed.ncbi.nlm.nih.gov/6682906

299. Kalter H, Warkany J. Congenital malformations (second of two parts). N Engl J Med. 1983; 308:491-7. https://pubmed.ncbi.nlm.nih.gov/6337336

300. Grodofsky MP, Wilmott RW. Possible association of use of Bendectin during early pregnancy and congenital lung hypoplasia. N Engl J Med. 1984; 304:732.

301. Hughes DT, Cavanagh N. Chromosomal studies on children with phocomelia, exposed to Debendox during early pregnancy. Lancet. 1983; 2:399. https://pubmed.ncbi.nlm.nih.gov/6135891

302. Smithells RW, Sheppard S. Teratogenicity of Debendox and pyrimethamine. Lancet. 1983; 2:623-4. https://pubmed.ncbi.nlm.nih.gov/6136770

303. Clarke M, Clayton DG. Safety of Debendox. Lancet. 1981; 1:659-60. https://pubmed.ncbi.nlm.nih.gov/6110878

304. Bracken MB, Berg A. Bendectin (Debendox) and congenital diaphragmatic hernia. Lancet. 1983; 1:586. https://pubmed.ncbi.nlm.nih.gov/6131274

305. Mitchell AA, Shapiro S. Bendectin (Debendox) and congenital diaphragmatic hernia. Lancet. 1983; 1:930. https://pubmed.ncbi.nlm.nih.gov/6132245

306. Merrell National laboratories. Decapryn prescribing information. Cincinnati, OH; 1975 Oct.

307. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: Williams & Wilkins; 1984;III-36-40.

308. Lee CC. Comparative pharmacologic responses to antihistamines in newborn and young rats. Toxicol Appl Pharmacol. 1966; 8:210-7. https://pubmed.ncbi.nlm.nih.gov/5956873

309. Cook TJ, MacQueen DM, Wittig HJ et al. Degree and duration of skin test suppression and side effects with antihistamines: a double blind controlled study with five antihistamines. J Allergy Clin Immunol. 1973; 51:71-7. https://pubmed.ncbi.nlm.nih.gov/4405284

310. Galant SP, Bullock J, Wong D et al. The inhibitory effect of antiallergy drugs on allergen and histamine induced wheal and flare response. J Allergy Clin Immunol. 1973; 51:11-21. https://pubmed.ncbi.nlm.nih.gov/4118408

311. Chipps BE, Talamo RC, Mellits ED et al. Immediate (IgE-mediated) skin testing in the diagnosis of allergic disease. Ann Allergy. 1978; 41:211-5. https://pubmed.ncbi.nlm.nih.gov/81630

312. Galant SP, Zippin C, Bullock J et al. Allergy skin test: I. Antihistamine inhibition. Ann Allergy. 1972; 30:53-63. https://pubmed.ncbi.nlm.nih.gov/4400814

313. Diamond GA, Dilibero RJ. Pharmacologic modification of the immediate intradermal skin reaction. Ann Allergy. 1966; 24:288-90. https://pubmed.ncbi.nlm.nih.gov/5328526

314. Kern GW IV. Letter to the editors. Clin Allergy. 1982; 12:321. https://pubmed.ncbi.nlm.nih.gov/6125277

315. Arnaud A, Vervloet D, Ostorero M et al. Effets des anti-histaminiques (H₁ et H₂) sur différents types de tests cutanés explorant l’allergie a médiation humorale ou cellulaire. (French; with English abstract.) Nouv Presse Med. 1980; 9:2849. Letter.

316. Johnson CE, Weiner JS, Wagner DS et al. Effect of H₁- and H₂-receptor blockade on the inhibition of immediate cutaneous reactions. Clin Pharm. 1984; 3:60-4. https://pubmed.ncbi.nlm.nih.gov/6141860

317. Smith JA, Mansfield LE, de Shazo RD. An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. J Allergy Clin Immunol. 1980; 65:118-21.

318. Gibbs CJ, Coutts II, Jackson SM et al. Skin test wheal size and erythema not reduced by topical antihistamine. BMJ. 1983; 287:1427-8. https://pubmed.ncbi.nlm.nih.gov/6139139 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549634/

319. Filloux F. Toxic encephalopathy caused by topically applied diphenhydramine. J Pediatr. 1986; 108:1018-20. https://pubmed.ncbi.nlm.nih.gov/3712143

320. Schering Corporation. Chlor-Trimeton Injection prescribing information. Kenilworth, NJ; 1985 Jun.

321. Mansfield LE, Smith JA, Nelson HS. Greater inhibition of dermographia with a combination of H1 and H2 antagonists. Ann Allergy. 1983; 50:264-5. https://pubmed.ncbi.nlm.nih.gov/6132569

322. The United States pharmacopeia, 21st rev, and The national formulary, 16th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1987(Suppl 5):2485.

323. Department of Health and Human Services National Toxicology Program. Toxicology and carcinogenesis studies of chlorpheniramine maleate (CAS No. 113-92-8) in F344/N rats and B6C3F₁ mice (gavage studies). Research Triangle Park, NC: National Toxicology Program; 1986 Sept. (NIH publication No. 86-2573; NTP TR No. 317).

324. Kok THHG, Taitz LS, Bennett MJ et al. Drowsiness due to clemastine transmitted in breast milk. Lancet. 1982; 1:914-5. https://pubmed.ncbi.nlm.nih.gov/6122135

325. Sandoz Pharmaceuticals Corporation. Tavist (clemastine fumarate) Syrup prescribing information. In: Huff BB, ed. Physicians’ desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987:1792-3.

326. Tham R, Norlander B, Hagermark O et al. Gaschromatography of clemastine (a study of plasma kinetics and biological effect). Arzneimittelforschung. 1978; 28:1017-20. https://pubmed.ncbi.nlm.nih.gov/35180

327. Paton DM, Webster DR. Clinical pharmacokinetics of H₁-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985; 10:477-97. https://pubmed.ncbi.nlm.nih.gov/2866055

328. Food and Drug Administration. Antiemetic drug products for over-the-counter human use; final monograph [21 CFR Parts 310, 366, 369; Docket No. 78N-036A]. Fed Regist. 1987; 52:15866-93.

329. Smith Kline & French Laboratories. Hispril (diphenylpyraline hydrochloride) Spansule capsules prescribing information. In: Huff BB, ed. Physician’s desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987:1918.

330. Westwood Pharmaceuticals Inc. Tacaryl (methdilazine) Chewable Tablets and Tacaryl (methdilazine hydrochloride) Tablets/Syrup prescribing information. In: Huff BB, ed. Physician’s desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc.; 1987:2101-2.

331. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use; warning statement. [21 CFR Part 201] Fed Regist. 1986; 51:43900-4.

332. American Medical Association Council on Scientific Affairs. Aspartame: review of safety issues. JAMA. 1985; 254:400-2. https://pubmed.ncbi.nlm.nih.gov/2861297

333. Gossel TA. A review of aspartame: characteristics, safety and uses. US Pharm. 1984; 9:26,28-30.

334. Food and Drug Administration. Aspartame as an inactive ingredient in human drug products; labeling requirements. [21 CFR Part 201] Fed Regist. 1983; 48:54993-5. (IDIS 178728)

335. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; aspartame. [21 CFR Part 172] Fed Regist. 1983; 48:31376-82. (IDIS 172957)

336. Anon. Aspartame and other sweeteners. Med Lett Drugs Ther. 1982; 24:1-2. https://pubmed.ncbi.nlm.nih.gov/7054648

337. Loan WB, Cuthbert D. Adverse cardiovascular response to oral trimeprazine in children. BMJ. 1985; 290:1548-9. https://pubmed.ncbi.nlm.nih.gov/3924159 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1415721/

338. Thomas DL, Vaughan RS, Vickers MD et al. Comparison of temazepam elixir and trimeprazine syrup as oral premedication in children undergoing tonsillectomy and associated procedures. Br J Anaesth. 1987; 59:424-30. https://pubmed.ncbi.nlm.nih.gov/2882766

339. Padfield NL, Twohig MM, Fraser ACL. Temazepam and trimeprazine compared with placebo as premedication in children. Br J Anaesth. 1986; 58:487-93. https://pubmed.ncbi.nlm.nih.gov/2870728

340. Yeh SY, Todd GD, Johnson RE et al. The pharmacokinetics of pentazocine and tripelennamine. Clin Pharmacol Ther. 1986; 39:669-76. https://pubmed.ncbi.nlm.nih.gov/3709032

341. Brand JJ, Perry WLM. Drugs used in motion sickness: a critical review of the methods available for the study of drugs of potential value in its treatment and of the information which has been derived by these methods. Pharmacol Rev. 1966; 18(1 Part II):895-924. https://pubmed.ncbi.nlm.nih.gov/5325212

342. Wood CD, Kennedy RS, Graybiel A. Review of antimotion sickness drugs from 1954–1964. Aerospace Med. 1965; 36:1-4. https://pubmed.ncbi.nlm.nih.gov/14243672

343. Chinn HI, Smith PK. Motion sickness. Pharmacol Rev. 1955; 7:33-82. https://pubmed.ncbi.nlm.nih.gov/14370919

344. Money KE. Motion sickness. Physiol Rev. 1970; 50:1-39. https://pubmed.ncbi.nlm.nih.gov/4904269

345. Cirillo VJ, Tempero KF. Pharmacology and therapeutic use of antihistamines. Am J Hosp Pharm. 1976; 33:1200-7. https://pubmed.ncbi.nlm.nih.gov/11685

346. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: The Macmillan Company; 1985:605-38.

347. Anon. Drugs for relief of nausea and vomiting. Med Lett Drugs Ther. 1974; 16:46-8.

348. Army, Navy, Air Force Motion Sickness Team. Evaluation of drugs for protection against motion sickness aboard transport ships. JAMA. 1956; 160:755-60.

349. Food and Drug Administration. External analgesic drug products for over-the-counter human use; establishment of a monograph and notice of proposed rulemaking. [21 CFR Part 348] Fed Regist. 1979; 44:69768-866.

350. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for OTC antihistamine drug products. [21 CFR Parts 201, 310, 341, 369] Fed Regist. 1987; 52:31892-914.

351. Spector R, Choudhury AK, Chiang CK et al. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther. 1980; 28:229-34. https://pubmed.ncbi.nlm.nih.gov/7398190

352. Meredith CG, Christian CD, Johnson RF et al. Diphenhydramine disposition in chronic liver disease. Clin Pharmacol Ther. 1984; 35:474-9. https://pubmed.ncbi.nlm.nih.gov/6705445

353. Berlinger WG, Goldberg MJ, Spector R et al. Diphenhydramine: kinetics and psychomotor effects in elderly women. Clin Pharmacol Ther. 1982; 32:387-91. https://pubmed.ncbi.nlm.nih.gov/7049503

354. Graham G, Bolt AG. Half-life of diphenylpyraline in man. J Pharmacokinet Biopharm. 1974; 2:191-5. https://pubmed.ncbi.nlm.nih.gov/4156058

355. American Academy of Pediatrics Committee on Drugs. Antihistamines in topical preparations. Pediatrics. 1973; 51:299-301. https://pubmed.ncbi.nlm.nih.gov/4144454

356. Fastner Z. Antihistamines (H₁-receptor antagonists). In: Dukes MNG, ed. Meyler’s side effects of drugs. 10th ed. New York: Elsevier Science Publishers BV; 1984:284-9.

357. AMA Department of Drugs. Drug Evaluations. 6th ed. Chicago: American Medical Association; 1986; 1019-20.

358. Arndt KA. Manual of dermatologic therapeutics. 2nd ed. Boston: Little, Brown and Company; 1978:266-72.

359. Calnan CD. Contact dermatitis from drugs. Proc R Soc Med. 1962; 44:39-42.

360. Coskey RJ. Contact dermatitis caused by diphenhydramine hydrochloride. J Am Acad Dermatol. 1983; 8:204-6. https://pubmed.ncbi.nlm.nih.gov/6219138

361. Fisher AA. Systemic eczematous “contact-type” dermatitis medicamentosa. Ann Allergy. 1966; 24:406-20. https://pubmed.ncbi.nlm.nih.gov/4223211

362. Fisher AA. Ethylenediamine dermatitis. Arch Dermatol. 1969; 100:519-20. https://pubmed.ncbi.nlm.nih.gov/4243136

363. Vickers CFH. Dermatitis medicamentosa. Br Med J. 1961; 1:1366-7. https://pubmed.ncbi.nlm.nih.gov/13781158 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1954471/

364. Shelley WB, Bennett RG. Primary contact sensitization site: a determinant for the localization of a diphenhydramine eruption. Acta Derm Venereol. 1972; 52:376-8. https://pubmed.ncbi.nlm.nih.gov/4117085

365. Horio T. Allergic and photoallergic dermatitis from diphenhydramine. Arch Dermatol. 1976; 112:1124-6. https://pubmed.ncbi.nlm.nih.gov/952531

366. Emmett EA. Diphenhydramine photoallergy. Arch Dermatol. 1974; 10:249-52.

367. Schreiber MM, Naylor LZ. Antihistamine photosensitivity. Arch Dermatol. 1962; 86:58-62. https://pubmed.ncbi.nlm.nih.gov/13909261

368. Epstein E. Allergy to dermatologic agents. JAMA. 1966; 198:517-20. https://pubmed.ncbi.nlm.nih.gov/4380680

369. Davenport PM, Wilhelm RE. An unusual vasculitis due to diphenhydramine: cutaneous and central nervous system involvement. Arch Dermatol. 1965; 92:577-80. https://pubmed.ncbi.nlm.nih.gov/4221165

370. Lawrence CM, Byrne JPH. Eczematous eruption from oral diphenhydramine. Contact Dermatitis. 1981; 7:276-7. https://pubmed.ncbi.nlm.nih.gov/7307489

371. Serafin WE, Austen KF. Mediators of immediate hypersensitivity reactions. N Engl J Med. 1987; 317:30-4. https://pubmed.ncbi.nlm.nih.gov/2438554

372. Ishikawa S, Sperelakis N. A novel class (H₃) of histamine receptors on perivascular nerve terminals. Nature. 1987; 327:158-60. https://pubmed.ncbi.nlm.nih.gov/3033517

373. Arrang JM, Garbarg M, Lancelot JC et al. Highly potent and selective ligands for histamine H₃-receptors. Nature. 1987; 327:117-23. https://pubmed.ncbi.nlm.nih.gov/3033516

374. Hill SJ. Histamine receptors branch out. Nature. 1987; 327:104-5. https://pubmed.ncbi.nlm.nih.gov/3033514

375. Arrang JM, Garbarg M, Schwartz JC. Stimulation sélective des aurorécepteurs H₃ de l’histamine. (French; with English abstract.) C R Acad Sc Paris. 1987; 304:11-4.

376. Antohe F, Heltianu C, Simionescu N. Further evidence for the distribution and nature of histamine receptors on microvascular endothelium. Microcirc Endothelium Lymphatics. 1986; 3:163-85. https://pubmed.ncbi.nlm.nih.gov/2438546

377. Ehrenpreis S, Kimura I, Kobayashi T et al. Histamine release as the basis for morphine action on bile duct and sphincter of Oddi. Life Sci. 1987; 40:1695-8. https://pubmed.ncbi.nlm.nih.gov/2436022

378. Movat HZ. The role of histamine and other mediators in microvascular changes in acute inflammation. Can J Physiol Pharmacol. 1987; 65:451-7. https://pubmed.ncbi.nlm.nih.gov/3555750

379. Fisher AA. Topical medicaments which are common sensitizers. Ann Allergy. 1982; 49:96-100.

380. Ellis FA, Bundick WR. Appraisal of topical use of antihistamines. JAMA. 1952; 150:773-6.

381. Lauderdale WH, Fred HL, Graver CD. Anaphylactoid reaction to diphenhydramine hydrochloride. Arch Intern Med. 1964; 114:693-5. https://pubmed.ncbi.nlm.nih.gov/14216000

382. Schuller DE. Adverse effects of brompheniramine on pulmonary function in a subset of asthmatic children. J Allergy Clin Immunol. 1983; 72:175-9. https://pubmed.ncbi.nlm.nih.gov/6886255

383. Adverse Drug Reactions Advisory Committee. Antihistamines. Med J Aust. 1982; 1:522.

384. Newill RGD. Photosensitivity caused by promethazine. Br Med J. 1960; 2:359-60. https://pubmed.ncbi.nlm.nih.gov/14426802 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2097502/

385. Epstein S, Rowe RJ. Photoallergy and photocross-sensitivity to Pheneugan. J Invest Dermatol. 1957; 28:319-26.

386. Adverse Drug Reactions Advisory Committee. Antihistamine sensitivity. Aust Prescr. 1979; 3:9.

387. Adverse Drug Reactions Advisory Committee. Treatment worse than disease? Aust Prescr. 1980; 4:44.

388. Lauderdale WH, Fred HL, Graver CD. Anaphylactoid reaction to diphenhydramine hydrochloride. Arch Intern Med. 1964; 114:693-5. https://pubmed.ncbi.nlm.nih.gov/14216000

389. Soter NA, Austen KF. The diversity of mast cell-derived mediators: implications for acute, subacute, and chronic cutaneous inflammatory disorders. J Invest Dermatol. 1976; 67:313-9. https://pubmed.ncbi.nlm.nih.gov/61246

390. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for combination drug products. [21 CFR Part 341] Fed Regist. 1988; 53:30522-64.

391. Merck & Co. Periactin (cyproheptadine) tablets and syrup prescribing information. West Point, PA; 1999 Sept.

392. Larrey D, Geneve J, Pessayre D et al. Prolonged cholestasis after cyproheptadine-induced acute hepatitis. J Clin Gastroenterol. 1987; 9:102-4. https://pubmed.ncbi.nlm.nih.gov/3559100

393. Merrell Dow Pharmaceuticals Inc. Seldane (terfenadine) prescribing information. Cincinnati, OH; 1987 Jan.

394. Larrey D, Palazzo L, Benhamou JP. Terfenadine and hepatitis. Ann Intern Med. 1985; 103:634. https://pubmed.ncbi.nlm.nih.gov/2864011

395. Henry DA, Lowe JM, Donnelly T. Jaundice during cyproheptadine treatment. Br Med J. 1978; 1:753. https://pubmed.ncbi.nlm.nih.gov/630329 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1603292/

396. Karkalas Y, Lal H. Jaundice following therapy with imipramine and cyproheptadine. Clin Toxicol. 1971; 4:47-53. https://pubmed.ncbi.nlm.nih.gov/5097484

397. Hendeles L, Weinberger M, Wong L. Medical management of noninfectious rhinitis. Am J Hosp Pharm. 1980; 37:496-504. https://pubmed.ncbi.nlm.nih.gov/7377212

398. Bryant BG, Cormier JF. Cold and allergy products. In: American Pharmaceutical Association. Handbook of nonprescription drugs. 8th ed. Washington, DC: American Pharmaceutical Association; 1986:127-74.

399. Food and Drug Administration. General guidelines for OTC drug combination products. [Docket No. 78D-0322, Dockets Management Branch.] 1978 Sep. (Notice of availability published in Fed Regist. 1978; 43:55466.)

400. Doyle WJ, McBride TP, Skoner DP et al. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. Pediatr Infect Dis J. 1988; 7:229-38. https://pubmed.ncbi.nlm.nih.gov/3282216

401. Crutcher JE, Kantner TR. The effectiveness of antihistamines in the common cold. J Clin Pharmacol. 1981; 21:9-15. https://pubmed.ncbi.nlm.nih.gov/7012191

402. Gaffey MJ, Gwaltney JM Jr, Sastre A et al. Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. Am Rev Respir Dis. 1987; 136:556-60. https://pubmed.ncbi.nlm.nih.gov/3307567

403. American Academy of Pediatrics Committee on Drugs. Ethanol in liquid preparations intended for children. Pediatrics. 1984; 73:405-7. https://pubmed.ncbi.nlm.nih.gov/6701068

404. Janssen Pharmaceutical. Hismanal(astemizole) tablets prescribing information. Piscataway, NJ; 1988 Dec.

405. Richards DM, Brogden RN, Heel RC et al. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1984; 28:38-61. https://pubmed.ncbi.nlm.nih.gov/6204835

406. Mann KV, Crowe JP, Tietze KJ. Nonsedating histamine H₁-receptor antagonists. Clin Pharm. 1989; 8:331-44. https://pubmed.ncbi.nlm.nih.gov/2568212

407. Food and Drug Administration. Nighttime sleep-aid products for over-the-counter human use; final monograph. [21 CFR Part 338] Fed Regist. 1989; 54:6814-27. (IDIS 250549)

408. Harvey SC. Hypnotics and sedatives. In: Gilman AG, Goodman L, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: The Macmillan Company; 1985:339-71.

409. Roila F, Donati D, Basurto C et al. Diphenhydramine and acute dystonia. Ann Intern Med. 1989; 111:92-3. https://pubmed.ncbi.nlm.nih.gov/2735633

410. Mendoza FS, Atiba JO, Krensky AM et al. Rhabdomyolysis complicating doxylamine overdose. Clin Pediatr. 1987; 26:595-7.

411. Parke-Davis. Benadryl (diphenhydramine hydrochloride injection) prescribing information. In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:2234.

412. Clark RF, Vance MV. Massive diphenhydramine poisoning resulting in wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med. 1992; 21:318-21. https://pubmed.ncbi.nlm.nih.gov/1311158

413. Hoechst Marion Roussel. Seldane (terfenadine) tablets prescribing information. Kansas City, MO: 1997 Sep.

414. Davies AJ, Harindra V, McEwan A et al. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ. 1989; 298:325. https://pubmed.ncbi.nlm.nih.gov/2564285 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1835615/

415. Dear doctor letter regarding important drug warning of Seldane. Cincinnati, OH: Marion Merrell Dow; 1990 Aug 6.

416. Monahan BP, Ferguson CL, Killeary ES et al. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990; 264:2788-90. https://pubmed.ncbi.nlm.nih.gov/1977935

417. Marion Merrell Dow, Kansas City, MO: Personal communication.

418. Cruzan S (US Food and Drug Administration). HHS News. Press release No. P92-22. 1992 Jul 7.

419. Marion Merrell Dow. Dear health care professional letter regarding appropriate use of Seldane. Kansas City, MO: July 7, 1992.

420. Zimmerman M, Duruz H, Guinand O et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 1992; 13:1002-3. https://pubmed.ncbi.nlm.nih.gov/1644069

421. Bastecky J, Kvasnicka J, Vortel J et al. [Severe antihistamine poisoning complicated by ventricular tachycardia.] Vnitr Lek. 1990; 36:266-9.

422. Venturini E, Borghi E, Maurini V et al. [Prolongation of the Q-T interval and hyperkinetic ventricular arrhythmias probably induced by terfenadine use in liver cirrhosis patients]. Recenti Prog Med. 1992; 83:21-2. https://pubmed.ncbi.nlm.nih.gov/1561478

423. MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine. BMJ. 1991; 302:1469. https://pubmed.ncbi.nlm.nih.gov/1676921 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1670151/

424. Revelle M (US Food and Drug Administration). HHS News. Press release No. P92-25. 1992 Jul 20.

425. Simons FER, Kesselman MS, Giddins NG et al. Astemizole-induced torsade de pointes. Lancet. 1988; 2:624. https://pubmed.ncbi.nlm.nih.gov/2900995

426. Tobin JR, Doyle TP, Ackerman AD et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA. 1991; 266:2737-40. https://pubmed.ncbi.nlm.nih.gov/1942426

427. Snook J, Boothman-Burrell D, Watkins J et al. Torsades de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract. 1988; 42:257-9. https://pubmed.ncbi.nlm.nih.gov/2905156

428. Kingswood JC, Routledge PA, Lazarus JH. A report of overdose with astemizole. Hum Toxicol. 1986; 5:43-4. https://pubmed.ncbi.nlm.nih.gov/3081429

429. Clark A, Love H. Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions. Int J Cardiol. 1991; 33:165-7. https://pubmed.ncbi.nlm.nih.gov/1937973

430. Anon. Canada moving Seldane and Hismanal behind the counter. FDC Rep. July 20, 1992; T&G-14.

431. Bastecky J, Kvasnicka J, Vortel J et al. [Severe antihistamine poisoning complicated by ventricular tachycardia.] Vnitr Lek. 1990; 36:266-9.

432. Bishop RO, Gaudry PL. Prolonged Q-T interval following astemizole overdose. Arch Emerg Med. 1989; 6:63-5. https://pubmed.ncbi.nlm.nih.gov/2565725 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1285561/

433. Klaumer MA. Dear doctor letter regarding the potential for serious cardiovascular effects in patients taking Hismanal (astemizole). Titusville, NJ: Janssen Pharmaceutica; July 20, 1992.

434. Anon. Safety of terfenadine and astemizole. Med Lett Drugs Ther. 1992; 34:9-10. https://pubmed.ncbi.nlm.nih.gov/1732711

435. Anon. Astemizole another non-sedating antihistamine. Med Lett Drugs Ther. 1989; 31:43-4. https://pubmed.ncbi.nlm.nih.gov/2565524

436. Clause DW, Zach GA. Reaction to diphenhydramine hydrochloride (Benadryl) used as a local anesthetic. Gen Dent. 1989; 37:426-7. https://pubmed.ncbi.nlm.nih.gov/2637894

437. Ramsdell WM. Severe reaction to diphenhydramine. Letter. J Am Acad Dermatol. 1989; 21:1318-20. https://pubmed.ncbi.nlm.nih.gov/2584476

438. Rinder CS, D’Amato SL, Rinder HM et al. Survival of complicated diphenhydramine overdose. Crit Care Med. 1988; 16:1161-2. https://pubmed.ncbi.nlm.nih.gov/3168512

439. Giotti A, Zilletti L. Antiarrhythmic actions of antihistamines. Pharmacol Ther Part B. 1976; 2:863-900.

440. Riccioppo Neto F. Effects of cyproheptadine on electrophysiological properties of isolated cardiac muscle of dogs and rabbits. Br J Pharmacol. 1983; 80:335-41. https://pubmed.ncbi.nlm.nih.gov/6652381 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2045038/

441. Dreifus LS, McGarry TF, Watanabe Y et al. Clinical and physiologic effects of antazoline, a new antiarrhythmic agent. Am Heart J. 1963; 65:607-14.

442. Freedberg RS, Friedman GR, Palu RN et al. Cardiogenic shock due to antihistamine overdose: reversal with intra-aortic balloon counterpulsation. JAMA. 1987; 257:660-1. https://pubmed.ncbi.nlm.nih.gov/3098994

443. Mathews DR, McNutt B, Okerholm R et al. Torsades de pointes occurring in association with terfenadine use. JAMA. 1991; 266:2375-6. https://pubmed.ncbi.nlm.nih.gov/1920744

444. Cortese L, Bjornson DC. Potential interaction between terfenadine and macrolide antibiotics. Clin Pharm. 1992; 11:675. https://pubmed.ncbi.nlm.nih.gov/1511540

445. Honig PK, Zamani K, Woosley RL et al. Erythromycin changes terfenadine pharmacokinetics & electrocardiographic pharmacodynamics. Clin Pharmacol Ther. 1992; 51:156.

446. Cortese LM, Bjornson DC. Comment: the new macrolide antibiotics and terfenadine. Ann Pharmacother. 1992; 26:1019. https://pubmed.ncbi.nlm.nih.gov/1504390

447. Anon. Labeling change to reflect drug interaction between terfenadine and ketoconazole. FDA Med Bull. 1991; 21(Jul):4-5.

448. Nightingale SL. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA. 1992; 268:705. https://pubmed.ncbi.nlm.nih.gov/1322467

449. Anon. New boxed warnings added for Seldane, Hismanal. FDA Med Bull. 1992; 22(Sep):2-3.

450. Hismanal (astemizole) tablets prescribing information. In: Physicians’ desk reference. 46th ed. Montvale, NJ; Medical Economics Company Inc; 1992:1138-9.

451. Filloux F. Toxic encephalopathy caused by topically applied diphenhydramine. J Pediatr. 1976; 108:1018-20.

452. Woodward GA, Baldassano RN. Topical diphenhydramine toxicity in a five year old with varicella. Pediatr Emerg Care. 1988; 4:18-20. https://pubmed.ncbi.nlm.nih.gov/3362727

453. Craft TM. Torsades de pointes after astemizole overdose. BMJ. 1986; 292:660. https://pubmed.ncbi.nlm.nih.gov/2868774 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1339646/

454. Reviewers’ comments (personal observations).

455. Roche. Posicor (mibefradil dihydrochloride) tablets prescribing infromation. Nutley, NJ; 1997 Jun.

456. Janssen Pharmaceutica, Titusville, NJ: Personal communication.

457. Janssen Pharmaceutica. Sporanox(itraconazole) capsules prescribing information. Titusville, NJ; 1992 Oct.

458. Janssen Pharmaceutica. Nizoral (ketoconazole) tablets prescribing information. Titusville, NJ; 1992 Oct.

459. Janssen Pharmaceutica. Hismanal (astemizole) tablets prescribing information. Titusville, NJ; 1992 Oct.

460. Klaumer MA. Dear health care professional letter regarding revisions to the Hismanal(astemizole) package insert concerning cardiac arrhythmias. Titusville, NJ: Janssen Pharmaceutica; July 20, 1992.

461. Wiley JF II, Gleber ML, Henretig FM et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr. 1992; 120:799-802. https://pubmed.ncbi.nlm.nih.gov/1578320

462. Chen Y, Gillis RA, Woosley RL. Block of delayed rectifier potassium current, I_K, by terfenadine in cat ventricular myocytes. J Am Coll Cardiol. 1991; 17(Suppl A):140A.

463. Levi R, Chenouda AA, Trzeciakowski JP et al. Dysrhythmias caused by histamine release in guinea pig and human hearts. Klin Wochenschr. 1982; 60:965-71. https://pubmed.ncbi.nlm.nih.gov/6182358

464. Levi R, Allan G, Zavecz JH. Cardiac histamine receptors. Fed Proc. 1976; 35:1942-7. https://pubmed.ncbi.nlm.nih.gov/5315

465. Levi R, Capurro N, Lee CH. Pharmacological characterization of cardiac histamine receptors: sensitivity to H₁- and H₂-receptor agonists and antagonists. Eur J Pharmacol. 1975; 30:328-35. https://pubmed.ncbi.nlm.nih.gov/236192

466. Honig PK, Woosley RL, Zamani K et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992; 52:231-8. https://pubmed.ncbi.nlm.nih.gov/1526078

467. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for OTC antihistamine drug products. 21 CFR Parts 201, 310, 341, and 369. Final rule. [Docket No. 76N-052H] Fed Regist. 1992; 57:58356-76.

468. Schering-Plough. Disophrol Chronotabs patient information. Kenilworth, NJ. Undated.

469. Wallace. Rynatuss tablets and pediatric suspension prescribing information. In: Physicians’ desk reference. 47th ed. Montvale, NJ: Medical Economics Company Inc; 1993:2503.

470. Schering Corp. Claritin product information. Kenilworth, NJ; 1995 Sep.

471. Quercia RA, Broisman L. Focus on loratadine: a new second-generation nonsedating H₁-receptor antagonist. Hosp Formul. 1993; 28:137-53.

472. Barenholtz AH, McLeod DC. Loratadine: a nonsedating antihistamine with once-daily dosing. DICP. 1989; 23:445-50. https://pubmed.ncbi.nlm.nih.gov/2525847

473. Simons FE. Loratadine, a non-sedating H₁-receptor antagonist (antihistamine). Ann Allergy. 1989; 63:266-8. https://pubmed.ncbi.nlm.nih.gov/2572187

474. Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1989; 37:42-57. https://pubmed.ncbi.nlm.nih.gov/2523301

475. Honig PK, Wortham DC, Zamani K et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993; 269:1513-8. https://pubmed.ncbi.nlm.nih.gov/8445813

476. Woosley RL, Chen Y, Freiman JP et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993; 269:1532-6. https://pubmed.ncbi.nlm.nih.gov/8445816

477. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. JAMA. 1993; 269:1550-2. https://pubmed.ncbi.nlm.nih.gov/8445821

478. Pohjola-Sintonen S, Viitasalo M, Toivonen L et al. Torsades de pointes after terfenadine-itraconazole interaction. BMJ. 1993; 306:186.

479. Terfenadine/azole antifungal agents. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1993(April):685a.

480. Nonsedating antihistamines/macrolide antibiotics. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1995(July):110c.

481. Meltzer EO. To use or not to use antihistamines in patients with asthma. Ann Allergy. 1990; 64(Part II):183-6. https://pubmed.ncbi.nlm.nih.gov/1967918

482. Lantner R, Tobin MC. Pharmacist advice to asthmatics regarding antihistamine use. Ann Allergy. 1991; 66:411-3. https://pubmed.ncbi.nlm.nih.gov/2035904

483. Berlex. Betapace (sotalol hydrochloride) prescribing information. Wayne, NJ; 1992 Jul.

484. Pierson WE, Virant FS. Antihistamines in asthma. Ann Allergy. 1989; 63(Part II):601-2. https://pubmed.ncbi.nlm.nih.gov/2574551

485. Food and Drug Administration. Antiemetic drug products for over-the-counter human use; proposed amendment to the monograph. 21 CFR Part 336. Notice of proposed rulemaking. [Docket No. 92N-0346] Fed Regist. 1993; 58:45216-7.

486. Food and Drug Administration. Sleep aids and antiemetics. From: FDA Bulletin Board. 1993 Aug 26.

487. Simons FER, Simons KJ. The pharmacology and use of H₁-receptor-antagonist drugs. N Engl J Med. 1994; 330:1663-70. https://pubmed.ncbi.nlm.nih.gov/7909915

488. Schering. Claritin (loratadine) tablets prescribing information. In: Physicians’ desk reference. 48th ed. Montvale, NJ: Medical Economics Company Inc; 1994(Suppl A):A122.

489. Erythromycin interactions: loratadine (Claritin). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1994:748-9.

490. Crane JK, Shih HT. Syncope and cardiac arrythmia due to an interaction between itraconazole and terfenadine. Am J Med. 1993; 95:445-6. https://pubmed.ncbi.nlm.nih.gov/8213879

491. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of final monograph for OTC antitussive drug products. 21 CFR Part 341. Final rule. [Docket No. 89P-0040] Fed Regist. 1994; 59:29172-4.

492. Kaplan AP. Anaphylaxis. In: Wyngaarden JB, Smith LH Jr, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders Company; 1992:1462-5.

493. Austen KF. Diseases of immediate type hypersensitivity. In: Isselbacher KJ, Braunwald E, Wilson JD et al, eds. Harrison’s principles of internal medicine. 13th ed. New York: McGraw-Hill Company; 1994:1632-4.

494. Burroughs Wellcome Co. Semprex-D (acrivastine and pseudoephedrine HCl) capsules. Research Triangle Park, NC; 1994 April.

495. Brogden RN, McTavish D. Acrivastine: a review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991; 41:927-40. https://pubmed.ncbi.nlm.nih.gov/1715267

496. Aaronson DW. Comparative efficacy of H₁ antihistamines. Ann Allergy. 1991; 67:541-7. https://pubmed.ncbi.nlm.nih.gov/1683523

497. Meltzer EO. Comparative safety of H₁ antihistamines. Ann Allergy. 1991; 67:625-33. https://pubmed.ncbi.nlm.nih.gov/1684274

498. Simons FER. H₁-receptor antagonists: comparative tolerability and safety. Drug Safety. 1994; 10:350-80. https://pubmed.ncbi.nlm.nih.gov/7913608

499. Cohen AF, Hamilton MJ, Peck AW. The effects of acrivastine (BW825C), diphenhydramine and terfenadine in combination with alcohol on human CNS performance. Eur J Clin Pharmacol. 1987; 32:279-88. https://pubmed.ncbi.nlm.nih.gov/2885203

500. Weintraub M. Histamine H₁ antagonists. N Engl J Med. 1994; 331:1019. https://pubmed.ncbi.nlm.nih.gov/7916125

501. Parke-Davis. Benadryl 25 tablets and kapseals (25 mg diphenhydramine HCl) prescribing information. In: Physicians’ desk reference. 48th ed. Montvale, NJ: Medical Economics Company Inc; 1994(Suppl A):A36.

502. Schering, Kenilworth, NJ: Personal communication.

503. Brannan MD, Reidenberg P, Radwanski E et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther. 1995; 58:269-78. https://pubmed.ncbi.nlm.nih.gov/7554700

504. Woosley RL, Chen Y, Freiman JP et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993; 269:1532-6. https://pubmed.ncbi.nlm.nih.gov/8445816

505. Good AP, Rockwood R, Schad P. Loratadine and ventricular tachycardia. Am J Cardiol. 1994; 74:207. https://pubmed.ncbi.nlm.nih.gov/7517624

506. Woosley R, Darrow WR. Analysis of potential adverse drug reactions—a case of mistaken identity. Am J Cardiol. 1994; 74:208-9. https://pubmed.ncbi.nlm.nih.gov/8023797

507. Biglin KE, Faraon MS, Constance TD et al. Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin. Ann Pharmacother. 1994; 28:282. https://pubmed.ncbi.nlm.nih.gov/8173153

508. Ketoconazole (Nizoral) interactions: astemizole (Hismanal). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1994:751.

509. Pfizer Laboratories. Zyrtec (cetirizine hydrochloride) tablets and syrup prescribing information. New York, NY; 1998 May.

510. Parke Davis. Eryc (erythromycin delayed-release capsules) prescribing information (dated 1994 June). In Physicians’ desk reference. 50th ed. Montvale, NJ: Medical Economics Company Inc; 1996:1915-7.

511. Klausner MA. Dear healthcare provider letter regarding new information concerning drug interaction of astemizole with quinine. Titusville, NJ; 1996 Mar 25.

512. Janssen Pharmaceutica. Hismanal (astemizole tablets) prescribing information. Titusville, NJ. 1998 Feb.

513. Janssen Pharmaceutica, Titusville, NJ: Personal communication.

514. Hoechst Marion Roussel, Kansas City, MO: Personal communication.

515. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA. 1996; 275:1339-41. https://pubmed.ncbi.nlm.nih.gov/8614120

516. Hoechst Marion Roussel. Allegra (fexofenadine hydrochloride) capsules prescribing information. Kansas City, MO; 1996 Jul.

517. Hoechst Marion Roussel, Inc. Product information form for American hospital formulary service: Allegra (fexofenadine HCl). Kansas City, MO: 1996.

518. Hoechst Marion Roussel. Seldane-D (terfenadine and pseudoephedrine hydrochloride) extended-release tablets prescribing information. Kansas City, MO; 1997 Sep.

519. Turner RB, Sperber SJ, Sorrentino JV et al. Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold. Clin Infect Dis. 1997; 25:824-30. https://pubmed.ncbi.nlm.nih.gov/9356796

520. Douglass JA, Dhami D, Gurr CE et al. Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. Am J Respir Crit Care Med. 1994; 150:1108- 13. https://pubmed.ncbi.nlm.nih.gov/7921444

521. Proud D, Naclerio RM, Gwaltney JM et al. Kinins are generated in nasal secretions during natural rhinovirus colds. J Infect Dis. 1990; 161:120-3. https://pubmed.ncbi.nlm.nih.gov/2295843

522. Proud D, Gwaltney JM Jr., Hendley JO et al. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis. 1994; 169:1007-13. https://pubmed.ncbi.nlm.nih.gov/8169385

523. Turner RB. Elaboration of intereleukin 8 from fibroblast cells and human nasal epithelium in response to rhinovirus challenge. Program and abstracts of the thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL: 1994. Abstract No. B43.

524. Berkowitz RB, Tinkelman DG. Evaluation of oral terfenadine for treatment of the common cold. Ann Allergy. 1991; 67:593-7. https://pubmed.ncbi.nlm.nih.gov/1750722

525. Gaffey MJ, Gwaltney JM, Sastre A et al. Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. Am Rev Respis Dis. 1987; 136:556-560.

526. Wallace Laboratories. Astelin (azelastine hydrochloride) nasal spray prescribing information. Cranbury, NJ; 1996 Oct.

527. Wallace Laboratories. Astelin (azelastine hydrochloride) nasal spray product monograph. Cranbury, NJ; 1997 Jan.

528. Wallace Laboratories. Product information form for American hospital formulary service: Astelin (azelastine hydrochloride) nasal spray. Cranbury, NJ; 1996 Oct 30.

529. Anon. Azelastine spray for allergic rhinitis. Med Lett Drugs Ther. 1997; 39:45-7. https://pubmed.ncbi.nlm.nih.gov/9150688

530. Pelucchi A, Chiapparino A, Mastropasqua B et al. Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. J Allergy Clin Immunol. 1995; 95:515-23. https://pubmed.ncbi.nlm.nih.gov/7852667

531. Spaeth J, Schultze V, Klimek L et al. Azelastine reduces histamine-induced swelling of nasal mucosa. ORL J Otorhin Relat Spec. 1996; 58:157-63.

532. LaForce C, Dockhorn RJ, Prenner BM et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol. 1996; 76:181-8. https://pubmed.ncbi.nlm.nih.gov/8595539

533. Gastpar H, Nolte D, Aurich R et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy. 1994; 49:152-8. https://pubmed.ncbi.nlm.nih.gov/7911010

534. Charpin D, Godard P, Garay RP et al. A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol. 1995; 252:455-8. https://pubmed.ncbi.nlm.nih.gov/8719584

535. Ratner PH, Findlay SR, Hampel F et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994; 94:818-25. https://pubmed.ncbi.nlm.nih.gov/7963150

536. Weiler JM, Meltzer EO, Benson PM et al. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol. 1994; 94:972-80. https://pubmed.ncbi.nlm.nih.gov/7798545

537. Passali D, Piragine F. A comparison of azelastine nasal spray and cetirizine tablets in the treatment of allergic rhinitis. J Int Med Res. 1994; 22:17-23. https://pubmed.ncbi.nlm.nih.gov/8187941

538. Conde Hernández DJ, Palma Aqilar JL, Delgado Romero J. Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Res Med Opin. 1995; 13:299-304.

539. Davies RJ, Bagnall AC, McCabe RN et al. Antihistamines: topical vs oral administration. Clin Exp Allergy. 1996; 26(Suppl 3):11-7. https://pubmed.ncbi.nlm.nih.gov/8735853

540. Crutcher JE, Kantner TR. The effectiveness of antihistamines in the common cold. J Clin Pharmacol. 1981; 21:9-15.

541. Benton RE, Honig PK, Zamani K et al. Grapefruit juice alters tefenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther. 1996; 59:383-8. https://pubmed.ncbi.nlm.nih.gov/8612381

542. Rau SE, Bend JR, Arnold MO et al. Grapefruit juice–terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther. 1997; 61:401- 9. https://pubmed.ncbi.nlm.nih.gov/9129557

543. Honig PK, Wortham DC, Lazarev A et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol. 1996; 36:345-51. https://pubmed.ncbi.nlm.nih.gov/8728348

544. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet. 1997; 33:103-21. https://pubmed.ncbi.nlm.nih.gov/9260034

545. Abbott Laboratories. Norvir (ritonavir) capsules and oral solution prescribing information. North Chicago, IL; 1996 Nov.

546. Piscitelli SC, Flexner C, Minor JR et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996; 23:685-93. https://pubmed.ncbi.nlm.nih.gov/8909827

547. Merck. Crixivan (indinavir sulfate) capsules prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:1670-3.

548. Agouron. Viracept (nelfinavir) tablets and oral powder prescribing information. La Jolla, CA. 1997 Jul.

549. Roche. Invirase (saquinavir maleate) capsules prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:2291- 4.

550. Pfizer. Zoloft(sertraline) tablets prescribing information. New York, NY; 1997 Jul.

551. Solvay. Luvox (fluvoxamine maleate) tablets prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:2273- 6.

552. Nonsedating antihistamines/fluvoxamine. In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1997 (Oct):110.

553. Bristol-Myers Squibb. Serzone (nefazodone hydrochloride) tablets prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997: 776-9.

554. Nonsedating antihistamines/indinavir. In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1997 (Oct):110c.

555. Nonsedating antihistamines/food (grapefruit juice). In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1997 (Oct):110a.

556. Food and Drug Administration. Labeling of diphenhydramine-containing drug products for over-the-counter human use. 21 CFR Parts 336, 338, 341, 348. Proposed rule. [Docket No. 97N-0128] Fed Regist. 1997; 62:45767-74.

557. Chan CYJ, Wallander KA. Diphenhydramine toxicity in three children with varicella- zoster infection. DICP. 1991; 25:130-2. https://pubmed.ncbi.nlm.nih.gov/2058184

558. Warner-Lambert. Benadryl Itch Relief Stick Extra Strength patient information (undated). In: Physicians’ desk reference for nonprescription drugs. 18th ed. Montvale, NJ: Medical Economics Company Inc; 1997:827.

559. Warner-Lambert. Benadryl Itch Stopping Cream Original Strength and Extra Strength patient information (undated). In: Physicians’ desk reference for nonprescription drugs. 18th ed. Montvale, NJ: Medical Economics Company Inc; 1997:827.

560. Warner-Lambert. Benadryl Itch Stopping Spray Original Strength and Extra Strength patient information (undated). In: Physicians’ desk reference for nonprescription drugs. 18th ed. Montvale, NJ: Medical Economics Company Inc; 1997:827-8.

561. Warner-Lambert. Benadryl Itch Stopping Gel Original Strength and Extra Strength patient information (undated). In: Physicians’ desk reference for nonprescription drugs. 18th ed. Montvale, NJ: Medical Economics Company Inc; 1997:827.

562. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-couunter human use; products containing diphenhydramine citrate or diphenhydramine hydrochloride; enforcement policy. 21 CFR Part 341. Final rule. [Docket No. 76N-052G] Fed Regist. 1996; 61:15700-3.

563. Warner-Lambert. Caladryl lotion, cream for kids, and clear lotion patient information (undated). In: Physicians’ desk reference for nonprescription drugs. 18th ed. Montvale, NJ: Medical Economics Company Inc; 1997:830.

564. Smith MBH, Feldman W. Over-the-counter cold medications: a critical review of clinical trials between 1950 and 1991. JAMA. 1993; 269: 2258-63. https://pubmed.ncbi.nlm.nih.gov/8097268

565. D Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther. 1995; 58:605-16. https://pubmed.ncbi.nlm.nih.gov/8529325

566. National Asthma Education Program. Expert Panel Report II: guidelines for the diagnosis and management of asthma. 1997 Feb.

567. Reviewers’ comments (personal observations) on Fexofenadine (Uses: Other Uses).

568. Cerio R, Lessof MH. Treatment of chronic idiopathic urticaria with terfenadine. Clin Allergy. 1984; 14:139-41. https://pubmed.ncbi.nlm.nih.gov/6423314

569. Fredriksson T, Hersle K, Hjorth N et al. Terfenadine in chronic urticaria: a comparison with clemastine and placebo. Cutis. 1986; 38:128-30. https://pubmed.ncbi.nlm.nih.gov/2874958

570. Ferguson J, MacDonald KJS, Kenicer KJA. Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomized double-blind study. Br J Clin Pharmacol. 1985; 20:639-41. https://pubmed.ncbi.nlm.nih.gov/3937549 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1400841/

571. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine: a randomized double-blind study in 45 patients. Eur J Clin Pharmacol. 1986; 31:277-80. https://pubmed.ncbi.nlm.nih.gov/2878811

572. Cainelli T, Seidenari S, Valsecchi R et al. Double-blind comparison of astemizole and terfenadine in the treatment of chronic urticaria. Pharmacotherapeutica. 1986; 4:679-86.

573. Ormerod AD, Baker R, Watt J et al. Terfenadine and brompheniramine maleate in urticaria and dermographism. Dermatologica. 1986; 173:5-8. https://pubmed.ncbi.nlm.nih.gov/2875904

574. Awni WM, Cavanaugh JH, Leese P et al. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol. 1997; 52:49-54. https://pubmed.ncbi.nlm.nih.gov/9143867

575. McGann KP, Pribanich S, Graham JA et al. Diphenhydramine toxicity in a child with varicella: a case report. J Fam Pract. 1992; 35:210,213-4. https://pubmed.ncbi.nlm.nih.gov/1645115

576. Woodward GA, Baldassano RN. Topical diphenhydramine toxicity in a five year old with varicella. Pediatr Emerg Care. 1988; 4:18-20. https://pubmed.ncbi.nlm.nih.gov/3362727

577. Sale ME, Barbey JT, Woosley RL et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther. 1994; 56:295-301. https://pubmed.ncbi.nlm.nih.gov/7924125

578. Barnes CL, McKenzie CA, Webster KD et al. Cetirizine: a new, nonsedating antihistamine. Ann Pharmacother. 1993; 27:464-70. https://pubmed.ncbi.nlm.nih.gov/8477125

579. Anon. Cetirizine—a new antihistamine. Med Lett Drugs Ther. 1996; 38:21-3. https://pubmed.ncbi.nlm.nih.gov/8598822

580. Simons FER. H₁-Receptor antagonists: comparative tolerability and safety. Drug Saf. 1994; 10:350-80. https://pubmed.ncbi.nlm.nih.gov/7913608

581. Wasserfallen JB, Leuenberger P, Pécoud A. Effect of cetirizine, a new H₁ antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol. 1993; 91:1189-97. https://pubmed.ncbi.nlm.nih.gov/8099593

582. Klausner MA. Dear doctor letter regarding important drug warning of Hismanal (astemizole). Titusville, NJ: Janssen Phrarmaceutica; 1998 Feb.

583. Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs1993; 46:1055-80.

584. Pfizer Laboratories. Zyrtec (cetirizine hydrochloride) tablets product monograph. New York, NY: Undated.

585. Novartis. Tavist (clemastine fumarate) tablets prescribing information. In: Physicians’ desk reference for nonprescription drugs. 52nd edition. Montvale NJ: Medical Economics Company Inc; 1998:708-9.

586. Warner-Lambert. Actifed cold and allergy tablets prescribing information. In: Physicians’ desk reference for nonprescription drugs. 52nd edition. Montvale NJ: Medical Economics Company Inc; 1998:798.

587. Schering Corp. Claritin-D 12 Hour (loratadine and pseudoephedrine sulfate) extended-release tablets prescribing information. Kenilworth, NJ; 1997 Feb.

588. Schering Corp. Claritin-D 24 Hour (loratadine and pseudoephedrine sulfate) extended-release tablets prescribing information. In: Physicians’ desk reference. 52nd ed. Montvale NJ: Medical Economics Company Inc; 1998 (Suppl A):A278-80.

589. Okerholm RA, Weiner DL, Hook RH et al. Bioavailability of terfenadine in man. Biopharm Drug Dispos. 1981; 2:185-90. https://pubmed.ncbi.nlm.nih.gov/6113858

590. Garteiz DA, Hook RH, Walker BJ et al. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung. 1982; 32:1185-90. https://pubmed.ncbi.nlm.nih.gov/6817765

591. Cook CE, Williams DL, Myers M et al. Radioimmunoassay for terfenadine in human plasma. J Pharm Sci. 1980; 69:1419-23. https://pubmed.ncbi.nlm.nih.gov/6109770

592. Munro NL, Robinson RE (Merrell Dow, Cincinnati, OH): Personal communication on terfenadine 4:00; 1985 Jul 19.

593. Reviewers’ comments (personal observations) on terfenadine 4:00.

594. Marion Merrell Dow. Seldane (terfenadine) tablets prescribing information. Kansas City, MO. 1993 Jan.

595. Rolf CN. Dear doctor letter regarding important drug warning of Seldane. Cincinnati, OH: Marion Merrell Dow; 1990 Aug 6.

596. Hoechst Marion Roussel. Seldane-D (terfenadine and pseudoephedrine hydrochloride) extended-release tablets prescribing information. Kansas City, MO; 1997 Sep.

597. Marion Merrell Dow, Kansas City, MO: Personal communication on terfenadine 4:00.

598. Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther. 1991; 49:130.

599. Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1991; 266:2376.

600. Torsades de pointes. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders; 1992:707-8.

601. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart. 1987; 113:1470-82.

602. Perticone F, Adinolfi L, Bonaduce D. Efficacy of magnesium sulfate in the treatment of torsade de pointes. Am Heart J. 1986; 112:847-9. https://pubmed.ncbi.nlm.nih.gov/3766386

603. Rogiers P, Vermeier W, Kesteloot H et al. Effect of infusion of magnesium sulfate during atrial pacing on ECG intervals, serum electrolytes, and blood pressure. Am Heart J. 1989; 117:1278-83. https://pubmed.ncbi.nlm.nih.gov/2729056

604. Eller MG, Okerholm RA. Effect of cimetidine on terfenadine and terfenadine metabolite pharmacokinetics. Pharm Res. 1991; 8(Suppl 10):297.

605. Antihistamines, nonsedating/azole antifungal agents. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1995(July):110a.

606. Antihistamines, nonsedating/macrolide antibiotics. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1997(October):110d.

607. Hoechst Marion Roussel. Seldane (terfenadine) 60-mg tablets prescribing information. Kansas City, MO; 1997 Sep.

608. Azithromycin (Zithromax) interactions: terfenadine (Seldane). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1994:743-4.

609. Muro Pharmaceutical Inc. Dynabac (dirithromycin tablets) prescribing information. Tewksbury, MA: 1999 Oct 11.

610. Honig P, Wortham D, Zamani K et al. Effect of erythromycin, clarithromycin and azithromycin on the pharmacokinetics of terfenadine. Clin Pharmacol Ther. 1993; 53:161.

611. Harris S, Hilligoss DM, Colangelo PM et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther. 1995; 58:310-5. https://pubmed.ncbi.nlm.nih.gov/7554704

612. Itraconazole (Sporanox) interactions: terfenadine (Seldane). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1994:750.

613. Clarithromycin (Biaxin) interactions: terfenadine (Seldane). In Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1994:747.

614. Janssen Pharmaceutica, Titusville, NJ: Personal communication on terfenadine 4:00.

615. Hoechst Marion Roussel, Kansas City, MO: Personal communication on terfenadine 4:00.

616. Anon. Grapefruit juice interactions with drugs. Med Lett Drugs Ther. 1995; 37:73-4. https://pubmed.ncbi.nlm.nih.gov/7630329

617. Honig P, Wortham D, Lazarev A et al. Pharmacokinetics and cardiac effects of terfenadine in poor metabolizers receiving concomitant grapefruit juice. Clin Pharmacol Ther. 1995; 57:185.

618. Bailey DG, Spence JD, Munoz C et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991; 337:268-9. https://pubmed.ncbi.nlm.nih.gov/1671113

619. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995; 57:485-91. https://pubmed.ncbi.nlm.nih.gov/7768070

620. Cyclosporine/food (grapefruit juice). In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1996(July):233b.

621. Midazolam (Versed) interactions: grapefruit juice. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1996:932.

622. Proppe DG, Hoch OD, McLean AJ et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol. 1995; 39:337-8. https://pubmed.ncbi.nlm.nih.gov/7619679 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365014/

623. Kupferschmidt HHT, Ha HR, Ziegler WH et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995; 58:20-8. https://pubmed.ncbi.nlm.nih.gov/7628179

624. Ameer B, Weintraub RA, Johnson JV et al. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther. 1996; 60:34-40. https://pubmed.ncbi.nlm.nih.gov/8689809

625. Yee GC, Stanley DL, Pessa LJ et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 345:955-6. https://pubmed.ncbi.nlm.nih.gov/7715295

626. Hollander AAMJ, van Rooij J, Lentjes EGWM et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 1995; 57:318-24. https://pubmed.ncbi.nlm.nih.gov/7697949

627. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet. 1994; 26:91-8.

628. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994; 46:175-7. https://pubmed.ncbi.nlm.nih.gov/8039540

629. Soons PA, Vogels BAPM, Roosemalen MCM et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991; 50:394-403. https://pubmed.ncbi.nlm.nih.gov/1914375

630. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993; 35:431-6. https://pubmed.ncbi.nlm.nih.gov/8485024 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1381556/

631. Campana C, Regazzi MB, Buggia I et al. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996; 30:141-179. https://pubmed.ncbi.nlm.nih.gov/8906896

632. Pfizer, New York, NY: Personal communication on terfenadine 4:00.

633. Goldberg MJ, De Sante K, Cerimele B et al. Effect of dirithromycin on terfenadine pharmacokinetics and Qtc in healthy men. Clin Pharmacol Ther. 1995; 57:176.

634. Dista. Ilotycin Gluceptate (erythromycin gluceptate) prescribing information. In: Physicians’ desk reference. 48th ed. Montvale, NJ: Medical Economics Company Inc; 1994:871-2.

635. Schering Corp. Claritin (loratadine) tablets, syrup and rapidly disintegrating tablets prescribing information. Kenilworth, NJ; 1997 Jan.

636. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYPTS inhibitors in grapefruit juice. Life Sci. 1996; 59:1025-30. https://pubmed.ncbi.nlm.nih.gov/8809221

637. Lundahl J, Regardh CG, Edgar B et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol. 1995; 49:61-7. https://pubmed.ncbi.nlm.nih.gov/8751023

638. Hoechst Marion Roussel. Allegra (fexofenadine hydrochloride) capsules prescribing information (dated 1996 Oct). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1997 (Suppl A):A37-8.

639. Roche, Nutley, NJ: Personal communication on terfenadine 4:00.

640. Pfizer. Zithromax (azithromycin) tablets, capsules, and for oral suspension prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997(Suppl A):A255-9.

641. Pfizer. Zoloft (sertraline) tablets prescribing information. New York, NY; 1997 Nov 4.

642. Nonsedating antihistamines/histamine H2 antagonists. In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1997 (Oct):110b.

643. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet. 1997; 350:1115-6. https://pubmed.ncbi.nlm.nih.gov/9343494

644. Ng PW, Chan WK, Chan TYK. Torsade de pointes during concomitant use of terfenadine and cimetidine. Aust N Z J Med. 1996; 26:120. https://pubmed.ncbi.nlm.nih.gov/8775544

645. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet. 1997; 349:1322. https://pubmed.ncbi.nlm.nih.gov/9142080

646. Clark S. Dangers of non-sedating antihistamines. Lancet. 1997; 349:1268. https://pubmed.ncbi.nlm.nih.gov/9142059

647. Pfizer Inc. Zoloft (sertraline hydrochloride) tablets prescribing information. New York; 1997 Oct.

648. Hoechst Marion Roussel, Kansas City, MO: Personal communication on fexofenadine 4:00.

649. Spence D. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther. 1997; 61:395-400.

650. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994; 48:617-37. https://pubmed.ncbi.nlm.nih.gov/7528133

651. Hilbert J, Radwanski E, Weglein R et al. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol. 1987; 27:694-8. https://pubmed.ncbi.nlm.nih.gov/2960701

652. Anon. Loratadine—a new antihistamine. Med Lett Drugs Ther. 1993; 35:71-2. https://pubmed.ncbi.nlm.nih.gov/8336639

653. Hilbert J, Moritzen V, Parks A et al. The pharmacokinetics of loratadine in normal geriatric volunteers. J Int Med Res. 1988; 16:50-60. https://pubmed.ncbi.nlm.nih.gov/2965043

654. Hilbert JM, Matzke GR, Radwanski E et al. Loratadine pharmacokinetics in renal impairment. J Allergy Clin Immunol. 1987; 79:206.

655. Marion Merrell Dow. Seldane (terfenadine) tablets prescribing information. Cincinnati, OH; 1990 Jul.

656. Merck. Crixivan (indinavir) capsules prescribing information (dated 1998 Feb). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998(Suppl A):A205-8.

657. Abbott Laboratories. Norvir (ritonavir) capsules and oral solution prescribing information (dated 1997 Mar). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:459-64.

658. Glaxo Wellcome. Raxar (grepafloxacin hydrochloride) tablets prescribing information. Research Triangle Park, NC; 1997 Nov.

659. Janssen. Dear health care professional letter regarding withdrawal of Hismanal (astemizole). Titusville, NJ: 1999 July 18.

660. Anon. Janssen Pharmaceutica announces the withdrawal of Hismanal from the market. FDA Talk Paper. Rockville, MD: Food and Drug Administration; 1999 Jun 21.

661. Dinndorf PA, McCabe MA, Frierdich S. Risk of abuse of diphenhydramine in children and adolescents with chronic illnesses. J Pediatrics. 1998; 133:293-5.

662. Watemberg NM, Roth KS, Alehan FK et al. Central anticholinergic syndrome on therapeutic doses of cyproheptadine. Pediatrics. 1999; 103:158-60. https://pubmed.ncbi.nlm.nih.gov/9917456

663. Carr RA, Edmonds A, Shi H et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrobial Agents Chemother. 1998; 42:1176-1180.

664. Rhone-Poulenc Rorer. Synercid I.V. (quinupristin/dalfopristin) for injection prescribing information. Collegeville, PA: 1999 Jul.

665. ECR Pharma. Lodrane Allergy (brompheniramine maleate) capsules prescribing information. Richmond, VA; 1999 Apr.

666. Biovail Pharmaceuticals Inc. Rondec-DM (brompheniramine maleate, pseudoephedrine hydrochloride, dextromethorphan hydrobromide) syrup prescribing information. Morrisville, NC; 2001 May.

667. Biovail Pharmaceuticals Inc. Rondec (carbinoxamine maleate and pseudoephedrine hydrochloride) oral drops prescribing information. Morrisville, NC; 2001 May.

668. Biovail Pharmaceuticals Inc. Rondec (brompheniramine maleate and pseudoephedrine hydrochloride) syrup prescribing information. Morrisville, NC; 2001 May.

669. McClellan K, Jarvis B. Desloratadine. Drugs. 2001; 61:789-96. https://pubmed.ncbi.nlm.nih.gov/11398910

670. Schering Corporation. Clarinex (desloratadine) tablets prescribing information. Kenilworth, NJ; 2002 Feb.

671. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs. 2001; 10:547-60. https://pubmed.ncbi.nlm.nih.gov/11424898

672. Food and Drug Administration. Labeling of diphenhydramine-containing drug products for over-the-counter human use. 21 CFR Parts 336, 338, 341, 348. Final rule. [Docket No. 97N-0128] Fed Regist. 2002; 67:72555-9.

673. Gottwald MD, Gidal BE, Flaherty J. Parkinson’s Disease. In: Koda-Kimble MA, Young LY eds. Applied therapeutics: the clinical use of drugs. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:51-1—51-27.

674. Young, R. Update on Parkinson’s disease. Am Fam Physician. 1999; 59:2155-69. https://pubmed.ncbi.nlm.nih.gov/10221302

675. Nelson MV, Berchou RC, LeWitt PA. Parkinson’s Disease. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. Stamford: The McGraw-Hill Companies, Inc.; 2002:1089-102.

676. Crimson ML, Dorson PG. Schizophrenia. In DiPiro JT, Talbert RL, Yee GG et al., eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. Stanford: The McGraw-Hill Companies, Inc.; 2002:1219-42.

677. Pamlab, LLC. Palgic (4 mg carbinoxamine maleate) prescribing information. Covington, IA; 2006 Jun.

678. Food and Drug Administration. Over-the-counter drug products intended for oral ingestion that contain alcohol. 21 CFR Part 328. Final Rule. [Docket No. 93N-0107] Fed Regist. 1995; 60:13590-5.

679. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. 21 CFR Part 341. Final Rule. [Docket No. 76N-052G] Fed Regist. 2002; 67:78158-72.

680. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24:1-16. https://pubmed.ncbi.nlm.nih.gov/16330665

681. de Blic J, Wahn U, Billard E et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005; 16:267-75. https://pubmed.ncbi.nlm.nih.gov/15853959

682. Potter PC for the Study Group. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy. 2003; 58:893-9. https://pubmed.ncbi.nlm.nih.gov/12911418

683. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol. 2006; 45:469-74. https://pubmed.ncbi.nlm.nih.gov/16650180

684. Nettis E, Colanardi MC, Barra L et al. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006; 154:533-8. https://pubmed.ncbi.nlm.nih.gov/16445787

685. UCB Inc. Xyzal (levocetirizine dihydrochloride) tablets prescribing information. 2007 May. From UCB web site. http://www.xyzal.com

686. Benedetti MS, Plisnier M, Kaise J et al. Absorption, distribution, metabolism, and excretion of [¹⁴C] levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 2001; 57:571-82. https://pubmed.ncbi.nlm.nih.gov/11758635

687. Layton D, Wilton L, Boshier A et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006; 29:897-909. https://pubmed.ncbi.nlm.nih.gov/16970513

693. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. https://pubmed.ncbi.nlm.nih.gov/17218934

694. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150441.htm

695. Anon. Drugs for allergic disorders. Treat Guidel Med Lett. 2007; 5:71-80.

696. Food and Drug Administration. Carbinoxamine products: Enforcement action dates (Docket No. 2006N-0229). Fed Regist. 2006; 71:33462-5.

697. Food and Drug Administration. Questions and answers about unapproved drugs and FDA’s enforcement action against carbinoxamine products. Rockville, MD; 2006 Jun. From FDA website. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm118712.htm

698. Anon. Makers pull cold medicines sold for infants. CNN News, 2007 Oct 11. From CNN.com website. http://www.cnn.com/2007/HEALTH/10/11/infant.drugs/index.html

699. Food and Drug Administration. FDA news: FDA releases recommendations regarding use of over-the-counter cough and cold products. Rockville, MD; 2008 Jan 17. From the FDA web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008

700. Richwine L. U.S. panel against cold drugs for kids under 6. Reuters, 2007 Oct 19. From Reuters website. http://www.reuters.com/article/domesticNews/idUSN1833809520071019

701. Food and Drug Administration. Over the counter cough and cold medications. Rockville, MD; October 2008. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094913.htm

702. Food and Drug Administration. FDA statement: FDA statement following CHPA’s announcement on nonprescription over-the-counter cough and cold medicines in children. 2008 Oct 8. From the FDA website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116964.htm

703. Consumer Healthcare Products Association. Statement from CHPA on the voluntary label updates to oral OTC children’s cough and cold medicines. 2008 Oct 7. http://www.chpa-info.org/10_07_08_pedcc.aspx

704. Heavey S. Don’t use cold drugs in kids under 4: manufacturers. Reuters, 2008 Oct 8. From Reuters website. http://uk.reuters.com/articlePrint?articleId=UKTRE4965S520081008

705. Duchesnay USA, Inc. Diclegis (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets prescribing information. Bryn Mawr, PA; 2013 Apr.

706. Duchesnay USA, Inc. Bonjesta (doxylamine succinate and pyridoxine hydrochloride) extended-release tablets prescribing information. Bryn Mawr, PA; 2016 Nov.

707. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 021876Orig1s000: Summary Review. From FDA website. Accessed 2017 Apr. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000SumR.pdf

708. Koren G, Clark S, Hankins GD et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol. 2010; 203:571.e1-7. https://pubmed.ncbi.nlm.nih.gov/20843504

709. US Department of Health and Human Services. Federal Register. Determination that Bendectin was not withdrawn from sale for reasons of safety or effectiveness. 1999; 64:43190-1.

710. . American College of Obstetricians and Gynecologists. Practice Bulletin No. 153: Nausea and vomiting of pregnancy. Obstet Gynecol. 2015; 126:e12-24. https://pubmed.ncbi.nlm.nih.gov/26287788

711. McKeigue PM, Lamm SH, Linn S et al. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology. 1994; 50:27-37. https://pubmed.ncbi.nlm.nih.gov/7974252

712. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988; 22:813-24. https://pubmed.ncbi.nlm.nih.gov/3229352

Medical Disclaimer